

**THE
AMERICAN ACADEMY
OF
NEUROLOGICAL SURGERY**



66th Annual Meeting

Four Seasons Berlin, October 3-5, 2004

Taschenbergpalais Dresden, October 5-8, 2004

**Joint Meeting with the Germany Academy of
Neurosurgery and the Germany Society of Neurosurgery**



**American
Association of
Neurological
Surgeons**

**Jointly Sponsored by the
American Association
of Neurological Surgeons**



FUTURE MEETINGS

2005

**September 21–24
Ritz-Carlton Half Moon Bay
Half Moon Bay, CA**

2006

**October 18–21
Ritz-Carlton Lodge, Reynolds Plantation
Greensboro, GA**

2007

**October 31–November 3
Ritz-Carlton, Lake Las Vegas
Henderson, NV**

Mark your calendars now!



**American
Association of
Neurological
Surgeons**

**Jointly Sponsored by
the Association of
Neurological Surgery**

2004 OFFICERS

PRESIDENT

Volker K.H. Sonntag

PRESIDENT-ELECT

Martin B. Camins

VICE PRESIDENT

William F. Chandler

SECRETARY

L. Nelson Hopkins, III

TREASURER

Ralph G. Dacey, Jr.

EXECUTIVE COMMITTEE

Volker K.H. Sonntag

Martin B. Camins

William F. Chandler

L. Nelson Hopkins, III

Ralph G. Dacey, Jr.

David G. Piepgras

Jon H. Robertson

HISTORIAN

David G. Piepgras

ACADEMY COMMITTEES 2004

Academy Award Committee:

Robert Solomon, Chair
Douglas Kondziolka
Charles Branch

Auditing Committee:

Martin Camins, Chair
Christopher Loftus
Paul Nelson

Future Sites Committee:

Martin Camins, Chair
Arthur Day
David Piepgras

Membership Advisory Committee:

Donald Quest, Chair
David Piepgras
Volker Sonntag
L. Nelson Hopkins, III
Ralph Dacey, Jr.
Warren Selman
Marc Mayberg

Subcommittee on Corresponding Membership:

Edward Laws, Jr., Chair
Ralph Dacey, Jr.
Michael Apuzzo

Nominating Committee:

David Piepgras
Volker Sonntag
Martin Camins

Scientific Program Committee:

James Rutka, Chair
Fredric Meyer
Stephen Papadopoulos

Round Robin Editor:

L. Nelson Hopkins, III

Local Arrangements:

Mario Brock – Berlin
Gabriele Schackert – Dresden

AANS Joint Sponsorship Education Representative:

Richard Morawetz

WFNS Delegates:

Roberto Heros – Senior
Volker Sonntag – Alternate

A Special Thank You to

CARL ZEISS SURGICAL, INC

and

MEDTRONIC SOFAMOR DANEK

and

MEDTRONIC NEUROLOGIC

TECHNOLOGIES

for providing educational grants in support of the

2004 Annual Meeting of the

American Academy of Neurological Surgery

GENERAL INFORMATION

REGISTRATION DESK LOCATION AND HOURS:

October 3-4, 2004, Berlin

Four Seasons Lobby

Sunday, October 3

1:00 pm – 6:30 pm

Monday, October 4

7:00 am – 1:00 pm

October 5-8, 2004, Dresden

Kempinski Hotel Taschenbergpalais

Lobby

Tuesday, October 5

1:30 pm – 7:00 pm

Wednesday, October 6

6:30 am – 1:00 pm

Thursday, October 7

6:30 am – 1:00 pm

HOTEL INFORMATION

October 3-4, 2004

Four Seasons Hotel Berlin

Charlottenstrasse 49

D-10117 Berlin

Germany

Phone: 011-49-30 20 33 8

FAX: 011-49-30 20 33 61 66

October 5-8, 2004

Kempinski Hotel Taschenbergpalais

Taschenberg 3

D-01067 Dresden

Germany

Phone: 011-49-351 49 12 0

FAX: 011-49-351 49 12 812

PROGRAM SUMMARY

SUNDAY, OCTOBER 3

EVENTS	TIME	LOCATION
Registration	1:00 pm – 6:30 pm	Four Seasons Lobby
Executive Committee Meeting	4:30 pm – 6:30 pm	Hofgarten I

OPENING RECEPTION

Drinks and heavy hor d'oeuvres	6:30 – 9:30 pm	Gontard & Langhans Rooms
--------------------------------	----------------	--------------------------

MONDAY, OCTOBER 4

EVENTS	TIME	LOCATION
Registration	7:00 am – 1:00 pm	Four Seasons Lobby
Scientific Session	8:00 am – 12:00 pm	Gontard Room

OTHER ACTIVITIES

Guided bus tour of Berlin	1:00 pm – 4:30 pm	Depart from lobby of Four Seasons Hotel
---------------------------	-------------------	---

Individual evening plans

PROGRAM SUMMARY

TUESDAY, OCTOBER 5

EVENT	TIME	LOCATION
Bus transportation to Dresden	10:30 am	Departing from Four Seasons Lobby
Arrival at Kempinski Hotel Taschenbergpalais	1:30 pm	
Registration	1:30 pm – 7:00 pm	Taschenbergpalais Lobby
Scientific Session	2:30 pm – 6:45 pm	Kurfürstensaal A
Opening Reception	7:00 pm – 10:00 pm	Bel Etage

PROGRAM FOR SPOUSES

Afternoon Tea	2:30 pm	Bel Etage
---------------	---------	-----------

OTHER ACTIVITIES

Golf	1:30 pm	Elbflorence course
Tennis	1:30 pm	Tennis Club "Blau Weiß Dresden e.V."

PROGRAM SUMMARY

WEDNESDAY, OCTOBER 6

EVENT	TIME	LOCATION
Registration	6:30 am – 1:00 pm	Hotel Lobby
Business Breakfast Meeting <u>For American Academy Members Only</u>	7:30 am – 8:30 am	Kurfürstensaal B
Guest/Spouse Breakfast	7:30 am – 9:00 am	Bel Etage
Scientific Session	8:30 am – 12:30 pm	Kurfürstensaal A
Snack Buffet	5:00 pm – 6:30 pm	Bel Etage

OTHER ACTIVITIES

Bus tour of town of Meissen & Meissen Porcelain Factory	8:30 am – 1:00 pm	Depart from hotel lobby
Walking tour through heart of Dresden	2:00 pm – 4:30 pm	Depart from hotel lobby
Golf	1:30 pm	Elbflorence course
Tennis	1:30 pm	Tennis Club "Blau Weiß Dresden e.V."

OFFSITE EVENT

Semper Opera Performance Of Beethoven's "Fidelio"	7:00 pm – 9:45 pm	Within walking distance (2-5 minutes)
---	-------------------	---------------------------------------

PROGRAM SUMMARY

THURSDAY, OCTOBER 7

EVENT	TIME	LOCATION
Registration	6:30 am – 1:30 pm	Hotel Lobby
Business Breakfast Meeting <u>For American Academy Members Only</u>	7:30 am – 8:30 am	Kurfürstensaal B
Guest/Spouse Breakfast	7:30 am – 9:00 am	Bel Etage
Scientific Session	8:30 am – 12:30 pm	Kurfürstensaal A
Presidential Address And Concluding Remarks	12:15 pm – 1:00 pm	Kurfürstensaal A

OTHER ACTIVITIES

Walking tour of Old Masters Gallery of Arts Or Walking tour of Museum of the Green Vault Treasury	9:00 am – 11:00 am	Depart from hotel lobby
Presidential Address	12:15 pm – 1:00 pm	Kurfürstensaal A
Bus tour of baroque hunting lodge, Schloss Moritzburg	1:30 pm – 4:30 pm	Depart from hotel lobby
Golf Tennis	1:30 pm 1:30 pm	Elbflorence course Tennis Club "Blau Weiß Dresden e.V."

DINNER

Cocktail reception	7:00 pm – 7:30 pm	Residence Castle
Black Tie Dinner and Dance	7:30 pm – 10:00 pm	Residence Castle (Within walking distance, 2-5 minutes)

PROGRAM SUMMARY

FRIDAY, OCTOBER 8

EVENT	TIME	LOCATION
Breakfast for members, guests, and spouses	7:30 am – 10:00 am	Bel Etage

SOCIAL ACTIVITIES FOR SPOUSES

The spouses of the American Academy members and guests are welcome to attend all events.

Sunday, October 3

6:30 pm – 9:30 pm

Opening Reception at Four Seasons Hotel, Rooms Gontard & Langhans (drinks and heavy hor d'oeuvres)

Monday, October 4

1:00 pm – 4:30 pm

*Guided bus tour of Berlin. Tour will depart from the lobby of the Four Seasons Hotel. Casual clothes are recommended

Individual evening plans

Tuesday, October 5

10:30 am

*Bus transportation to Dresden (3 hours)

1:30 pm

Arrival at Kempinski Hotel Taschenbergpalais

2:30 pm

Afternoon tea at Bel Etage

7:00 pm – 10:00 pm

Opening reception at Bel Etage

Wednesday, October 6

7:30 am – 9:00 am

Guest/spouse breakfast at Bel Etage

8:30 am – 1:00 pm

*Guided bus tour to the 1000-year-old town of Meissen (includes a guided tour of the renowned Meissen Porcelain Factory) Departs from hotel lobby

1:30 pm

*Golf at Elbflorence Course or Tennis at Tennis Club "Blau Weiß Dresden e.V."

2:00 pm – 4:30 pm

*Guided walking tour through historical heart of Dresden, including Royal Palace, the Zwinger, and the Catholic Court Church. Departs from hotel lobby.

5:00 pm – 6:30 pm

Snack buffet at Bel Etage

7:00 pm – 9:45 pm

*Semper Opera Performance of Beethoven's "Fidelio"

Thursday, October 7

7:30 am – 9:00 am

Guest/spouse breakfast at Bel Etage

9:00 am – 11:00 am

*Guided walking tour of the Old Masters Gallery of Arts

or

*Guided walking tour of the Museum of the Green Vault Treasury. Departs from hotel lobby.

12:15 pm – 1:00 pm

Presidential Address

1:30 pm

*Golf at Elbflorence Course or Tennis at Tennis Club "Blau Weiß Dresden e.V."

1:30 pm – 4:30 pm

*Guided bus tour to the baroque hunting lodge, Schloss Moritzburg, 18th century residence of King August the Strong during hunting season. Departs from hotel lobby.

7:00 pm – 7:30 pm

Cocktail reception at Residence Castle (within walking distance)

7:30 pm – 10:00 pm

Black Tie Dinner and Dance at Residence Castle

Friday, October 8

7:30 am – 10:00 am

Breakfast for all members, guests, spouses at Bel Etage

* Activities require prior registration.

SCIENTIFIC PROGRAM AMERICAN ACADEMY OF NEUROLOGICAL SURGERY 2004 LEARNING OBJECTIVES

Jointly sponsored by The American Association of Neurological Surgeons,
October 3-8, 2004.

Upon completion of this program, the participants should be able to:

1. Critique the value of surgical and non-surgical options presented in the scientific papers.
2. Evaluate the relevance of research methodologies and the findings and potential usefulness in practice of the topics presented for cerebrovascular, neoplastic, spinal, and developmental and functional nervous system diseases.



American
Association of
Neurological
Surgeons

This activity was planned and implemented in accordance with the essentials and standards of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of the American Association of Neurological Surgeons and the American Academy of Neurological Surgery. The American Association of Neurological Surgeons is accredited by the ACCME to sponsor continuing medical education for physicians.

The American Association of Neurological Surgeons designates this educational activity for a maximum of 14 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits actually spent in the educational activity.

DISCLOSURE INFORMATION

The American Association of Neurological Surgeons and The American Academy of Neurological Surgery control the content and production of this CME activity and attempt to assure the presentation of balanced, objective information. In accordance with the Standards for Commercial Support established by the ACCME speakers and paper presenters are asked to disclose any relationship they or their co-authors have with commercial companies which may be related to the content of their lecture.

Speakers and paper presenters/authors who have disclosed a relationship* with commercial companies whose products may have a relevance to their presentation are listed below.

<u>Faculty Name</u>	<u>Disclosure</u>	<u>Type of Relationship</u>
Canute, GW	Inclone Systems, Inc.	Stock Shareholder
Fessler, RG	Medtronic Sofamor Danek	Consultant
Haid, R	MDT; Johnson & Johnson	Stock Shareholder
Kalfas, IH	Z-KAT	Consultant
Levy, EI	Boston Scientific; Cordis Corporation Cordis Corporation	Grants/Research Support Consultant
Macdonald, RL	Corporate Organization NIH; American Heart Assoc. Actelion Pharmaceuticals, Brainsgate	Affiliation/Financial Interest Grants Consultant
Rosenwasser, RH	Corporate Organization	Affiliation\Financial Interest
Spetzler, RF	Medtronic, Zeiss Synergetics Allegiance, Portal Vision	Consultant Stock Shareholder Financial/Material Support

*Relationship refers to receipt of royalties, consultantship, funding by research grant, receiving honoraria for educational services elsewhere, or any other relationship to a commercial company that provides sufficient reason for disclosure.

Speakers and their paper presenters/authors who have reported they do not have any relationships with commercial companies:

Faculty Name

Barnett, GH	Krauss, WE
Black, P	Lawton, MT
Bricolo, A	Leuthardt, E
Brotchi, J	Lonser, RR
Carmel, PW	Olivi, A
Chandler, WF	Oyesiku, NM
Couldwell, WT	Robertson, JH
Dempsey, RJ	Shaffrey, ME
Flamm, ES	Shields, CB
Harbaugh, RE	Young, AB
Hodge, C	Zager, EL
Hudson, AR	

Speakers and their paper presenters/authors who have refused to disclose whether they have any relationships with commercial companies:

Faculty Name

None

Speakers who have disclosed that their presentations will include discussion of an off-label or investigational drug or device:

Faculty Name

Canute, GW
Haid, R

SCIENTIFIC PROGRAM
American Academy of Neurological Surgery Annual Meeting
Jointly Sponsored by the American Association of Neurological Surgeons
Berlin, Germany
October 3-5, 2004

MONDAY, OCTOBER 4	BERLIN <i>American Academy Members</i>
8:00-10:00 am	Scientific Paper Presentations, Moderator: Jim Rutka
8:00-8:15 am	Recent Developments in Image-Guided Minimally Invasive Neurosurgery. <u>Peter Black</u> , R Kinkinis, E Claus, A Golby, D Oh, F Jolesz
8:15-8:30 am	Molecular Targeting, and Imaging of Nonfunctional Pituitary Tumors. <u>Nelson M. Oyesiku</u>
8:30-8:45 am	Cancer Care Ontario Policies Regarding Malignant Brain Tumors. <u>Alan R Hudson</u> , T Sullivan, JT Rutka, H-P Richter
8:45-9:00 am	The Treatment of Advanced Sinonasal Malignancies with Preoperative Intra-arterial Cisplatin and Concurrent Radiation. <u>Jon H Robertson</u> , LM Michael, S Samant
9:00-9:15 am	Surgery of Brainstem Gliomas. <u>Albino Bricolo</u>
9:15-9:30 am	Surgical Strategy in Spinal Cord Hemangioblastomas. Experience in 30 Cases. <u>Jacques Brotchi</u> , F Lefranc

MONDAY, OCTOBER 4 (continued)

- 9:30-9:45 am Cyclooxygenase 2 (COX-2) is Ubiquitously Expressed in Meningiomas and Treatment in Vitro with the COX-2 Inhibitor Celecoxib Decreases Cell Growth: Potential Therapeutic Application. BT Ragel, RL Jensen, William T Couldwell
- 9:45-10:00 am Deficiency in Low-density Lipoprotein Receptor-related Protein (LRP) Expression Favors a More Invasive Glioblastoma Growth Phenotype. M Mut, MD Brown, JE Carpenter, GT Redpath, SR Vanderberg, M-B S Lopez, IM Hussaini, Mark E Shaffrey
- 10:00-10:30 am *Beverage Break*
- 10:30-11:00 am **Special Academy Lecture**
Berlin: 14 Years After Unification and 767 Years After Its Foundation.
Ambassador Leopold-Bill von Bredow,
to be introduced by Mario Brock
- 11:00 am -12:00 pm **Scientific Paper Presentations, Moderator:**
Steve Papadopoulos
- 11:00-11:15 am Mechanisms of Cortical Reorganization: An Experimental Study. Charles Hodge,
A Siddiqui, J Dubrof, R Stevens,
J McCasland
- 11:15-11:30 am Avoiding Mount Everest - Assessing the Risks of Cerebral Aneurysms and Their Treatment. Eugene S Flamm
- 11:30-11:45 am Unilateral Intraputaminal GDNF Improves Bilateral Motor Functions in Patients with Parkinson's Disease. JT Slevin, GA Gerhardt, CD Smith, DM Gash, R Kryscio, A Byron Young

MONDAY, OCTOBER 4 (continued)

11:45 am-12:00 pm

Human Dorsal Root Ganglion Neurons
as Live Nerve Constructs: Implications
for Transplantation. Eric L Zager,
JH Huang, EM Wilensky,
BJ Pfister, DH Smith

SCIENTIFIC PROGRAM

**Joint Meeting of the American Academy of Neurological Surgery, the
German Academy of Neurosurgery and the German Society of
Neurosurgery, Dresden, Germany
October 5-8, 2004**

TUESDAY, OCTOBER 5

DRESDEN

2:30-2:45 pm

Reflections on Joint Meetings Between the
American Academy of Neurological
Surgery and German Neurosurgeons.
Rudolf Fahlbusch

2:45-4:30 pm

Scientific Paper Presentations,
Moderators: Jim Rutka, Hans-Peter Richter

2:45-3:00 pm

Cortical and Striatal Migration of
Endogenous Adult Stem Cells from the
Sub-ventricular Zone and Posterior Peri-
ventricular Region in Response to
Stroke. Robert J Dempsey, KA Sailor

3:00-3:15 pm

Genetic Variants of Matrix
Metalloproteinase Genes and Their Inhibitors
in Patients with Intracranial Aneurysms.
Dietmar Krex, IR König, A Ziegler, HK
Schackert, G Schackert

3:15-3:30 pm

Downregulation of Potassium Channels
After Subarachnoid Hemorrhage: A
Possible Mechanism for Cerebral
Vasospasm. BS Jahromi, Y Aihara,
G Weyer, E Nikitina, M Agbaje-Williams,
D Ryan, R Yassari, Robert Loch Macdonald

3:30-3:45 pm

Prospective Evaluation of Surgical
Microscope Based Indocyanine Green
Video Angiography in Aneurysm Surgery.
Andreas Raabe, P Nakaji, J Beck, J
Kammerman, V Seifert, RF Spetzler

TUESDAY, OCTOBER 5 (continued)

- 3:45-4:00 pm **Multivariate Analysis of a Consecutive Prospective Series of Carotid Endarterectomies.** Robert E Harbaugh, A Agarwal, V Chinchilli
- 4:00-4:15 pm **A Phase IIa, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Tolerability of the Selective Endothelin A (ETA) Receptor A Antagonist Clazosentan (AVX-034343) for the Prevention of Cerebral Vasospasm, Following Severe Aneurysmal Subarachnoid Hemorrhage (aSAH).** Bernhard Meyer for the Axovan Study Group
- 4:15-4:30 pm **Endovascular Management of Intracranial Aneurysms: An Experience of 1321 Aneurysms in 1101 Patients: Single Center Experience.** Robert H Rosenwasser, E Veznedaroglu, S Whang
- 4:30-4:45 pm *Beverage Break*
- 4:45-6:45 pm **Scientific Paper Presentations,**
Moderators: Gabriele Schackert, Steve Papadopoulos
- 4:45-5:00 pm **Susceptibility of Murine Neural Stem Cells and of Tumor Cells to Respond to Regenerative Signals of Axolotl Tissue.** Matthias Kirsch, E Schnapp, S Lydia, E Tanaka, P Weigel, G Schackert, HK Schackert
- 5:00-5:15 pm **Local Delivery of a Fragment of Human Endostatin Combined with Systemic Administration of BCNU Prolongs Survival in a Rodent Experimental Glioma Model.** Alessandro Olivi, FG Legnani, G Pradilla, BM Tyler, F Chillemi, F Di Meco

TUESDAY, OCTOBER 5 (continued)

- 5:15-5:30 pm Expression of Hypoxia-inducible
Carbonic Anhydrases in Brain Tumors.
Martin Proescholdt, C Mayer, M Merrill, A
Brawanski
- 5:30-5:45 pm Anti-EGFR Monoclonal Antibody
Cetuximab Augments Radiation and
Chemotherapeutic Effects in Glioblastoma
Multiforme *in vitro* and *in vivo*. JL Eller,
SL Longo, MM Kyle, D Bassano, DJ
Hicklin, Gregory W Canute
- 5:45-6:00 pm Multicentric Phase III Study, Fluorescence-
guided Resection of Malignant Gliomas
with 5-ALA: Preliminary Results on Interim
Analysis of 270 Assessable Patients. Walter
Stummer, T Meinel, the ALA-Glioma Study
Group, U Pichlmeier, OD Wiestler, FE
Zanella, HJ Reulen
- 6:00-6:15 pm Is Gross Total Resection Sufficient
Treatment for Posterior Fossa
Ependymoma? L Rogers, J Pueschel, Robert
Spetzler, W Shapiro, S Coons, T Thomas,
B Speiser
- 6:15-6:30 pm Management of Optic Nerve Sheath
Meningiomas. U Schick, Werner Hassler
- 6:30-6:45 pm The Role of Endogenous Growth
Hormone-Releasing Hormone (GHRH) in
Acromegaly. William F Chandler,
EV Dimaraki, AL Barkan, MB Brown,
V Padmanabhan, SY Kim, R Taussig

WEDNESDAY, OCTOBER 6 DRESDEN

- 8:30–9:15 am **Point - Counterpoint Debate**
Intraoperative MRI, Gimmick or Godsend?
Robert Spetzler and Rudolf Fahlbusch
- 9:15-10:30 am **Scientific Paper Presentations**
Moderators: William Couldwell, Johannes Schramm
- 9:15-9:30 am Selection of the Optimal Entry Zone to the Brain Stem for Removal of Intraaxial Cavernous Angiomas. Helmut Bertalanffy
- 9:30-9:45 am The Synthetic ACDF: Experience with Rh-BMP-2 and Peek Cages. Regis Haid, P Mummaneni, G Rodts, M Boakye
- 9:45-10:00 am Role of EphB4 Signaling in the Regulation of Vascular Morphogenesis and Vascular Permeability in Malignant Glioma. Peter Vajkoczy, R Erber, U Eichelsbacher, V Powajbo, P Knyazev, A Ullrich
- 10:00-10:15 am Gamma Knife Radiosurgery in the Management of Glomus Tumors—A Volumetric Study of 17 cases. Gene H Barnett, A Varma, JH Suh, J Ross
- 10:15-10:30 am Intraoperative Functional MRI. First Results and Technical Considerations. Thomas Gasser, D Stolke, R Fahlbusch, C Nimsky
- 10:30–10:45 am *Beverage Break*
- 10:45–12:30 pm **Scientific Paper Presentations**
Moderators: James Rutka, Dietmar Stolke
- 10:45-11:00 am Sirolimus-Eluting Stents in the Canine Cerebral Vasculature: Assessment of Safety Profile and Vessel Response. Elad I Levy, RA Hanel, AS Boulos, FO Tio, AM Paciorek, KS Kagan-Hallet, MD Fronckowiak, LR Guterman, LN Hopkins

WEDNESDAY, OCTOBER 6 (continued)

- 11:00-11:15 am **Brain Tumor Surgery in the Vicinity of Short-Term Memory Representation— Results of Neuronavigation using fMRI Images.** Veit Braun, A Albrecht, A Wunderlich, H-P Richter
- 11:15-11:30 am **Fiber Tract Deformation as Visualized with Sequential Acquisitions of 3D-Ultrasound (3DUS) During Intracranial Surgery.** Volker A Coenen, T Krings, J Weidemann, FJ Hans, P Reinacher, JM Gilsbach, V Rohde
- 11:30-11:45 am **German Society First Prize Award - (Wilhelm Tönnis Preisträger) Mechanical Response of a Cervical Spine Motion Segment on Removing a Local Autograft.** Tobias Pitzen, CJ Kempf, WI Steudel, TR Oxland
- 11:45 am-12:00 pm **American Academy Honorable Mention Award**
Selective Ablation of Vanilloid Receptor 1 Positive Nociceptive Neurons for Elimination of Hyperalgesia and Neuropathic Pain. Russell R Lonser, GC Tender, S Walbridge, Z Olah, L Karai, M Iadarola, EH Oldfield
- 12:00-12:15 pm **German Academy First Prize Award**
Identification of Brain Tissue Necrosis by MRI: Validation by Histomorphometry. Michael Stoffel, C Blau, H Reinl, J Breidt, K Gersonde, A Baethmann, N Plesnila
- 12:15-12:30 pm **American Academy Award**
Achieving a Multidimensional Brain Computer Interface in Humans Using Electrographic Signal. Eric Leuthardt, G Schalk, JR Wolpaw, JG Ojemann, DW Moran

THURSDAY, OCTOBER 7

DRESDEN

8:30–9:15 am

Point - Counterpoint

The Fate of the Academic Neurosurgeon,
Viewpoints from the United States: Peter Black, and Germany: Hans-Peter Richter

9:15–10:45 am

Scientific Paper Presentations

Moderators: Steve Papadopoulos,
Hansdetlef Wassman

9:15-9:30 am

Clinical Outcome Following
Transforaminal Lumbar Interbody Fusion
(TLIF): One Year Follow-up of Prospective
Data. Richard G Fessler

9:30-9:45 am

Transgenic Arteriovenous Fistula in the Rat:
An Experimental Model of Gene Therapy
for Brain Arteriovenous Malformations.
Michael T Lawton, C Stewart, AWulfstat,
N Derugin, T Hashimoto, W Young

9:45-10:00 am

Application of Image-Guided Spinal
Navigation to Decompression and Internal
Fixation of the Upper Cervical Spine. Iain H Kalfas

10:00-10:15 am

Laboratory Testing of an Implantable
Microsensor System for Intraoperative 3D-
Computer Animation of Vertebral Body
Motion in Cervical Spinal Surgery.
Olaf Stüss, T Kombos, S Schönherr, S
Mularski, B Kühn, M Brock

10:15-10:30 am

Transthoracic Discectomy Without
Interbody Fusion. D Edwards,
A Cohen-Gadol, William E Krauss

10:30-10:45 am

Treatment of Spinal Cord Injury Via
Topical Perfusion with an ATP Solution.
Christopher B Shields, YP Zhang, S Chien,
Y Han, LBE Shields, M Li, B Chiang,
DA Burke

THURSDAY, OCTOBER 7 (continued)

10:45–11:00 am

Beverage Break

11:00 am –1:00 pm

Scientific Paper Presentations

Moderators: Joachim Gilsbach, James Rutka

11:00-11:15 am

IOMaster 7D, a New Device for Virtual Neuroendoscopy. Christos Trantakis, J Meixensberger, G Strauß, E Nowatius, D Lindner, HK Cakmak, H Maaß, C Nagel, U Kühnapfel

11:15-11:30 am

Fedor Krause, The Krause Operations, and Krause's Impact on American Neurosurgeons. Pctcr W Carmel, M Buchfelder

11:30-11:45 am

Diffusion Tensor Imaging for 3-D Fiber Tract Visualization in Navigated Glioma Surgery. Christopher Nimsky, O Ganslandt, AG Sorensen, R Fahlbusch

11:45 am -12:00 pm

Changes of the Astrocytic Matrix and Reappearance of Radial Glia in Hippocampi of Patients Suffering From Temporal Lobe Epilepsy. Thomas M Freiman, J Eismann, M Frotscher, J Zentner

12:00-12:15 pm

Surgical Treatment of Hemispheric Intractable Epilepsy in Childhood With Functional Hemispherectomy or Peri-insular Hemispherectomy. Falk Oppel, V Zountsas, HW Pannek

12:15 – 1:00 pm

Presidential Address:

Volker Sonntag, *to be introduced by Bill Chandler*

1:00 pm

Concluding Remarks: Rudolf Fahlbusch, Volker Sonntag, Dietmar Stolke

Meeting Adjournment

MONDAY PROGRAM

MONDAY, OCTOBER 4

8:00 – 8:15 AM

Recent Developments in Image-guided Minimally Invasive Neurosurgery

Peter Black, R Kikinis, E Claus, A Golby, D Oh, F Jolesz

Image-guided minimally invasive techniques have significantly changed the approach to brain tumor surgery at our institution. Diffusion tensor imaging has allowed the routing anatomical mapping of fibre tracts. Functional MR with new paradigms especially created for pre-surgical planning has extended our understanding of brain function. Mathematical models have created new understandings of what factors are responsible for deficits after surgery for low-grade gliomas. Outcome analysis has begun to define what lesions are best for what technique.

These new developments now can begin to define the appropriate role of intraoperative imaging opposed to image-guided surgery in the traditional operating room. Using an experience of 240 frameless stereotactic cases and 640 intraoperative MR cases, the senior author will develop these themes to begin to present a comprehensive scheme for the use of image-guided techniques in neurosurgical oncology.

MONDAY, OCTOBER 4

8:15 – 8:30 AM

Molecular Targeting and Imaging of Nonfunctional Pituitary Tumors

Nelson M. Oyesiku

Introduction/Objectives: Our long-term goal is to determine molecular pathogenesis of pituitary tumors and to exploit these insights for diagnostic and therapeutic benefit. We have identified new molecular targets in these tumors and have developed a novel molecular-targeted imaging agent – Folatescan, to identify them.

Methods: Tumor specimens from surgery were used in the molecular and cell-culture studies. GeneChip arrays were performed and verified by RT-qPCR. Western analysis, immunochemistry and folate-binding studies were performed to determine folate expression. Cell culture and cytotoxicity studies were performed with MTT assays. In vivo imaging was performed by injection of Folatescan followed by planar and SPECT/CT imaging.

Results: Several genes, including GATA3, GATA2, PITX2, HLF, SMARCD3, and Histone deacetylase HD1 were upregulated in non-functional pituitary adenomas. The cyclin-dependent kinase inhibitor 1C (p57, Kip2), insulin-like growth factor binding protein 3 (IGFBP3), and frizzled homolog 7 (FZD7) were strongly downregulated in non-functional pituitary adenomas. In particular the folate-receptor (FR) was significantly and uniquely upregulated in nonfunctional pituitary adenomas. Folatescan successfully imaged folate receptor expressing tumors and was validated by Westerns. Similarly, non-FR expressing tumors were not imaged by Folatescan. Folate-targeted liposomes containing doxorubicin induced cell-death in folate-receptor expressing pituitary tumors in vitro, as measured by MTT assays.

Conclusions: These preliminary data demonstrate that Folatescan can successfully target FR+ pituitary tumors and provide preliminary evidence that folate can be used as a delivery system for successful tumor-targeted delivery of drugs into non-functional pituitary tumors opening the possibility of novel chemotherapy and molecular imaging of these tumors.

Cancer Care Ontario Policies Regarding Malignant Brain Tumors

Alan R Hudson, T Sullivan, JT Rutka, H-P Richter

Canada spends 10% of GDP on health. Ontario has the largest population of any Province (State) in Canada. The total Ontario health budget is \$27 Billion.

The Ontario Provincial Government pays for all its hospitals, physicians, nurses, drugs and radiotherapy from its tax income. Cancer Care Ontario (CCO) advises the Provincial Government on spending \$2 Billion on Oncology Services in Ontario. The Ontario Cancer Registry compiles data on all patients suffering from malignancy. No consent is required. CCO has access to all Ontario surgical billing and, hence, has the ability to link the billing data base with the Cancer Registry, and other data bases in the Province, provided privacy legislation is not contravened.

Cancer surgery is practiced in a dispersed system throughout Ontario, in non-teaching and teaching hospitals. Neurosurgery is an exception, with concentration of service provision to a limited number of facilities. Radiation of malignant neurosurgical disease is confined to specific centres in the Province and CCO has recently integrated these units with their adjacent general hospitals. Drug therapy for malignancy is provided at a wide array of sites.

This paper will present the Provincial policies underlying provision of neurosurgical treatment of malignancies in virtual regional networks, and will provide detailed numerical information concerning neurosurgical malignancy traffic patterns in a population of 12 million people. These policies and delivery systems will be compared to cancer policies and practices in Germany.

MONDAY, OCTOBER 4

8:45 – 9:00 AM

The Treatment of Advanced Sinonasal Malignancies with Preoperative Intra-arterial Cisplatin and Concurrent Radiation

Jon H. Robertson, LM Michael, S Samant

Malignancies of the nasal and paranasal sinuses are uncommon tumors, accounting for only 3% of all aerodigestive tract neoplasms and less than 1% of all malignant diseases. For many years, the treatment of paranasal carcinomas consisted of surgery via a transfacial approach +/- radiation therapy. Despite significant procedural progress since the 1950's, 5-year survival for sinonasal tumors remains less than 50%. Even less encouraging results are found in more advanced disease (T3 and T4 stage), with 5-year survival being 7% to 29% for T4 cancers. The major cause of death is locoregional failure with a small minority of patients succumbing to distant metastases.

Between July 1996 and August 2003, eleven patients with advanced sinonasal malignancies (T3 and T4 stage) underwent treatment utilizing neoadjuvant selective intra-arterial cisplatin with concurrent radiation therapy (RADPLAT) followed by a planned surgical resection via a craniofacial approach at the University of Tennessee Health Science Center in Memphis. Patient charts, operative notes, histopathological studies, follow-up clinic notes, and pre- and post-operative imaging studies were reviewed in detail for each patient.

Histopathological analysis of the tumors revealed 7 squamous cell carcinomas (64%), 2 adenocarcinomas (18%), 1 adenoid cystic carcinoma (9%), and 1 sinonasal undifferentiated carcinoma (9%). There was a clear sex predilection, with a higher incidence among males (81%).

T4N0M0 disease was present in 9 patients (81%), and two patients had T3N0M0 disease (19%). Staging was performed using the American Joint Committee Classification for Cancer Staging and End Result Reporting (5th Edition, 1997). No patients harbored node-positive disease, as this was felt to be a relative contraindication for surgical resection.

Nine of the eleven patients (81%) included in the study are alive at present and eight (72%) have no evidence of disease. Mean follow-up is 58.7 months ranging from 10 months to 94 months. Only one patient (9%) developed a major complication as a result of radiation necrosis. The only minor complication was related to the chemotherapeutic regimen. Excellent functional status was preserved in all of the patients.

The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation results in significant improvement in survival. This can be done safely with superb cosmetic results, high response rates, and excellent loco-regional control in T3 and T4 disease. Although our results are encouraging, there is a need for a cooperative, multi-institutional, prospective study.

MONDAY, OCTOBER 4

9:00 – 9:15 AM

Surgery of Brainstem Gliomas

Albino Bricolo

Background: For many years gliomas growing inside the brainstem were considered malignant in themselves and managed homogeneously by radiation therapy with disappointing results. In the last two decades a series of favorable concomitant factors made this pathology more accessible for direct surgery. Based on MRI brainstem glioma can now be categorized in four groups (focal, cervico-medullary, dorsally exophytic and diffuse) which reflect different growth patterns and assist in selecting those amenable for surgery.

Method and results: Since 1982 we have treated 230 brainstem gliomas (1, 2, 3) by using direct surgery designed for extensive or possibly total excision. The majority (163) were focal and benign astrocytomas (128), whereas almost all the 67 diffuse tumors (92%) were malignant. A gross total removal was achieved in 74% of the 163 focal low-grade gliomas, while in only 4% of the 67 diffuse high-grade gliomas. Overall results were favorable: 85% of the patients with focal low-grade astrocytomas had a good outcome and resumed normal life; 70% of the patients with malignant gliomas died during the follow-up period (mean 7.1 years). The main problem in direct surgery is how to reach and remove the tumor avoiding damage in highly critical places such as corpora quadrigemina, facial colliculi, medial longitudinal fasciculus and calamus scriptorius. Suitable safer entry zones for entering the brainstem have been identified and their introduction correlated with a decrease in surgically-related morbidity.

Conclusions: (a) a number of brainstem gliomas are focal masses that dislocate nervous structures without invading them; (b) the brainstem can be surgically violated with low risk by entering it through safer entry zones; and (c) direct microsurgery can obtain complete removal of many brainstem gliomas with good results and even permanent cure.

Surgical Strategy in Spinal Cord Hemangioblastomas. Experience in 30 Cases

Jacques Brotchi, F Lefranc

The complete removal of spinal cord hemangioblastomas (SCH) must be a neurosurgeon's ultimate goal. We have tried to draw up a simple topographic classification in order to achieve this goal with respect to patients' preoperative neurological status.

We have classified the lesions in three topographical categories:

- A. Subpial posterior and postero-lateral SCH (n=15)
- B. Small subpial lateral or anterior-sided SCH (9 lateral, 1 anterior)
- C. Pure intramedullary SCH (n=5)

Different surgical approaches related to topographic classification were used:

- A. Classical "en-bloc" resection with careful dissection of the lesion from spinal cord.
- B. A tense syringomyelic cyst, which was present in all the cases, was aspirated with a 22G needle, so deflating the spinal cord and giving an easy access to the solid nodular tumor either when it was lateral or even anterior.
- C. When the hemangioblastoma was not visible we opened the posterior *sulcus* along the midline using the same procedure as for any other intramedullary spinal cord tumor.

Complete surgical removal was achieved in all cases except in one previously operated upon twice and irradiated in another institution. Improvement was observed in 18, stabilization in 10 and worsening in 2 patients. The results were closely related to the pre-operative status. Patients with a good pre-operative neurological status or harboring a large cystic cavity had a better prognosis than others.

Cyclooxygenase 2 (COX-2) Is Ubiquitously Expressed in Meningiomas and Treatment in Vitro with the COX-2 Inhibitor Celecoxib Decreases Cell Growth: Potential Therapeutic Application

BT Ragel, RL Jensen, William T Couldwell

Introduction: Meningiomas are the second most common primary central nervous system tumor in adults. Epidemiologic data suggest a causal relationship with a history of head trauma. Cyclooxygenase-2 (COX-2), an inducible inflammatory enzyme, converts arachidonic acid to prostaglandins, which have angiogenic, anti-apoptotic, and cell proliferative effects. Human meningioma tumors show extensive immunohistochemical staining for COX-2. The authors investigated the effects of celecoxib, a COX-2 inhibitor, on meningioma cell growth in vitro.

Methods: Human meningioma surgical specimens were immunohistochemically stained for COX-2, HIF-1 alpha, and vascular endothelial growth factor (VEGF). Six fields in each tumor were graded from 0 to 4. Human meningioma cells grown in cell culture were treated with vehicle (0.1% DMSO) or celecoxib (0.25mM – 1.00mM). Cell viability assays (MTT), TUNEL apoptosis assays, and FACS analysis were performed.

Results: Eighty-seven percent (111/128) of benign meningiomas and 86% (6/7) of atypical meningiomas had high COX-2 immunoreactivity (grade 4). COX-2 was not correlated with HIF-1alpha or VEGF. Celecoxib inhibited cell growth in a dose-dependent fashion and induced apoptosis by day 2. FACS analysis showed that 74% of treated cells were in G1 cell-cycle phase versus 67% of the control group.

Conclusion: COX-2 is universally expressed in the cytoplasm of meningiomas but not correlated with markers of hypoxia (HIF-1 alpha) or angiogenesis (VEGF). The absence of correlative findings is probably a result of the overall high level of COX-2 staining. Celecoxib inhibits meningioma growth in vitro in a dose-dependent fashion, with evidence of apoptosis and a G1 cell-cycle arrest. COX-2 inhibitors may have a role in the treatment of recurrent meningiomas.

Deficiency in Low-density Lipoprotein Receptor-related Protein (LRP) Expression Favors a More Invasive Glioblastoma Growth Phenotype

M Mut, MD Brown, JE Carpenter, GT Redpath, SR Vanderberg, M-B S Lopez, IM Hussaini, Mark E Shaffrey

Low-density lipoprotein receptor-related protein (LRP) mediates the endocytosis of a wide variety of ligands that are upregulated with anaplasia (including urokinase and urokinase-type plasminogen activator receptors) and is implicated in cellular growth, adhesion, and proteinase catabolism. Epidermal growth factor treatment in astrocytomas significantly reduces total and cell surface LRP. Functional effects of LRP elimination and overexpression in U-1242 human glioblastoma multiforme cells were assessed. LRP-deficient GBM cells (L α -42) were prepared from U-1242, which were transfected with the antisense constructs. LRP in L α -42 was completely eliminated (Western blot). LRP-expressing U-1242 cells were transfected with the LRP gene (L δ -32 clones) and 3-4 times greater expression of LRP was confirmed (Western blot). Non-transfected U-1242 cells (ntU-1242) have intermediate LRP expression. In vitro, L α -42 invaded fibrin-coated transwell membranes more than ntU-1242, and urokinase neutralizing antibody reduced the invasiveness of the L α -42 to control levels. Gelfoam® three-dimension cultures of L α -42, ntU-1242 and L δ -32 clones were implanted in the brains of mice (n=30) and tumor growth were assessed at 5 and 9 weeks. At 5 weeks, L α -42 presented a faster growth pattern, ntU-1242 cells showed an intermediate growth pattern without apparent invasion. L δ -32 did not have apparent tumor growth. At 9 weeks, L α -42 showed a diffusely invasive pattern with comparably larger tumors. LRP expressing clones (ntU-1242 and L δ -32) were also found to be invasive, but showed only focal invasion with "pushing" borders and more prominent surrounding gliosis. These results suggest that LRP expression may be critical in determining the invasive growth phenotype of glioblastomas.

MONDAY, OCTOBER 4

11:00 – 11:15 AM

Mechanisms of Cortical Reorganization: An Experimental Study

Charles Hodge, A Siddiqui, J Dubrof, R Stevens, J McCasland

Reorganization of cortex after injury is an important and under-studied aspect of trauma and ischemia. Understanding the phenomenon of cortical plasticity will allow manipulation of these mechanisms for patient benefit. We used the rodent sensory cortex representing the contralateral snout whiskers in this study. Small excitotoxic lesions were made in a single whisker representation and the reorganization that ensued studied using determination of somatosensory cortical maps using optical imaging techniques and a variety of anatomic techniques.

We present evidence indicating sprouting and alterations in excitatory/inhibitory balance occur as concomitants of cortical plasticity. Retrograde transport of fluoro ruby was used to demonstrate that, after a small cortical lesion, there is dramatic increase in apparent afferent input to the damaged area. There was nearly a two fold increase in input to the reorganizing area from adjacent cortex, the thalamus, the second somatosensory area and the homologous sensory cortex. Additional evidence of sprouting was an increase in GAP-43 and BDNF, both associated with neurite outgrowth. Microarray analysis indicates that there is up regulation of these compounds as well as change in the balance of inhibitory and excitatory transmitters. The excitatory/inhibitory balance change is distinctly different when plasticity is induced by peripheral perturbation as opposed to small central lesions.

Demonstration of sprouting and alterations in transmitter and receptor messages point to the dynamic responses that result from even small cortical lesions. Understanding how to maximize these responses through pharmacologic means might allow better recovery of our patients from a variety of nervous system injuries.

Avoiding Mount Everest – Assessing the Risks of Cerebral Aneurysms and Their Treatment

Eugene S Flamm

Case reports, personal experience, institutional series, national and international studies all provide data, often conflicting and non-intuitive, about when, if and how to manage cerebral aneurysms. With improved screening methods and several alternative methods of therapy available, it is important to determine not only the methods to be used but what the risk-benefit ratios for a given case. We must avoid the Mount Everest syndrome of treating an aneurysm simply because it is there.

Based on personal experience with over 1700 treated cerebral aneurysms, the author has used several methods to analyze the risks of treatment and how to apply these outcome measures on a case by case basis. While this approach cannot completely resolve the question, it is helpful to define the risks, determine the factors that contribute to the risk, and incorporate these data into an algorithm on which to base therapeutic recommendations.

We have used epidemiological techniques such as comparisons with large studies of demographics and natural history as well as analyses of outcome measures such as Quality Adjusted Life Years (QALYs). While helpful in determining generalized trends, these methods are difficult to apply on a case by case basis. More recently we have utilized a Factor Accumulation Index (FAI), the sum of 7 different factors observed in a given patient to determine potential risk factors that might adversely affect to outcome in patients with unruptured aneurysms. In patients with more that 3 of these factors, an unexpected neurological deficit was observed. Finally we have developed an algorithm that takes into account the age of the patient and known natural history factors as well as the anticipated treatment risks based on location, size and experience with the site specific aneurysms. These techniques seem applicable to retrospective data and are currently being applied prospectively to determine their true utility.

MONDAY, OCTOBER 4

11:30 – 11:45 AM

Unilateral Intraputaminal GDNF Improves Bilateral Motor Functions in Patients with Parkinson's Disease

JT Slevin, GA Gerhardt, CD Smith, DM Gash, R Kryscio, A Byron Young

Objective: Glial cell line-derived neurotrophic factor (GDNF) has significant antiparkinsonian actions in several animal models of Parkinson's disease (PD) and in a recent pilot study in five patients in England, of which four received bilateral putamenal delivery. Here, we present results from unilateral intraputaminal GDNF infusion in six advanced PD patients receiving a dose-escalation regimen of GDNF for six months.

Methods: PD patients were evaluated in a functionally defined OFF and ON state at -1, +1 and +4 weeks after intraputaminal catheter implantation contralateral to the most affected side. Subjects then received a dose-escalation regimen of GDNF: 3 mcg/day, 10 mcg/day and 30 mcg/day at successive eight week intervals, followed by a five-week washout period.

Results: Total UPDRS OFF and ON scores were significantly improved (34% and 29%, respectively) at 24 weeks (OFF = 47 +/- 7; ON = 36 +/- 6) compared to baseline (OFF = 72 ± 7; ON = 51 ± 5). Measures using CAPSIT-PD criteria showed significant bilateral improvements (40-50%) in fine motor control and speed. The bilateral effects included improved postural stability and gait. All motoric improvements continued through washout. The only side effect observed was transient Lhermitte's symptoms in 2 subjects.

Conclusions: This open label study of unilateral intraputaminal GDNF demonstrates safety of the procedure and its potential efficacy. There were significant sustained bilateral effects from unilateral administration of the protein.

**Human Dorsal Root Ganglion Neurons as Live Nerve Constructs:
Implications for Transplantation**

Eric L Zager, JH Huang, EM Wilensky, BJ Pfister, DH Smith

Introduction: We sought a clinically applicable source of neurons that could be engineered into transplantable nerve constructs for neural repair. We chose dorsal root ganglion (DRG) neurons due to both their accessibility and their robustness in culture. These neurons can be harvested from a patient for reimplantation as an autograft or from organ donors to serve as allografts.

Methods: Human DRGs were harvested from patients during C2 ganglionectomy for intractable occipital neuralgia. Additionally, we harvested DRG neurons from thoracic ganglia of organ donor patients within 2 hours post-aortic clamping. Harvested ganglion cells were dissociated and cultured on two adjacent membranes in a bio-elongator. We then used a microstepper motor system to progressively separate the two membranes, elongating the axons at a maximal rate of 2 mm/day.

Results: These cultures were maintained for up to three months and surviving DRG neurons were positively identified using antibodies NF 100, SMI-254, SMI-32 and CGRP (calcitonin-gene related peptide). In the bio-elongator, bundles of axons grew across the membranes, integrating with the DRGs on the other side. By 10 days of stretch, axons spanning the two membranes had grown to 10mm in length, creating a living nerve construct. These constructs were implanted in a rat sciatic nerve injury model and a spinal cord injury model. Preliminary results of behavioral, histological, and electrophysiological studies will be presented.

Conclusions: The viability of adult human DRG neurons coupled with their capacity to grow under continuous mechanical tension underscores their promise as a novel means of repairing spinal cord and nerve injuries.

Supported by NIH grants NS46170-01 (JHH), AG 21527(DHS) and NS38104 (DHS), and an AANS Codman Award (JHH).

TUESDAY PROGRAM

TUESDAY, OCTOBER 5

2:45 – 3:00 PM

Cortical and Striatal Migration of Endogenous Adult Stem Cells from the Sub-ventricular Zone and Posterior Peri-ventricular Region in Response to Stroke.

Robert J Dempsey, KA Sailor

The proliferation of endogenous adult stem cells represents a potential therapy for repair after a stroke. Adult neurogenesis is a phenomenon that occurs in the subventricular zone (SVZ) at the lining of the lateral ventricles and in the dentate gyrus (DG) of the hippocampus, and has been shown to be stimulated by various interventions including stroke. Migration of these cells is necessary for them to repopulate a region of stroke damage. Normally the adult stem cells located in the SVZ are only seen migrating anteriorly to the olfactory bulbs where they differentiate into olfactory interneurons. After 1 hour of focal cerebral ischemia in rats, and at 2, 4, 6 and 8 days of reperfusion, we observed these cells also migrating laterally, extending their axons in their path of migration toward the infarct, into the striatum. These cells were labeled with the immature migrating neuronal marker doublecortin (DCX) and the extent of the migration was correlated with the amount of injury to the striatum. In addition to this, we have observed cells in the posterior peri-ventricular region (pPV), a posterior extension of the SVZ, migrating directly to the ipsilateral cortex. By imaging these regions at two-day time intervals we were able to observe an abrupt increase in proliferation in the ipsilateral pPV at day 2 after ischemia, with localized migration along the corpus callosum. By days 8 and 12, we observed DCX positive cells that had migrated laterally into the ischemic penumbra with their axons extending into the ischemic core. This study demonstrates that there is an endogenous response to injury by these cells. By understanding the factors that attract such cells, future therapies may enhance this migration for possible restoration of function to the damaged region of the brain.

Genetic Variants of Matrix Metalloproteinase Genes and their Inhibitors in Patients with Intracranial Aneurysms

Dietmar Krex, IR König, A Ziegler, HK Schackert, G Schackert

Department of Neurosurgery (D.K., K.K., G.S.) and Department of Surgical Research (H.K.S.), University Hospital Carl Gustav Carus, University of Technology, Dresden, and Institute of Medical Biometry and Statistics (I.R.K., A.Z.), University at Lübeck, Germany

Objective: There are several lines of evidence that remodeling of the extracellular matrix is a crucial event in the pathogenesis of cerebral aneurysms. Matrix-metalloproteinases (MMPs) are the most important degrading enzymes in the extracellular matrix. Their activity is predominantly controlled by tissue inhibitors of metalloproteinases (TIMPs). To investigate the possible impact of genetic variants within the genes encoding *TIMP-1*, -2, and -3, and *MMP-2*, -3, -9, and -14, respectively, we conducted a case-control study.

Methods: The entire coding regions and parts of the promoter sequences of the referring genes were investigated using the automated laser fluorescence (A.L.F.) technique. Genotypes and allele frequencies were determined in a primary study sample comprising 44 well defined aneurysm patients and 40 controls. Those being in Hardy-Weinberg disequilibrium were analyzed in another sample of 40 cases and 40 controls, respectively. Odds ratios (ORs) and exact 95% confidence intervals (CIs) were calculated to compare allele frequencies and genotype frequencies using the Cochrane-Armitage trend test.

Results: A total of 38 single nucleotide polymorphism (SNPs) were identified: 3, 4, and 2 in *TIMP-1*, -2, and -3 genes, and 10, 4, 11, and 4 in *MMP-2*, -3, -9, and -14 genes, respectively. SNPs -621C>T, -596A>C, -261G>A of the *TIMP-2* gene were new identified polymorphisms. Deviations from Hardy-Weinberg equilibrium were particularly found for *MMP-2* and *MMP-9* SNPs, however, there were no significant differences in genotype and allele frequencies in those or between any of the other groups.

Conclusions: Our analysis of the entire coding region of three *TIMPs* and four *MMPs*, which are main contributors to extracellular matrix remodeling in vessel walls, failed to show an association of genetic polymorphisms with an intracranial aneurysm. However, deviations from Hardy Weinberg equilibrium found for *MMP-2*, and *MMP-9*, but also for *MMP-3*, and *TIMP-1* SNPs suggest that there might be additional more distantly located genetic variants of functional impact, which are the subject of ongoing studies.

Downregulation of Potassium Channels After Subarachnoid Hemorrhage: A Possible Mechanism for Cerebral Vasospasm

BS Jahromi, Y Aihara, G Weyer, E Nikitina, M Agbaje-Williams, D Ryan, R Yassari, Robert Loch Macdonald

Cerebral vasospasm remains a significant adverse prognostic factor for outcome after subarachnoid hemorrhage (SAH) and is a significant cause of morbidity and mortality in such patients. The pathogenesis remains ill-defined but it is clear that the narrowing is primarily due to abnormally sustained contraction of arterial smooth muscle cells. Cerebrovascular arterial constriction is regulated by membrane potential which in turn is determined by potassium conductance.

These studies examined expression of the major potassium channels by real time polymerase chain reaction and Western blotting and their function using whole cell and perforated patch clamp electrophysiology in normal dog basilar artery smooth muscle cells and in these cells obtained during vasospasm 7 days after SAH.

There were no significant changes in messenger ribonucleic acid and protein of the large-conductance, calcium-activated potassium channel (BK, alpha and beta subunits). There was significant downregulation of Kv2 class of voltage-gated potassium channels. Furthermore, of the two dominant potassium conductances in cerebrovascular smooth muscle cells, BK currents were unaffected by SAH whilst Kv2 class currents were nearly halved after SAH. Immunohistochemistry confirmed localization of Kv 2 (Kv2.1, 2.2) class channels to normal dog basilar smooth muscle and showed that immunoreactivity was reduced after SAH. Vasospastic myocytes were depolarized and showed decreased contribution of potassium conductance towards maintenance of membrane potential. Pharmacological block of Kv but not BK channels in control myocytes mimicked the depolarization observed in vasospastic myocytes and contracted basilar artery rings.

We propose that decreased Kv channel function contributes to the pathogenesis of cerebral vasospasm after SAH.

Prospective Evaluation of Surgical Microscope Based Indocyanine Green Video Angiography in Aneurysm Surgery

Andreas Raabe, P Nakaji, J Beck, J Kamerman, V Seifert, RF Spetzler¹

Department of Neurosurgery, Neurocenter, Johann Wolfgang Goethe University Frankfurt am Main, Frankfurt am Main, Germany and ¹Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona

Objective: We report about the final results of a prospective trial comparing a new technique of surgical microscope based indocyanine green video angiography (ICGA) with intraoperative or postoperative DSA.

Method: ICGA was performed during aneurysm surgery using a newly developed setup with the Zeiss microscope (Zeiss, Oberkochen, Germany). A microscope integrated light source containing infrared excitation light illuminates the operating field. After intravenous injection of the indocyanine dye (25 mg), intravascular fluorescence of ICG from within vessels is imaged by a microscope video camera. Patency of parent, branching and perforating arteries and clip occlusion of the aneurysm as found by ICGA were compared to intraoperative or postoperative DSA findings. The study is expected to close in May after inclusion of 100 patients.

Results: After including 90% of cases, 153 ICGA procedures were performed. The results of ICGA were concordant with postoperative DSA in 36 of 38 cases. One case of mild stenosis and one case of a 4 mm residual aneurysm were missed by ICGA. Compared with intraoperative DSA, the results of ICGA were concordant in 36 of 41 cases. In 4 cases a mild stenosis and in one case a severe stenosis was missed by ICGA. All false negative ICG findings were inconsequential. ICGA led to clip intraoperative clip correction in 7% of cases. None of the cases had clip correction after intraoperative or postoperative DSA when performed after ICGA. The final results will be reported at the meeting.

Conclusions: Microscope based ICGA is simple and provides real-time information about the patency of arterial and venous vessels of all relevant diameters and about the aneurysm sac. ICGA may fill the gap between intraoperative DSA and intraoperative Doppler. It may be used as an alternative to intraoperative DSA in many cases.

Multivariate Analysis of a Consecutive Prospective Series of Carotid Endarterectomies

Robert E Harbaugh, A Agarwal, V Chinchilli

Objective: We performed a multivariate analysis to determine predictors of adverse clinical outcomes following carotid endarterectomy (CEA). Numerous variables, including gender, age, medical comorbidities, contralateral internal carotid artery occlusion, choice of anesthetic, presentation and resident or faculty surgeon were evaluated in regard to the incidence of neurological and non-neurological perioperative complications.

Methods: A prospective series of nearly 1200 CEAs were analyzed. All patients were operated upon under the direction of one neurosurgeon (REH). Clinical outcomes measures evaluated were any stroke, death or myocardial infarction within 30 days of operation. All patients were followed to a clinical endpoint and/or six weeks postoperatively. All outcomes were adjudicated by third party observers.

Results: The ipsilateral stroke rate within 30 days of CEA was 2.25%. None of the commonly cited risk factors such as advanced age, medical co-morbidities or contralateral carotid occlusion were associated with a significantly ($P<0.05$) increased risk of perioperative morbidity or mortality. The use of regional anesthesia was associated with a significantly decreased risk of non-neurological perioperative complications. Other details of the multivariate analysis will be presented.

Conclusion: CEA using regional anesthesia can be performed in patients with advanced age, diabetes mellitus, atherosclerotic coronary vascular disease and contralateral ICA occlusion with acceptably low perioperative morbidity.

A Phase IIa, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Tolerability of the Selective Endothelin A (ETA) Receptor Antagonist Clazosentan (AXV-034343) for the Prevention of Cerebral Vasospasm, Following Severe Aneurysmal Subarachnoid Hemorrhage (aSAH)

Bernhard Meyer for the Axovan Study Group

Department of Neurosurgery, University of Bonn, Germany

Objective: To assess whether the endothelin A (ETA) receptor antagonist clazosentan can reduce the incidence and severity of angiographic vasospasm on Day 9 post rupture (primary endpoint) in a selected high-risk population of patients with aSAH (Fisher Grade ≥ 3 / Hunt & Hess Grade III to IV) compared to placebo.

Methods: The study was divided into a double-blind Part A (randomized continuous iv. Infusion of clazosentan 0.2 mg/kg/h versus placebo starting within 48h post aSAH up to Day 14 post rupture) and an open-label Part B (clazosentan 0.4 mg/kg/h for 12 h followed by 0.2 mg/kg/h up to Day 14 for patients with persistent vasospasm as documented by DSA on Day 9). The primary endpoint was determined in comparison to baseline-DSA via central evaluation, secondary variables included daily blood flow velocities by TCD, incidence of infarcts on CT and outcome according to NIH-SS/mGCS score on Day 14. 34 patients were recruited over a 7-month period in 5 centers (safety population: 16 clazosentan, 18 placebo, analyzed post-hoc according to ITT). 32 patients remained in the intent-to-treat A (ITT-A) and per protocol (PP) population (15 clazosentan, 17 placebo), 19 patients entered Part B and were analyzed according to ITT (ITT-B; 7 clazosentan, 12 post-placebo). Two-sided Fisher's exact test was used to compare the incidence of vasospasm. Differences in severity of vasospasm were tested with the Wilcoxon test.

Results: The ITT-A population showed a significant reduction in the occurrence and severity of angiographic vasospasm in the clazosentan group ($p=0.008$, relative risk reduction: 55%; from 88.2% to 40.0% and odds ratio of 0.089). Even after conservative analysis (i.e., counting deaths and cerebral vasospasms during Part B of the study as treatment failures in the ITT post-hoc population), there was still a trend towards a lower incidence ($p=0.052$) and severity ($p=0.061$) of vasospasm (relative risk reduction of 37%; from 88.9% to 56.3%). A lower incidence of new infarcts was observed in patients randomized to

TUESDAY, OCTOBER 5 (continued)

clazosentan group (15.4% vs. 43.8%) and TCD measurements yielded lower median Lindegaard indices for patients randomized to clazosentan suggesting a milder form of vasospasm.

Conclusions: Clazosentan showed a statistically significant reduction in the frequency and severity of vasospasm compared with placebo. When subsequent analysis incorporating imputation rules for missing data was performed there was still a statistical trend in favor of patients treated with clazosentan. The incidence/severity of adverse events observed with clazosentan was comparable to placebo.

Endovascular Management of Intracranial Aneurysms: An Experience of 1321 Aneurysms in 1101 Patients: Single Center Experience

Robert H Rosenwasser, E Veznedaroglu, S Whang

Introduction/Purpose: Endovascular management of intracranial aneurysms has become an option in certain patient populations based on age, neurologic condition, and anatomical location.

Clinical Materials/Methods: At TJUH from July 1994 through December, 2003, 2294 patients were treated for intracranial aneurysms. Age range was 9 – 89 years. Out of this group, 1192 patients (52%) underwent transcranial surgery and 1101 patients (48%) underwent Endovascular treatment. Eight hundred and sixty-nine patients (78%) presented with SAH. Patient selection for endovascular occlusion was based on physiologic age, Neurologic grade, and anatomy. Patients were treated under general anesthesia with neurophysiologic monitoring and full heparinization.

Results: A technical failure rate of 16% was noted and 175 patients underwent transcranial surgery when the lesion could not be endovascularly treated. The rate of intraprocedural rupture was 1.4%. The rate of embolic events were 2.9% acutely (intraprocedural) and 5.9% delayed. Mortality related to the procedure was 2.5%. The complete occlusion rate was 64% in the first 5 years and was 205 in the last 4 years. To date 4.7% of patients have required retreatment due to recurrence and longer followup is demonstrating that this number is increasing. Thirty-six percent were G1,2 and had a good/fair outcome (GOS), 64% were G3, 4; 87% good/fair; 6% fair; 7% dead; G4; 28% fair, 52% poor, 20% dead. No patient was treated as a G5.

Conclusions: Endovascular occlusion of intracranial aneurysms is a reasonable alternate to microsurgical intervention, particularly in elderly patients and patients in poor neurological grade. Incomplete occlusion and durability remain problematic.

Susceptibility of Murine Neural Stem Cells and of Tumor Cells to Respond to Regenerative Signals of Axolotl Tissue.

Matthias Kirsch, E Schnapp, S Lydia, E Tanaka, P Weigel, G Schackert, HK Schackert

Neurosurgery, Carl Gustav Carus Universitätsklinikum, Technische Universität Dresden and Max-Planck-Institute for Cell Biologie and Genetics, Dresden

Objective: Regeneration of the nervous system in humans and other vertebrates is not sufficient to allow functional recovery. In contrast, urodele and axolotl amphibians are able to regrow organs, such as the limbs and the tail including the peripheral nerves and spinal cord representing central nervous system tissue. Several reports indicate that axolotl do not reject foreign tissue. In-vitro fusion of axolotl with murine cells were successful. The purpose of this study was to evaluate the ability of regenerative axolotl tissue to recruit transplanted vertebrate (mouse) cells to follow the regenerative process.

Methods: Cross-species xenotransplantation was evaluated, both the transplantation of murine neural progenitor cell precursors and of murine brain tumor cells into the regenerating tail of an axolotl and the transplantation of axolotl cell spheroids, spinal cord, or regenerating tail tissue into the chronic cranial window of nude mice.

Results: Temperature-adapted cells and tissues were transplanted. The regenerating axolotl blastema was invaded by murine neural progenitor cells which remained within the growth cone. Three days post implantation, no living murine cells were observed. In the cranial window of mice, axolotl spinal cord and blastema pieces, as well as spheroids from cultured myotubes were implanted. None of the transplants showed invasion of single cells into the surrounding parenchyma. A steadily increasing number of cells were observed that underwent apoptotic cell death. On day four post-implantation, no viable axolotl cells remained in the murine environment. However, in vitro confrontation studies using spheroids and blastema tissue, revealed a shift of the vertebrate cells to a regenerative phenotype.

Conclusion: Xenotransplantation of axolotl cells into nude mice and murine pluripotent neural progenitor cells into the axolotl blastema did not induce a regenerating phenotype. In vitro experiments confronting tumor tissue and blastema revealed a phenotypic change revealing an increase of precursor markers.

Local Delivery of a Fragment of Human Endostatin Combined with Systemic Administration of BCNU Prolongs Survival in a Rodent Experimental Glioma Model

Alessandro Olivi, FG Legnani, G Pradilla, BM Tyler, F Chillemi, F Di Meco

Introduction: Endostatin is an anti-angiogenic agent currently tested for several solid malignancies. A fragment of endostatin (43 amino acids), easily synthesized with high stability and water solubility was incorporated into controlled-release polymers and tested to determine its efficacy when combined with conventional chemotherapy for treatment of experimental gliomas.

Methods: Cytotoxicity of the endostatin fragment against 9L gliosarcoma, and F98 glioma was determined *in vitro*. The fragment was incorporated into polyanhydride-poly-[bis-(carboxyphenoxy-propane)-sebacic-acid] (pCPP:SA) at different loading concentrations and its pharmacokinetics were analyzed *in vitro*. The rat cornea micropocket assay was used to evaluate the anti-angiogenic activity of the fragment/polymer formulations. Systemic toxicity and efficacy of locally delivered endostatin fragment/polymers combined with systemic BCNU were determined in Fischer 344 rats (n=64) using the intracranial 9L gliosarcoma model.

Results: Endostatin fragment showed significant cytotoxicity *in vitro* against 9L and F98. Comparable sustained release was seen by day 19 in all polymer formulations. Corneas implanted with 40% endostatin fragment/pCPP-SA polymers had a mean angiogenesis index of 4.5 ± 0.7 when compared to 8.5 ± 1.3 in controls ($p=0.01$). Survival was prolonged in animals treated with the combination of intracranial 40% endostatin fragment/pCPP:SA polymers and systemic BCNU (mean survival of 120 days) when compared to controls (mean survival 11 days, $p<0.001$, with 33% long term survivors).

Conclusions: Controlled release polymers can effectively deliver a biologically active fragment of endostatin in a sustained fashion. This novel endostatin fragment inhibits angiogenesis *in vitro* and *in vivo*, and exhibits a synergistic effect when combined with systemically delivered with BCNU in the intracranial 9L gliosarcoma model.

Expression of Hypoxia-inducible Carbonic Anhydrases in Brain Tumors

Martin Proescholdt, C Mayer, M Merrill, A Brawanski

Introduction: Malignant Gliomas are the most frequent intrinsic brain tumors in adults. Metabolically, these tumors display a distinct pattern: First, they show a high glucose utilization rate combined with significant levels of lactate production, probably due to aerobic glycolysis. Surprisingly, the intracellular pH of malignant brain tumors has been found to be significantly more alkaline compared to normal brain, whereas the extracellular space displays an acidic pH as demonstrated by *in vivo* studies using pH microelectrodes. Secondly, malignant gliomas display large areas of intratumoral hypoxia as shown *in vivo* by polarographic measurements as well as by PET studies using ¹⁸F-misonidazole as hypoxia specific tracer. Carbonic anhydrase (CA) IX and XII are transmembrane isoenzymes which are induced by tissue hypoxia. They participate in the regulation of pH homeostasis by catalyzing the reversible hydration of carbon dioxide. We hypothesize, that CA IX and XII may be overexpressed in malignant brain tumors due to intratumoral hypoxia. Induction of these enzymes in brain tumors might contribute to an aggressive phenotype by improved acid clearance. The aim of our study was to investigate, whether brain tumors of different histology and grade of malignancy express elevated levels of CA IX and XII compared to normal brain.

Methods: We analyzed 112 fresh frozen tissue samples from primary and metastatic brain tumors for CA IX and XII expression by immunohistochemistry. 8 brain tissue samples obtained from patients who died from extracerebral disease were used as normal brain control. The staining was semiquantitatively graded by three independent investigators blinded to the underlying histology. To confirm the immunostaining results, Western Blot analysis was performed from total protein extract of the tumor tissue. The CA IX and XII mRNA expression was investigated by *in situ* hybridization. To correlate CA IX and XII with tissue hypoxia, immunohistochemical staining for hypoxia inducible factor (HIF-1 α) was performed on adjacent sections.

Results: While normal brain tissue showed minimal CA IX and XII expression, we found a profound upregulation of both enzymes in the brain tumor tissue both by immunohistochemistry and Western blot. The levels of CA IX and XII induction correlated with the grade of malignancy. CA IX and XII mRNA levels were elevated particularly around areas of micronecrosis. Accordingly, the highest levels of CA IX and XII protein expression was found to be in

TUESDAY, OCTOBER 5 (continued)

perinecrotic pseudopallisading cells indicating hypoxic induction. Also, comparison of CA IX and XII staining and HIF-1 α staining revealed a similar microanatomical distribution, confirming hypoxia as the main factor of induction.

Conclusion: The results demonstrate that CA IX and XII are upregulated in intrinsic and metastatic brain tumors compared to normal brain tissue. Hypoxia seems to be the major mechanism of induction highlighting the importance of hypoxia as a pathogenetic factor in brain tumors. This may contribute to maintain the pH gradient with alkaline intracellular and acidic extracellular pH observed in brain tumors. Since powerful inhibitors of carbonic anhydrases are clinically available, CA IX and XII may be an important target for future treatment of brain tumors.

TUESDAY, OCTOBER 5

5:30 – 5:45 PM

Anti-EGFR Monoclonal Antibody Cetuximab Augments Radiation and Chemotherapeutic Effects in Glioblastoma Multiforme *in vitro* and *in vivo*.

JL Eller, SL Longo, MM Kyle, D Bassano, DJ Hicklin, Gregory W Canute

Objective: We previously demonstrated that anti-EGFR monoclonal antibody Cetuximab was effective against EGFR-amplified glioblastoma multiforme (GBM) cells *in vitro* and *in vivo*. This work examines the combination of Cetuximab with radiation or chemotherapy.

Methods: Cells were implanted intracranially to verify whether Cetuximab crosses the blood brain barrier. To determine the efficacy of Cetuximab on increasing tumor burden, mice with different size flank GBM were used. Finally, mice with flank GBM were exposed to Cetuximab alone, or in combination with radiation. EGFR-amplified GBM lines were also exposed to Cetuximab and chemotherapeutic agents *in vitro*.

Results: Cetuximab treated-mice had a significant increase in median survival when compared to sham-treated mice for both intracranial and flank tumor models. The inhibition of tumor growth obtained with Cetuximab in mice with flank GBM was inversely proportional to tumor size at the beginning of treatment. Tumor cells undergoing apoptosis was greater upon exposure to Cetuximab and radiation than with either treatment alone. The combination of Cetuximab and radiation treatment increased median survival in mice with flank GBM compared to either treatment alone. The combination of Cetuximab and chemotherapeutic agents increased cytotoxicity *in vitro* when compared to either treatment alone.

Conclusions: The effectiveness of Cetuximab as a solo agent is dependent upon tumor burden. Cetuximab was effective when administered systemically for mice harboring intracranial GBM. Cetuximab plus radiation was more effective against EGFR-amplified GBM than either treatment alone. Cetuximab in combination with chemotherapeutic agents had an additive effect *in vitro*. These results confirm EGFR blockade as a potential chemotherapeutic treatment against human GBM.

Multicentric Phase III Study, Fluorescence-guided Resection of Malignant Gliomas with 5-ALA: Preliminary Results on Interim Analysis of 270 Assessable Patients

¹Walter Stummer, ^{2,3}T Meinel, ALA-Glioma Study Group*, ⁴U Pichlmeier, ⁵OD Wiestler, ⁶FE Zanella, ³HJ Reulen

¹Neurochirurgische Klinik, Heinrich-Heine Universität Düsseldorf, ²Clinstud, clinical research institute Hamburg, ³Ludwig-Maximilians-Universität München, ⁴medac Gesellschaft für medizinische Spezialpräparate mbH, ⁵Institut für Neuropathologie, Universitätsklinikum Bonn, ⁶Institut für Neuroradiologie, Klinikum der J.-W. Goethe Universität Frankfurt

Objective: 5-Aminolevulinic acid (5-ALA) leads to the accumulation of fluorescent porphyrins in malignant gliomas, a phenomenon under investigation for the enhancement of tumor resection. In order to determine patient benefit in terms of resection radicality, progression-free survival and morbidity, a pivotal two-armed, randomized, group-sequential, blinded-observer trial was designed together with the sponsor Medac. This paper gives preliminary results of the interim analysis on the first 270 patients in the full analysis set (intent-to-treat principle population).

Methods: Patients with suspected malignant gliomas bearing the potential for complete resection of contrast-enhancing tumor were randomized to receive either 20 mg 5-ALA/kg body weight for fluorescence-guided resection (ALA-group) or nothing for conventional microsurgery (white light group). Surgery was performed using identical microscopes (Zeiss OPMI Neuro FI) available to each participating center. Primary study aim was to determine the number of patients without contrast-enhancing tumor on early postoperative MRI and progression free survival at six months.

Results: Postoperative MRI was devoid of residual, contrast-enhancing tumor in 65 % of patients in the ALA group compared to 36 % in the white light group ($p < 0.001$). Preliminary Kaplan-Meier analyses revealed prolonged progression-free survival in ALA patients ($p < 0.01$ compared to white light) with cumulative 6-months progression-free survival rates of 41% and 21%, respectively. Median survival was significantly prolonged in patients devoid of contrast-enhancing tumor (16 vs. 12 months, $p < 0.001$). Postoperative neurological status and Karnofsky Index did not differ between ALA or white light patients.

TUESDAY, OCTOBER 5 (continued)

Conclusions: Fluorescence-guided resections using 5-ALA allow a larger number of complete resections without endangering patients. Complete resections have a direct impact on overall survival.

**ALA-Glioma Study Group: F. Oppel, A. Brune (Krankenanstalten Gilead gGmbH, Bielefeld), W. Lanksch, C. Woiciechowsky (Virchow-Klinikum der HU Berlin), M. Brock, J. Vesper (Universitätsklinikum Benjamin Franklin, Berlin), J.-C. Tonn, C. Goetz (universitätsklinikum München), J.M. Gilsbach, L. Mayfrank (Med. Einrichtungen der RWTH, Aachen), V. Seifert, K. Franz, A. Bink (J.W. Goethe Universitätsklinikum, Frankfurt a. M.), G. Schackert, T. Pinzer (Universitätsklinikum Carl Gustav Carus an der TU, Dresden), W. Hassler, A. Bani (Klinikum Duisburg gGmbH, Duisburg), H.-J. Meisel, B.C. Kern (Bergmannstrost Krankenhaus, Halle), H.M. Mehdorn, A. Nabavi (Universitätsklinikum Kiel), A. Brawanski, O.W. Ullrich (Klinikum der Universität Regensburg), D.K. Böker, M. Winking (Universitätsklinikum Giessen), F. Weber, U. Langenbach (Klinikum Saarbrücken), M. Westphal, U. Kähler (Universitätsklinikum Hamburg-Eppendorf), H. Arnold, U. Knopp (Med. Universität zu Lübeck), T. Grumme, T. Stretz (Zentralklinikum Augsburg), D. Stolke, H. Wiedemayer (Universitätsklinikum Essen), B. Turowski (Universitätsklinikum Düsseldorf), T. Pietsch ((Unviersitätsklinikum Bonn)*

TUESDAY, OCTOBER 5

6:00 – 6:15 PM

Is Gross Total Resection Sufficient Treatment for Posterior Fossa Ependymoma?

L Rogers, J Pueschel, Robert Spetzler, W Shapiro, S Coons, T Thomas, B Speiser

All newly diagnosed intracranial ependymoma patients (n=45) treated at our institution from 1983 to 2002 were identified to determine whether gross total resection (GTR) alone serves as definitive treatment and to evaluate the role of radiation therapy (RT) after either GTR or subtotal resection (STR). Patients with supratentorial primaries, subependymomas, or neuraxis dissemination were excluded. GTR was accomplished in 32 (71%) and STR in 13 (29%). RT was delivered to 25 patients: 13 after GTR and 12 after STR. RT fields were craniospinal followed by a posterior fossa boost in 6, and posterior fossa or local only in 19. With a median follow-up of 66 months, the median local control (LC) was 73.5 months with GTR alone, but has not yet been reached for GTR+RT patients. Median LC after STR+RT was 79.6 months. Ten-year actuarial LC (10y-LC) was 100% for GTR+RT, 50% for GTR alone, and 36% STR+RT, representing significant differences between GTR+RT and GTR alone ($p=0.018$) and between GTR+RT versus STR+RT ($p=0.003$). There was no significant difference in 10y-LC between GTR alone and STR+RT ($p=0.370$). The 10-year overall survival rate of GTR+RT was 83%, 67% for GTR alone, and 43% for STR+RT. RT, tumor grade, and resection extent were significant predictors of LC. GTR should be the intent of surgery when feasible with acceptable morbidity. Even after GTR confirmed with postoperative imaging, adjuvant RT significantly improved LC. We recommend postoperative RT after both gross total or subtotal resection.

Management of Optic Nerve Sheath Meningiomas

U Schick, Werner Hassler

Neurosurgery, Wedau Kliniken, Duisburg, Germany

Object: The management of optic nerve sheath meningiomas (ONSM) remains controversial, but includes surgery, radiotherapy and plain observation. We introduce a new classification scheme and derive treatment modalities from the different types and subtypes.

Methods: A retrospective analysis was performed on 73 patients with optic nerve sheath meningiomas who underwent surgery between 1991 and 2002. The follow-up period ranged from between 6 to 144 months (mean 45.4 mo). Our classification system differentiates between intraorbital (type 1), intracanalicular or intrafissural (type 2), and intraorbital and intracranial (type 3) types of ONSMs. 32 tumors demonstrated extension through the optic canal (type 2a). 29 further tumors reached the chiasm (type 3a) or contralateral side (type 3b). Intraorbital flat tumors (type 1a) should be radiated with visual decline. Type 1b tumors with a large intraorbital mass should be observed, radiated with visual decline, and operated on without useful vision. Only type 1c tumors with exophytic tumor growth should undergo excision. Type 2 tumors are amenable to decompression to save vision and type 3 tumors are amenable to resection of the intracranial part. The intraorbital part should be radiated. The visual acuity was not significantly influenced by surgery. Visual acuity became worse with longer duration of preoperative symptoms and longer follow-up period. Location in the optic canal was another negative factor. Radiotherapy could preserve vision in 5 out of 10 cases.

Conclusions: Loss of vision in optic nerve sheath meningiomas is a question of time. The role of radiotherapy has to be reevaluated and offered to adults once mild vision loss develops in intraorbital ONSMs. Surgery with decompression of the optic canal and intracranial tumor resection is favored for tumors with intracanalicular and intracranial extension.

The Role of Endogenous Growth Hormone-Releasing Hormone (GHRH) in Acromegaly

William F Chandler, EV Dimaraki, AL Barkan, MB Brown, V Padmanabhan, SY Kim, R Taussig

There is indirect evidence suggesting hypothalamic control of GH secretion in acromegaly. To examine whether GH secretion in acromegaly is dependent on GHRH, we studied 8 patients with classic untreated acromegaly due to a GH producing pituitary tumor. All patients were admitted to the General Clinical Research Center and underwent an intravenous infusion of normal saline for 24 hours and GHRH-antagonist at 50 µg/kg/h for 7 days. GH was measured every 10 min for 24h during the normal saline infusion and on the last day of the GHRH- antagonist infusion. A group of 9 different patients with untreated acromegaly served as the control group and underwent blood sampling for GH every 10 min for two consecutive 24h periods to assess the day-to-day variability of GH secretion. All 8 study patients underwent transsphenoidal surgery and RNA was extracted from the each tissue specimen and tested for *gsp* mutations.

In 6 of 8 experimental subjects 24h mean GH decreased by 5.8-30.0 % during GHRH-antagonist infusion and in 3 of 8 subjects the decline of the 24h mean GH was greater than twice the average Coefficient of Variation in the control group. The probability of this magnitude of change to occur in 3/8 subjects by chance is 0.0058. Although 3 of 8 subjects were found to have *gsp* mutations (2 at site R201, 1 at site R227), no relationship was noted between the presence of *gsp* mutation and GH suppression with GHRH- antagonist.

We conclude that in a subset of patients with acromegaly due to a pituitary adenoma, GH secretion is under partial control by GHRH.

WEDNESDAY PROGRAM

WEDNESDAY, OCTOBER 6

9:15 – 9:30 AM

Selection of the Optimal Entry Zone to the Brain Stem for Removal of Intraaxial Cavernous Angiomas

Helmut Bertalanffy

Objective: Cavernous malformations located within the brainstem show a substantially higher propensity for bleeding than those in other locations. Since radiosurgery appears to be inappropriate for prevention of bleeding, microsurgical removal of brainstem cavernomas is the favored therapeutic option. To completely remove an intraaxial cavernoma without additional morbidity, however, an individually tailored specific entry zone to the brainstem is required, particularly in those cases, in which the lesion is not visible on the surface of the brainstem.

Patients and Methods: During the past 7 years we have treated surgically 56 individuals who harbored - with one exception - a symptomatic brainstem cavernoma. Fourteen of the lesions were located in the midbrain, 36 in the pons and 6 in the medulla. The patient's records, pre- and postoperative images and surgical video tapes were analyzed. To obtain an optimal surgical window and viewing trajectory to the brainstem, we carefully selected the surgical approach in each single case. Intraoperative electrophysiological monitoring was used in all, neuronavigation in the majority of patients.

Results: The surgical approaches included the pterional/orbitozygomatic, the subtemporal transtentorial, the retrosigmoid, the suboccipital lateral transcondylar, the supracerebellar infratentorial and the suboccipital median telovelomedullary routes. The lesion itself or the bulging hematoma with xanthochromic coloration was seen in 30 cases, while an apparently normal brainstem was found in 26 cases. In the latter, the brainstem was incised at a site where the shortest distance to the lesion was suspected and confirmed by neuronavigation. The exact site, however, was slightly modified when direct electrical stimulation dictated a different safe entry zone to the brainstem. Postoperatively, 9 patients (16 %) showed transient additional neurological deficits whereas 6 individuals (11 %) experienced permanent neurological morbidity, of whom four are completely independent. One patient died from a disease unrelated to the cavernous malformation. The remaining patients of this series were either in the same neurological condition or improved.

WEDNESDAY, OCTOBER 6 (continued)

Conclusions: A carefully planned and individually tailored approach was essential to obtain a specific exposure of the brainstem which depended upon the size and exact location of the lesion. The optimal entry zone to the brainstem was based on precise anatomical criteria, on the local vascular pattern, on electrophysiological mapping and neuronavigation. In combination with modern neuroanesthesia and advanced microsurgical techniques, excellent results have been achieved with this method.

The Synthetic ACDF: Experience with Rh-BMP-2 and Peek Cages

Regis Haid, P Mummaneni, G Rodts, M Boakye

We evaluated the fusion status and clinical outcomes following ACDF using polyetheretherketone (PEEK) spacers filled with recombinant bone morphogenetic protein (rhBMP-2) and covered with a cervical plate.

Methods: 26 patients (13 men and 13 women)(mean age 54 years, range 36-71 years) were retrospectively evaluated. 4 of the 26 patients were smokers. Single level ACDF was performed in 13 patients, 2 level ACDF in 10 patients, and 3 level ACDF in 3 patients. The patients' pathologies included 11 with disc herniations, 10 with spondylosis, 2 with OPLL, 1 with pseudoarthrosis from prior ACDF, 2 with instability. Clinical outcomes were assessed using Odom's criteria. Radiographic outcomes were evaluated using flexion-extension x-rays, and CT was utilized in cases where fusion as questionable.

Results: Of the 26 patients, 1 was lost to follow-up, 2 died of complications unrelated to surgery, and 23 were followed for a mean of 13 months (range 10 months to 2 years). Clinical outcomes (Odom's) were rated as good-excellent in 20 patients, fair in 4 patients. All patients achieved solid radiographic fusion by three months postop. Complications included recurrent laryngeal nerve palsy (1 patient), transient dysphagia (3 patients), CSF leak (1 patient), and transient C5 paresis (1 patient). Evaluation of radiographs showed asymptomatic posterior osteophyte formation in 7 patients.

Conclusion: ACDF with PEEK and BMP with cervical plate fixation affords a fusion rate equivalent to autograft in our experience. Unlike autograft, bone graft harvest site morbidity is avoided. Transmission of disease is not a concern with PEEK spacer and BMP (unlike allograft). New osteophytes may form with PEEK and BMP use, but they were not clinically significant.

A Role for EphB4 Signaling in the Regulation of Vascular Morphogenesis and Vascular Permeability in Malignant Glioma

¹Peter Vajkoczy, ¹R Erber, ²U Eichelsbacher, ¹V Powajbo, ²P Knyazev,
²A Ullrich

¹Department of Neurosurgery, University Hospital Mannheim; ²Max-Planck-Institute for Biochemistry, Martinsried

Objective: Several endothelial-specific receptor tyrosine kinases (RTKs) and their ligands have been implicated in glioma angiogenesis. Recently, members of the Eph-group of RTKs (Ephs) and their ligands (ephrins) have been suggested to be involved in developmental angiogenesis and embryonal vascular differentiation. The role of ephrin/Eph signaling in adult angiogenesis, however, has remained unknown so far. The objective of the present study was to assess the role of ephrin/Eph signaling for glioma biology.

Methods: Expression of ephrins and Ephs was assessed in glioma cell lines, human glioma xenografts as well as low- and high-grade human astrocytoma using c-DNA-array analysis, RT-PCR and in-situ hybridization. To further study the role of EphB4 signaling for glioma angiogenesis we used Phoenix E cells producing (i) ecotropic retroviral constructs for EphB4-WT, (ii) EphB4-DN, i.e. a truncated dominant-negative mutant form of EphB4 lacking the kinase domain, and (iii) Phoenix E cells producing an empty vector (mock). Phoenix E cells were co-implanted with glioma cells into flanks or the dorsal skinfold chamber preparation of nude mice. Glioma angiogenesis and glioma growth were assessed by immunohistochemistry and intravital multi-fluorescence videomicroscopy.

Results: Expression of several ephrins (EphrinA1, EphrinB1, EphrinB2) and Ephs (EphA2, EphA5, EphB2, EphB3, EphB4) could be detected in human gliomas. Compared to normal brain, expression of EphB4, EphB3 and EphrinB2 mRNA was increased in glioma, whereas expression of EphA5 and EphA2 mRNA was reduced in glioma. Interestingly, expression of ephrins and Ephs in glioma xenografts was detected on both blood vessels and tumor cells. In situ hybridization of human astrocytoma specimens further demonstrated that, while ephrinB2 was homogeneously expressed by tumor cells and tumor blood vessels, EphB4 mRNA was predominantly expressed by perinecrotic tumor cells and tumor blood vessels. Based on these results we next set out to study the role of EphB4 signaling for glioma angiogenesis in detail. *In vivo* manipulation of endothelial EphB4 signaling with EphB4-WT and EphB4-DN

WEDNESDAY, OCTOBER 6 (continued)

constructs did not affect initial sprouting tumor angiogenesis, but markedly altered the vascular phenotype of the tumors. Compared to mock tumors, both EphB4 WT- and EphB4-DN tumors were characterized by a rather circumferential than branching vessel growth, resulting in extremely large (>200 μ m) tumor vessels, and by a significant reduction in tumor vessel permeability.

Conclusions: Our results suggest a role for ephrin/Eph signaling in glioma tumorigenesis and angiogenesis through a complex interaction between ephrins and Ephs expressed by tumor cells and endothelial cells. EphB4 signaling in endothelial cells seems to play a central role in the regulation of glioma vascular morphogenesis and vascular permeability. Our results contribute to a better understanding of basic mechanisms underlying glioma angiogenesis and uncover further steps in glioma vascularization beyond the sprouting angiogenesis mediated by VEGF, the angiopoietins and their receptors.

Gamma Knife Radiosurgery in the Management of Glomus Tumors – A Volumetric Study of 17 Cases

Gene H Barnett, A Varma, JH Suh, J Ross

Twenty patients with glomus jugulare tumors underwent Gamma Knife radiosurgery (GKRS) at the Cleveland Clinic during a 6-year period from 1997 to 2002. Three patients with follow up of less than 10 months were excluded. Clinical and radiological data from 17 patients were retrospectively analyzed. MRI tumor volumes at treatment and follow-up were assessed.

There were 15 women and 2 men, with an average age of 63.1 years (range 22 to 87). Follow up was 10 to 79 months (average 44.5 months). Six patients had undergone previous surgical resection of the same tumor, two had multiple tumors and one had a functional chemodectoma. Symptoms were tinnitus (n=12), hearing loss (n=12), lower cranial nerve paresis (n=6) and otalgia (n=5). Tumor margins received 13 to 18 Gy (average = 15 Gy, median = 15 Gy) at 48% to 63% (average = 53%, median = 50%) isodose line. Eight patients clinically improved, 2 patients worsened and 7 patients were unchanged. One patient experienced transient hearing impairment. Tinnitus and otalgia responded most favorably to GKRS. Initial tumor volumes ranged from 0.4 to 26.1 cm³. Tumor volume showed a transient increase in 7 patients though ultimately decreased in 8 patients (4 clinically improved, 3 unchanged & 1 worse), increased in 4 patients (2 clinically unchanged, 1 improved, 1 worse) and was unchanged in 5 patients (3 clinically improved and 2 unchanged).

GKRS is a safe, effective treatment for glomus jugulare tumors, particularly in elderly patients and patients with serious medical conditions.

Intraoperative Functional MRI. First Results and Technical Considerations.

Thomas Gasser*, D Stolke*, R Fahlbusch°, C Nimsky°

* Department of Neurosurgery, University of Essen, ° Department of Neurosurgery, University of Erlangen

Objective: The preservation of eloquent cortex during a neurosurgical intervention is essential for the functional outcome. Functional MRI represents an established concept to map functional units. However, fMRI paradigms are generally active in nature, limiting the method to awake and cooperative patients and to the preoperative period. However, a novel passive fMRI paradigm for localization analysis of the sensorimotor cortex allows functional analysis of neurologically impaired or anaesthetized patients. The paradigm is based on peripheral electrical nerve stimulation during echo-planar image acquisition. Preceding studies have already established clinical applications of this fMRI-paradigm.

The present prospective study evaluates the feasibility of true intraoperative fMRI utilizing this paradigm in anaesthetized patients undergoing brain tumour resection. The study focused as well on the technical setup and the intraoperative management.

Methods: In 3 anaesthetized patients with centrally localized lesions intraoperative fMRI scans were acquired at 3 distinct stages of the surgical procedure employing an intraoperative 1.5 Tesla MR scanner. The data were analyzed statistically and co-registered with the Talairach space. Additionally the data were validated by electrophysiology.

Results: Utilizing this passive fMRI paradigm, the sensorimotor cortex could be identified intraoperatively in 2 of the 3 patients. We observed a significant change in signal intensity in the course of the operation and detected regularly an inverted BOLD-signal response, which may be caused by an inhibition of cerebrovascular autoregulation under total intravenous anaesthesia (TIVA). Susceptibility artefacts influenced image quality marginally.

Conclusion: We could demonstrate the feasibility of this method to identify the sensorimotor cortex in anesthetized patients in the surgical setup. Further studies will have to evaluate the BOLD-signal characteristics under anaesthesia and the clinical impact of intraoperative fMRI.

Sirolimus-Eluting Stents in the Canine Cerebral Vasculature: Assessment of Safety and Vessel Response

Elad I Levy, RA Hanel, AS Boulos, FO Tio, AM Paciorek, KS Kagan-Hallet, MD Fronckowiak, LR Guterman, LN Hopkins

Purpose: The treatment of intracranial atherosclerosis with bare-metal stents results in excessive restenosis rates. Neurotoxicity effects and vessel injury following implantation of drug-eluting stents are unknown in the cerebrovasculature. To assess the safety and vascular effects of sirolimus-coated stents, we conducted a prospective comparison study of drug-eluting and bare metal stent implantation in the canine basilar artery.

Method: Sixteen mongrel dogs were randomized to receive either bare metal 1.5- x 8-mm (6-cell) stents or sirolimus-eluting stents of the same dimensions. Serial peripheral blood samples were obtained during the first week after stent implantation to determine the time-dependent serum sirolimus concentration. Angiograms were performed 30 days post-implantation to assess the effects of stent placement on the basilar artery and brainstem perforators. Stent and basilar artery explantation was performed immediately after angiography. Histological and computer-assisted morphometric analyses of specimens obtained were performed.

Results: No sirolimus was detected in peripheral blood samples obtained later than 24 hours post-treatment. On follow-up angiography, no evidence of parent vessel damage or pseudoaneurysm formation was seen. Explanted vessels and brainstem sections showed no evidence of neurotoxicity. No significant differences were found in the time to endothelialization of bare-metal and sirolimus-coated stents. Smooth-muscle cell proliferation was lower in animals receiving sirolimus-coated stents ($p = 0.003$). Additionally, intimal fibrin density was increased in the group treated with sirolimus-coated stents ($p < 0.0001$). Histological evidence of an inflammatory response indicated a trend toward a reduced response in the sirolimus group.

Conclusion: These findings suggest that sirolimus-coated stents may inhibit in-stent stenosis. Further studies with longer-term follow-up are required to assess the restenosis rates of sirolimus-coated stents implanted in intracranial vessels.

Brain Tumor Surgery in the Vicinity of Short-Term Memory Representation –Results of Neuronavigation Using fMRI Images.

Viet Braun, A Albrecht¹, A Wunderlich², H-P Richter¹

¹ University of Ulm, Department of Neurosurgery, Ludwig-Heilmeyer-Str. 2, 89312 Guenzburg, Germany, ² University of Ulm, Department of Radiology, Robert-Koch-Str. 8, 89070 Ulm, Germany

Objective: Functional informations concerning the surrounding brain are mandatory for a good clinical outcome in brain tumour surgery. The value of fMRI to detect the motorcortex and the Broca area is widely accepted today. If an appropriate paradigm is used, short-term memory areas can be visualized as well. Obviously these informations must be integrated into cranial neuronavigation for an appropriate intraoperative use. We report our first experiences with the direct integration of short-term memory fMRI into cranial neuronavigation.

Method: From January 2001 to March 2002 14 patients were operated on for intracranial tumors with short-term memory fMRI imaging, using the „two-back-paradigm“. Both pre- and postoperatively, the short-term memory of all patients was tested additionally by a standardized test battery including 16 different verbal and visuo-spatial items. FMRI was repeated postoperatively as well.

Results: In all 14 patients the general level of working memory capacity was preserved after surgery and we found an improvement in verbal short-term memory items. In contrast, the visuo-spatial performance kept unchanged or deteriorated slightly and the alertness slightly worsened as well.

Conclusion: Functional fMRI basing on a short-term memory paradigm is able to improve the outcome after surgery for cortical and subcortical brain tumors localized in the frontal and precentral area. The so-called two-back paradigm mainly serves for verbal memory tasks. For visuo-spatial items, we are going to design a new paradigm. Unfortunately it has to be mentioned, that irradiation may deteriorate this capacity as well.

Fiber Tract Deformation as Visualized with Sequential Acquisitions of 3D-Ultrasound (3DUS) During Intracranial Surgery

Volker A Coenen, T Krings, J Weidemann, FJ Hans, P Reinacher, JM Gilsbach, V Rohde

Objective: We present a technique that intraoperatively allows displaying brain shift and its effects on fibre tracts that preoperatively were studied with diffusion-weighted imaging (DWI). With DWI the pyramidal tract and the optic radiation can be displayed among other fiber tracts. Intraoperative 3D – ultrasound (3DUS) has the ability to directly compare ultrasound and MRI (or DWI) anatomy. 3DUS cannot directly visualize fiber tracts in the white substance of the brain. However, it is possible to estimate a fiber tract's position by defining an environment of ultrasound landmarks on the basis of the US – DWI comparison.

Methods: In three patients intracranial lesions (1 malignant glioma, 1 metastasis, 1 cavernoma) with contact to either the corticospinal or the geniculostriate tracts were removed microneurosurgically. Preoperatively, diffusion weighted magnetic resonance imaging (DWI) was obtained to visualize the fiber tract at risk. DWI data were fused with the anatomical T1-weighted magnetic resonance (MR) image. A single rack 3D - ultrasound (3DUS) neuronavigation system, which displays simultaneously the MR image and the corresponding ultrasound image was used intra-operatively for 1) navigation 2) definition of fixed and shiftable ultrasound-landmarks in vicinity to the fiber tract 3) sequential image update at different steps of resection resulting in time dependent brain deformation data. Using a standard personal computer equipped with Windows®-based image software, the brain shift-associated fiber tract deformation was assessed by sequential landmark registration. After surgery, DWI was obtained to directly confirm the predicted fiber tract deformation.

Results: The lesions were removed without any morbidity. The comparison of 3DUS with DWI and T1-weighted MRI allowed to define fixed and shiftable landmarks close to the respective fiber tract. Postoperative DWI confirmed, that the actual fiber tract position corresponded to the sonographically predicted fiber tract position at the end of surgery.

Conclusion: By definition and sequential intraoperative registration of ultrasound landmarks in vicinity to a fiber tract, brain shift associated deformation of the sonographically not visible tract can be correctly assessed. This approach appears to be helpful to identify and avoid eloquent brain during intracranial surgery.

GERMAN SOCIETY FIRST PRIZE AWARD
(Wilhelm Tönnis Preisträger)

Mechanical Response of a Cervical Spine Motion Segment on Removing a Local Autograft

Tobias Pitzen¹, CJ Kempf¹, TR Oxland², WI Steudel¹

¹Neurochirurgische Klinik, Universitätskliniken des Saarlandes, 66421 Homburg/ Saar. ²Division of Orthopaedic Engineering Research, Departments of Orthopaedics and Mechanical Engineering, University of British Columbia, Vancouver, Canada

Objective: There is evidence, that filling a cervical spine fusion cage with either bone substitute or autologous bone graft from the iliac crest is beneficial with respect to speed and rate of the bony fusion. However, both bone substitutes and the iliac crest autograft have specific disadvantages. Using a local autograft from the cervical spine vertebral bodies to fill a cervical spine fusion cage might be an alternative. However, removing the local autograft from the vertebral bodies of the cervical spine could result in reduced strength of the spinal segment, thus again leading to severe complications. Therefore, mechanical testing of such a procedure should be performed before the method is to be used in clinical practice. The objective of the study was to investigate, if removing a local autograft from the cervical spine vertebral bodies significantly reduces compression strength of a cervical spine segment.

Methods: 14 human cervical spine segments (C4-C5 and C6-C7) were used. According to bone mineral density they were assigned to either control or test group. Each specimen underwent anterior discectomy and insertion of a titanium cage (Rabea, Signus Medizintechnik, Alzenau). Within the specimen, assigned to the test group, a cylindrical bone dowel of 5 mm depth and 5 mm diameter was removed from the anterior aspect of each vertebra. The specimens were then loaded in flexion-compression. We looked at the force resulting in the first failure, at the force resulting in 4 mm displacement of the construct and at the correlation of these parameters to the bone density of the segment.

Results: Then mean force resulting in initial failure was 1149 N for the test and 1647 N for the control group ($p = 0,252$). The force resulting in 4 mm displacement was 1064 N for the test and 1574 N for the control group ($p = 0,155$). There was a strong and significant correlation of these parameters versus bone density for the control group, however, the correlation was moderate and not significant within the test group.

WEDNESDAY, OCTOBER 6 (continued)

Conclusion: Removing a cylindrical dowel of 5 x 5 mm from the anterior aspect of the cervical spine vertebral bodies does result in a not significant reduction of strength in flexion-compression.

AMERICAN ACADEMY
HONORABLE MENTION AWARD

Selective Ablation of Vanilloid Receptor 1 Positive Nociceptive Neurons for Elimination of Hyperalgesia and Neuropathic Pain

Russell R Lonser, GC Tender, S Walbridge, Z Olah, L Karai, M Iadarola, EH Oldfield

Objectives. Neuropathic pain is mediated by nociceptive neurons that selectively express the vanilloid receptor 1 (VR1). Resiniferatoxin, an excitotoxic VR1-agonist, destroys VR1-positive neurons. To determine if resiniferatoxin can selectively ablate VR1-positive neurons and eliminate neuropathic pain without affecting tactile sensation and motor function, we infused it unilaterally into primate trigeminal ganglia.

Methods. We perfused resiniferatoxin (experimental=3) or vehicle (control=1) into the right trigeminal ganglia of Rhesus primates and tested tactile and hyperalgesic sensation in trigeminal-innervated territories (corneal application of saline and capsaicin, respectively) at 1, 4 and 7 weeks postoperatively. Number of blinks, eye wipes, and duration of squinting were recorded after application. Neurogenic inflammation, mediated by VR1-positive neurons, was tested by facial application of capsaicin cream. Immunohistochemical analyses were performed after euthanization.

Results. Consistent with elimination of hyperalgesia on the side of resiniferatoxin-treated ganglia, there was a dramatic reduction in the number of blinks (mean±S.D.: 25.7±4.4 versus 106±20.8, and 112.8±19.7), eye wipes (1.4±0.8 versus 19.3±5.0 and 16.7±4.5), and duration of squinting (1.4±0.7 seconds versus 11.4±1.6 and 14.8±1.7) in response to corneal application of capsaicin, compared to the vehicle and untreated sides, respectively ($p<0.01$). Tactile sensation (mean blinks after saline application; 18.8±2.3, versus 18.0±2.6, and 18.4±3.3, respectively; $p>0.05$) and motor function (mastication) remained intact. Neurogenic inflammation was blocked on the resiniferatoxin-treated side. Animals showed no adverse clinical effects. Immunohistochemical analysis revealed selective ablation (mean decrease, 79.3±2.8%; $p<0.001$) of VR1-positive neurons in the resiniferatoxin-treated ganglia.

WEDNESDAY, OCTOBER 6 (continued)

Conclusions. VR1-positive nociceptive neurons can be safely and selectively ablated by intraganglionic resiniferatoxin infusion, eliminating hyperalgesia and neurogenic inflammation while maintaining intact tactile sensation and motor function. Intraganglionic resiniferatoxin infusion could provide a new site-specific, mechanism-based treatment approach for neuropathic pain.

GERMAN ACADEMY FIRST PRIZE AWARD

Identification of Brain Tissue Necrosis by MRI: Validation by Histomorphometry

Michael Stoffel^{1,2}, C Blau³, H Reint³, J Breidt³, K Gersonde³,
A Baethmann², N Plesnila²

¹Dept. of Neurosurgery, Rheinische Friedrich-Wilhelms-University, Sigmund-Freud-Str. 25, 53105 Bonn (Tel.:+49-228-287-6521, Fax:+49-228-287-4758, mail: michael.stoffel@ukb.uni-bonn.de). ²Institute for Surgical Research, Klinikum Großhadern, Ludwig-Maximilians-University, Marchioninistr. 15, 81366 Munich (Tel.:+49-89-7095-4352, Fax:+49-89-7095-4353, mail: plesnila@icf.med.uni-muenchen.de). ³Fraunhofer Institut für Biomedizinische Technik, Ensheimerstr. 48, 66386 St. Ingbert (Tel.:+49-6894-980-274, Fax:+49-6894-980-400, mail: blauc@ibmt.fhg.de), Germany

The volume of an experimental necrotic lesion of the cortex expands up to 400 % of its initial size within the first 24 hrs after the insult. Lesion expansion, a clinically well known phenomenon, is often accompanied by perifocal brain edema and consequently difficult to image and to analyze by magnetic resonance imaging (MRI). Therefore we aimed to validate a T₂-weighted spin echo sequence upon its ability to distinguish necrotic from edematous brain tissue.

Male Sprague-Dawley rats (n=5 per group) were subjected to a cortical freezing lesion leading to immediate tissue necrosis with subsequent perifocal vasogenic brain edema. Immediately, 4, 12, and 24 hrs after the lesion the maximal area of necrosis was quantified longitudinally by coronal T₂-weighted spin echo MRI-scans. After the last scan, animals were sacrificed for direct comparison of the lesion area obtained by MRI and histomorphometry. In parallel groups of animals, lesion expansion was quantified by histology.

The acquired T₂-maps clearly distinguish the cortical necrosis from perifocal edema and healthy brain. Focal freezing led to a cortical lesion of 5.24 ± 0.36 mm² immediately after trauma (0 h; 100 %) which expanded progressively to a maximum of 6.82 ± 0.34 mm² after 24 hrs (131 %; * $p < 0.01$ vs. 0h). Lesion expansion quantified by histology was almost identical (132 % within 24 hrs). Histological assessment resulted in smaller absolute lesion areas compared to MRI, most likely due to shrinking during tissue processing (4.72 ± 0.26 mm² vs. 6.82 ± 0.34 mm², $p < 0.01$).

WEDNESDAY, OCTOBER 6 (continued)

The current study shows that necrotic brain tissue can be distinguished from surrounding brain edema by T₂-mapping. The technique is sensitive enough to detect small changes in necrosis expansion in vivo as validated by histology. The presented technique may be a useful future tool for the non-invasive identification of necrotic brain tissue following brain injury, e.g. from trauma or ischemia.

AMERICAN ACADEMY AWARD

Achieving a Multidimensional Brain Computer Interface in Humans Using Electrographic Signal

Eric C Leuthardt, G Schalk, JR Wolpaw, JG Ojemann, DW Moran

Brain-computer interfaces (BCIs) enable users to control devices with electroencephalographic (EEG) activity from the scalp or with single-neuron activity from within the brain. Both methods have disadvantages: EEG has limited resolution and requires extensive training, while single-neuron recording entails significant clinical risks and has limited stability. This research demonstrates that electrocorticographic (ECoG) activity recorded from the surface of the brain can enable users to control a computer cursor rapidly and accurately. Previously, over brief training periods (several minutes), four patients mastered control and achieved high success rates in one dimensional tasks. In additional experiments, we found that ECoG signals at frequencies up to 180 Hz accurately reflected the direction of two-dimensional joystick movements. These techniques derived to achieve one dimensional control were then used to translate this to two dimensional control in one patient with success rates of 70-94%. These results suggest that an ECoG-based BCI could provide people with severe motor disabilities a non-muscular multidimensional communication and control option that is more powerful than EEG-based BCIs and is significantly easier and safer than BCIs that use electrodes penetrating the brain.

THURSDAY PROGRAM

THURSDAY, OCTOBER 7

9:15 – 9:30 AM

Clinical Outcome Following Transforaminal Lumbar Interbody Fusion (TLIF): One Year Follow-up of Prospective Data

Richard G Fessler

METHODS: Two studies were completed using a prospective, non-randomized design.

Study 1: 50 patients underwent either open TLIF or minimal access TLIF (MAST TLIF). 25 patients were in each group. All patients receiving open TLIF were performed by one surgeon, and all MAST TLIFs were performed by a second surgeon. Surgeries were performed over the same period of time. Data collected included age, sex, levels operated, operative time, blood loss, transfusions, pain medications received, and length of stay. Results were analyzed using Wilcoxon Signed Rank analysis and Student's t-test analysis.

Study 2: 56 patients who were scheduled to undergo MAST TLIF were pre-operatively administered VAS, Oswestry Disability Scale, and SF-36 questionnaires. Surgery was then performed and the same tests were re-administered at 6 wks, 4 ½ months, and 1 year post-operatively. Data at 1 year was compared to the pre-operative data using the Wilcoxon Signed rank analysis for VAS scores and repeated measures ANOVA for the Oswestry Disability Scores and SF-36 scores.

RESULTS:

Study 1: Patient demographics, including age and levels operated were not significantly different. More males were done through mast technique than open. Operative time was not significantly different between the groups. Patients undergoing MAST TLIF lost significantly less blood (200 v 1100 cc, $p < .002$), required significantly fewer transfusions (0 v 33 %, $p < .001$), and took significantly less pain medicine (130 v 180 MSO4 equivalents, $p < .05$). Length of stay was less for MAST TLIF patients, but did not reach statistical significance.

Study 2: Patients followed for 1 year after MAST TLIF experienced a 98 % fusion rate. Visual analog scores decreased from 5.5 to 3.5 ($p < .008$). Oswestry disability scores decreased from 45 to 30 ($p < .0001$), and SF-36 scores for physical functioning increased from 35 to 46 ($p < .01$).

THURSDAY, OCTOBER 7 (continued)

Discussion: The MAST TLIF technique for performing lumbar interbody fusion and stabilization is a safe and effective procedure. In similar groups of patients it can be performed in the same or less time than open procedures, while causing less blood loss, fewer blood transfusions, and requiring less pain medicine and possibly shorter hospital stays. Long term follow-up demonstrate significant improvement in pain, disability, and overall satisfaction with life compared to pre-operative values.

Transgenic Arteriovenous Fistula in the Rat: An Experimental Model of Gene Therapy for Brain Arteriovenous Malformations

Michael T Lawton, C Stewart, A Wulfstat, N Derugin, T Hashimoto, W Young

Objective: To introduce the transgenic arteriovenous fistula (AVF) model in the rat, constructed by interposing mouse aorta in a fistula between the common carotid artery and external jugular vein in a nude rat; to describe the model's technical feasibility, long-term patency, and expression of reporter genes.

Methods: Carotid-jugular fistulas were surgically created in 112 rats. In 25 immunodeficient nude rats, wild-type mouse thoracic aorta (TAo) was interposed in the fistula; in 10 immunocompetent rats, TAo was interposed; in 19 nude rats, transgenic TAo with reporter genes for beta-galactosidase (lac-Z) or green fluorescent protein (GFP) was interposed; in 18 nude rats, wild-type mouse ascending aorta (AAo) was interposed; and in 40 rats, a simple fistula was constructed without an interposition graft. Host tolerance and graft viability were determined by histopathology and immunohistochemistry for CD31 (mouse endothelial cell marker), endothelial nitric oxide synthase (eNOS), smooth muscle actin, fibronectin, beta-galactosidase, and GFP.

Results: The transgenic AVF was technically feasible and immunologically tolerated in nude rats, but not in immunocompetent rats. The overall angiographic patency rate was 41% with TAo grafts and 56% with AAo grafts, both lower than the 98% patency rate in fistulas with a single anastomosis and no interposition graft. Mouse endothelium survived on the graft for 3 months according to CD31 staining, but longer survival by transgenic smooth muscle cells resulted in continued expression of lac-Z for 6 months and GFP for 4 months. Endothelium and smooth muscle in the fistula were functional, with normal expression of eNOS, and smooth muscle actin and fibronectin, respectively.

Conclusion: The transgenic arteriovenous fistula model enhances other carotid-jugular fistula models by integrating transgenic tissue, thereby creating an experimental system for investigating the molecular biology of and gene therapies for arteriovenous malformations.

Application of Image-Guided Spinal Navigation to Decompression and Internal Fixation of the Upper Cervical Spine

Iain H Kalfas

The techniques for decompression and internal fixation of the upper cervical spine have evolved significantly. This has resulted from an improved understanding of spinal biomechanics, improvements in spinal imaging, the refinement of surgical exposure techniques as well as continued advances in the design of internal fixation devices.

Despite these advances, the anatomic complexity of the upper cervical region can present difficulties for even the most experienced spinal surgeons. In particular, orientation to the pertinent neural, vascular and bony structures is critical to optimizing the outcome of surgery. While intraoperative fluoroscopy can help facilitate anatomic orientation, it has several technical limitations.

Computed tomography-based image-guided spinal navigational technology has evolved over the past decade. Unlike, fluoroscopy, it provides the surgeon with multiplanar images through the upper cervical region. These images can be manipulated intraoperatively to provide enhanced orientation to the surgical anatomy.

Forty patients underwent surgery for decompression and internal fixation of the upper cervical spine using image-guided spinal navigation. Thirty-two patients underwent posterior C1-2 screw fixation, 5 patients underwent transoral surgery with posterior C1-2 screw fixation and 3 patients underwent anterior odontoid screw fixation. Fluoroscopy was also used on a limited basis during each case to validate the navigational information.

Satisfactory screw placement was achieved in all patients. There were no incidences of neural or vascular injury due screw placement. The technique of using image-guided technology for upper cervical surgery will be reviewed.

Laboratory Testing of an Implantable Microsensor System for Intraoperative 3D-Computer Animation of Vertebral Body Motion in Cervical Spinal Surgery

Olaf Süß, T Kombos, S Schönherr*, S Mularski, B Kühn, M Brock

Neurochirurgische Klinik, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin* Institut für Informatik, Freie Universität Berlin

Objective: Degenerative diseases of the cervical spine may not only cause neurological deficits due to direct compression of the spinal cord or the spinal nerves, but also alter its biomechanical function and statics. In such cases, the aim of surgery is double: to decompress neural structures and to provide the highest possible stability and the best possible preservation of function. Regardless of the surgical technique used, intraoperative prediction of the functional (neurological and biomechanical) results of surgery, might represent a major progress.

Materials & Methods: Navigationsystems have been used in spinal surgery for specific surgical planning, optimization of anatomical orientation and improvement of surgical accuracy. In the present research project (sponsored by the Deutsche Arthrose Hilfe e.V.), reference sensors of an electromagnetic navigation system (ACCIS II™, Schaerer Mayfield Technologies) have been miniaturized for direct implantation into one or more vertebral bodies with the aim of providing precise additional spatial online information on the location of the vertebral bodies and their orientation in space. In laboratory tests, up to three microsensors were implanted into several cervical vertebrae of cadaver specimens.

Results: Five different surgical techniques (ventral fusion, dorsal fixateur implantation, ventrolateral plate osteosynthesis, foraminotomy, cage implantation) were performed in a total of ten cervical spine models using different segments (C1-3, C5/6, C6-T1). The isolated vertebral body movements were registered and visualized online on the navigation screen.

Conclusion: The implanted reference sensors allow computer-animated, real-time visualization of isolated movements of individual vertebral bodies or of entire motion segments. This means that motion can be visualized immediately

THURSDAY, OCTOBER 7 (continued)

during surgery without the need for additional intraoperative imaging procedures such as fluoroscopy or computed tomography. These results indicate that reliable information on the expected postoperative biomechanical outcome can be obtained by continuous intraoperative three-dimensional animation.

Transthoracic Discectomy Without Interbody Fusion

D Edwards, A Cohen-Gadol, William E Krauss

Object: Transthoracic discectomy is an established surgical procedure for the treatment of thoracic disc disease. Most authors advocate interbody fusion following transthoracic discectomy. The purpose of this study was to determine if there were adverse consequences in forgoing interbody fusion following transthoracic discectomy.

Methods: From 1996 to 2002, the senior author performed transthoracic discectomy without fusion on eighteen patients. There were eleven women and seven men in this series. Their mean age was 54 years (SD=17, range 28-84). Surgical indications were radiculopathy in 1 patient, myelopathy in 14 patients, and radiographic cord compression in 3 patients. We obtained postoperative CT scans to evaluate the decompression in most patients. We obtained followup data from clinic visits and telephone surveys. We obtained and compared pre and postoperative radiographs to determine the incidence of postoperative kyphosis at the operated level. Mean followup was 2.3 years. No patients reported the new onset of axial spine pain postoperatively. Fourteen of 18 patients had significant improvement in neurological symptoms and signs. The only three non-ambulatory patients regained ambulation. One 83 year-old patient had a slight increase in gait difficulties postoperatively. There were three major complications: 1 wound infection, 1 sympathetic pleural effusion requiring pleurodesis, and 1 case of disabling postthoracotomy pain. No patients developed a clinically significant kyphotic deformity.

Conclusions: These results indicate that interbody fusion may not be necessary in all patients undergoing transthoracic discectomy.

Treatment of Spinal Cord Injury via Topical Perfusion with an ATP Solution

Christopher B Shields, YP Zhang, S Chien, Y Han, LBE Shields, M Li, B Chiang, DA Burke

ATP depletion damages ATP sensitive ion channels following spinal cord injury (SCI), leading to membrane failure and cell death. These processes may be reversed by the application of exogenous ATP. ATP solution, stabilized in a lecithin suspension, has been shown to protect hepatic tissue and skin following injury (unpublished data). Besides supporting metabolism, ATP may be trophic in neurogenesis and cell survival by acting on its P2X and P2X receptor subunits. We suggest that exogenous administration of ATP solution to the spinal cord following SCI may prevent irreversible damage and improve functional recovery.

Sixteen Sprague-Dawley rats received a 25 gm-cm SCI at T10 and were assigned into one of two groups: 1) injury/vehicle (control: n = 8) and 2) injury/ATP enhanced solution containing 3000 μmol ATP/ml (n = 8). A perfusion well was designed to irrigate ATP solution to the injured spinal cord. Flow rate was 5 ml/hour for 24 hours. Locomotion was tested weekly for 6 weeks after SCI using the BBB score. At week 6, rats were fixed, and their spinal cords are being assessed for lesion size and tissue preservation.

BBB scores were higher in rats irrigated with the ATP enhanced solution compared to the control group. Locomotor function was significantly better in the ATP-treated groups at 2, 4, and 5 weeks ($p \leq 0.05$). Tissue sparing and lesion size of the spinal cords will be analyzed after 6 weeks.

We conclude that topical application of exogenous ATP provides functional and possibly anatomical neuroprotection following moderate SCI.

IOMaster 7D – A New Device for Virtual Neuroendoscopy

Christos Trantakis¹, J Meixensberger¹, G Strauß², E Nowatius³, D Lindner¹,
HK Cakmak⁴, H Maaß⁴, C Nagel¹, U Kühnapfel⁴

¹Department of Neurosurgery, ²Department of ENT, University of Leipzig
³Zwonull Media GmbH, Leipzig ⁴Institut für Angewandte Informatik, Research
Center Karlsruhe

Abstract: Objective: To create a VR training system for neuroendoscopy. A new force feedback device was intended to be developed and evaluated regarding the suitability for the simulation of endoscopic ventriculocisternostomy.

Methods: A VR model for ventriculostomy was generated based on a MRI dataset. Software modules were used for segmentation (VESUV), modelling (KisMo) and visualization (KISMET) and implemented on a WIN32 platform. Real instruments (MINOP, Aesculap, Germany) were adapted to the simulator. The system was evaluated in 79 procedures.

Results: The “IOMaster 7D” offers 7 degrees of freedom. Both the trocar and the acting instruments are captured separately. The trocar’s position determines the view of the camera, the access to the target, and the operating range. An elastodynamic hydrocephalic ventricular system with realistic proportions was modeled. An interactive virtual preparation with force feedback was implemented. The system provides for axial movement or rotation of the instruments, cutting, grasping and realistic elastodynamic deformations of the ventricle wall. First evaluations proved a reduction of the median failure rate and a reduction of the median time to reach the target. Analysis of the total distance of instruments movement showed a reduction, too.

Conclusion: VR systems can simulate realistic and real time surgical procedures and may open new perspectives for the neurosurgical training. Integrating haptic information increases the quality. The definition of no touch areas and targets and the possibility of registration of both kinetic parameters, failure rate and the time course of the procedure provide objective criteria for the appreciation of a learning effect.

Fedor Krause, The Krause Operations, and Krause’s Impact on American Neurosurgeons

Peter W Carmel, M Buchfelder

Fedor Krause (1856-1937), the pioneering German neurosurgeon, is widely known and revered in Germany, but is poorly known among American neurosurgeons. He is slightly better known for his innovative cranial approaches; the “Krause operations”.

We have assessed Krause’s impact on contemporaneous American neurosurgeons by review of references in over 30 books and monographs by Cushing, Dandy, Elsberg, and Frazier. This informal “citation index” permitted comparison with other contemporaneous authors.

Each of the four authors cited Krause frequently, not only from the English translation of his book (1909-1911), but from his papers in German as well. Indeed, Elsberg’s “Surgical Diseases of the Spinal Cord” (1916) cites Krause more often than any other author. Elsberg and Frazier credited Krause with innovation of two further “Krause operations”; a form of osteoplastic laminectomy, and mid-line cord myelotomy for pain.

This generation of neurosurgeons knew German, (the language of science), and several had spent a *Wanderjahre* in Europe while training. These four American neurosurgeons were clearly highly influenced by Krause’s work. Why is he not better known in America today? It may be related to the fact that subsequent neurosurgical generations were less likely to read German, and after 1933, less likely to travel to Germany. They only knew of Krause through his 1911 book, which had been through many revisions in German (68 editions!) but not in English.

We will review the career, surgical innovations, and impact of this unique neurosurgical progenitor, with the hope of wider understanding of his contributions.

Diffusion Tensor Imaging for 3-D Fiber Tract Visualization in Navigated Glioma Surgery

Christopher Nimsky, O Ganslandt, AG Sorensen, R Fahlbusch

Department of Neurosurgery, University Erlangen-Nürnberg, Erlangen, Germany (CN, OG, RF), Department of Radiology/Nuclear Magnetic Resonance Center, Massachusetts General Hospital, Boston, USA (AGS)

Objective: To investigate the intraoperative displacement of major white matter tracts during navigated glioma resection by comparing pre- and intraoperative diffusion tensor imaging (DTI) based fiber tracking.

Methods: In 37 patients undergoing glioma surgery pre- and intraoperative DTI was performed with a 1.5 T magnetic resonance scanner applying an echo-planar imaging sequence with 6 diffusion directions. For 3-D tractography we implemented a knowledge-based multiple-ROI (region of interest) approach applying user-defined seed regions in the color-encoded maps of fractional anisotropy (FA). Tracking was initiated in both retrograde and orthograde directions according to the direction of the principal eigenvector in each voxel of the ROI. The tractography results were also assigned color applying the convention used in color-encoded FA maps. In 15 patients DTI data were integrated into the navigation setup.

Results: Pre- and intraoperative fiber tracking was technically feasible in all cases. Fiber tract visualization gave a quick and intuitive overview of the displaced course of white matter tracts in 3-D space. Comparing pre- and intraoperative tractography depicted a marked shifting of major white matter tracts during glioma removal. Maximum white matter tract shifting ranged from -8 to +15 mm ($+2.7 \pm 6.0$ mm; mean \pm standard deviation); in 29.7% an inward, in 62.2% an outward shifting was detected. DTI based neuronavigation allowed identification and preservation of deep seated eloquent brain areas.

Conclusion: Comparing pre- and intraoperative fiber tracking visualizes a marked shifting and deformation of major white matter tracts due to tumor removal. This brain shift of deep structures emphasizes the need for an intraoperative update of navigation systems, when navigation is applied during resection of deep-seated tumor portions near eloquent brain areas.

Changes of the Astrocytic Matrix and Reappearance of Radial Glia in Hippocampi of Patients Suffering from Temporal Lobe Epilepsy

¹Thomas M Freiman, ^{1,2}J Eismann, ²M Frotscher, ¹J Zentner

¹Department of Neurosurgery, ²Institute for Anatomy and Cell Biology, Albert-Ludwigs-University, D-79106 Freiburg in Breisgau

Objective: Temporal lobe epilepsy (TLE) is frequently associated with a sclerosis of the hippocampus, also known as Ammon's horn sclerosis (AHS). These hippocampi show a significant neuron loss with astrogliosis. In the recent literature most attention was paid to neuronal changes. However these hippocampi show complex remodeling of synapses and neuronal layers, as a widening of the usually very slim granule cell layer (GCL dispersion) which might be influenced by the change of the glial matrix.

Methods: Hippocampal specimens were obtained from hippocampi of patients treated for pharmaceutically intractable TLE (n=12) and from patients with intracerebral tumors, who served as controls (n=3). The GCL dispersion and the back-grown mossy fibres of the two groups were compared with immunohistochemistry against glial fibrillary acid protein (GFAP) and Silver-Impregnations. The astrocytes were reconstructed and the morphology was evaluated by an optical analysis system (NeuroLucida).

Results: Astrocytes proximal to the granule cell layer display a change of their processes. The usually star-like shape of the processes changed into longer processes projecting vertical through the dispersed GCL. Some radial glial cells were observed projecting also vertical to GCL.

Conclusion: Hippocampi of patients with AHS demonstrate a change of the glial scaffold and a new appearance of progenitor cells which project vertical through the GCL along the embryonal sprouting direction of neurons in the hippocampus.

Surgical Treatment of Hemispheric Intractable Epilepsy in Childhood with Functional Hemispherectomy or Peri-insular Hemispherectomy.

Falk Oppel, V Zountsas, HW Pannek

Neurochirurgische Klinik Krankenanstalten Gilead Bethel Bielefeld

Objective: To present the surgical and clinical results of the therapy of 71 hemispherical intractable epilepsies in children and juveniles, who were operated on in Bethel Epilepsy Centre between May 1990 and August 2003, undergoing either hemispherectomy or hemispherotomy.

Method: We analyzed retrospectively these 71 cases. The age at the operation ranged from 4 months to about 17 years (30% aged 3-14 years, 33% 1-3 years and 29% infants). The indication for hemispherectomy was set in 44 cases with congenital etiologies (25 hemimegalencephaly, 14 cortical dysplasia and 5 Sturge-Weber cases) as well as in 27 cases with acquired lesions (11 Rasmussen encephalitis, 13 porencephaly cases after MCA-infarct and 3 other encephaloclastic lesions). By the functional hemispherectomy, the big central region tissue resection was followed from the temporal lobectomy, amygdalohippocampectomy, callosotomy and undercutting disconnection of frontal and occipital lobes. By the hemispherotomy we achieved through smaller craniotomies, shorter operating times and less blood loss, the disconnection of the hemisphere from inside the lateral ventricle. The epilepsy outcome is evaluated according to the Engels classification, with mean follow up of 6 years and 4 months.

Results: 28 patients underwent functional hemispherectomy and 43 patients peri-insular hemispherotomy. The advantages of hemispherotomy are obvious in the porencephalic and the atrophic lesions. The epilepsy outcome is 71 % seizure free or almost seizure free and additionally 17% of cases benefited from the operation (Engels III). The rates of incomplete disconnection have been reduced by the hemispherotomy, 7 % of cases needed a shunt implantation. The mortality was 2,8 %.

Conclusion: The peri-insular hemispherotomy can be safely applied in all etiologies of hemispheric intractable epilepsy and comparable to functional hemispherectomy, has better surgical and clinical results. The early operation is beneficial for the development of the children, taking full advantage of the brain plasticity in this age.

SPECIAL GUESTS

GUESTS

SPONSORS

✓ Markus Bittl (fellow)
Charlottesville, VA

John Jane

Greg Canute
Syracuse, NY

Charles Hodge

✓ Richard Fessler
Chicago, IL

Hunt Batjer

✓ William Friedman
Gainesville, FL

Academy

Regis Haid
Atlanta, GA

Volker Sonntag

William Krauss
Rochester, MN

David Piegras

Joung Lee
Cleveland, OH

Iain Kalfas

✓ Eric Leuthardt (resident)
St. Louis, MO

Academy Award
Recipient

Elad Levy
Buffalo, NY

Nick Hopkins

✓ Russell Lonsler
Bethesda, MD

Academy Award
Honorable Mention

Rajiv Midha
Calgary, Canada

Alan Hudson

Alessandro Olivi
Baltimore, MD

Donlin Long

Nelson Oyesiku
Atlanta, GA

Arthur Day

Sunil Patel
Charleston, SC

✓ **Mark Shaffrey**
Charlottesville, VA

Michael Wang
Los Angeles, CA

Clarence Watridge
Memphis, TN

J. Peter Witt
Denver, CO

Eric Zager
Philadelphia, PA

Phanor Perot

John Jane

Michael Apuzzo

Fremont Wirth

Glenn Kindt

Sean Grady

ACADEMY AWARD WINNERS

Paul M. Lin	1955
Hubert L. Rosomoff	1956
Byron C. Pevehouse	1957
Norman Hill	1958
Jack Stern	1959
Robert Ojemann	1960
Lowell E. Ford	1962
Charles H. Tator	1963
Earle E. Crandall	1964
Stephen Mahaley, Jr.	1965
Chun Ching Kao	1966
John P. Kapp	1967
Yoshio Hosobuchi	1968
Gary G. Ferguson	1970
Richard L. Pressley	1971
David G. McLone	1972
Arden F. Reynolds, Jr.	1973
Richard L. Rapport	1974
Andrew G. Shetter	1975
John R. Howe	1976
Howard W. Blume	1977
Howard J. Senter	1978
Elisabeth M. Post	1979
David Dubuisson	1980
Dennis A. Turner	1981
Marc R. Mayberg	1982
David S. Baskin	1983
Kevin J. Kiwak	1984
Terry Lichtor	1985
Michael G. Nosko	1986
Joseph R. Madsen	1987
James T. Rutka	1988
Christopher D. Heffner	1989
Scott I. Gingold	1990
Mary Louise Hlavin	1991
Adam P. Brown	1992
Michael Tymianski	1993
David Garrett, Jr.	1994
L. Brannon Thomas	1995
John S. Yu	1996
Gregory Canute	1997

Nathan R. Selden	1998
Robert M. Friedlander	1999
Tien T. Nguyen	2000
Peng Chen	2001
Ganesh Rao	2002
Gelareh Zadeh	2003
Eric C. Leuthardt	2004

MEETINGS OF THE ACADEMY

Hotel Netherland Plaza, Cincinnati, Ohio	October 28-29, 1938
Roosevelt Hotel, New Orleans, Louisiana	October 27-29, 1939
Tudor Arms Hotel, Cleveland, Ohio	October 21-22, 1940
Mark Hopkins Hotel, San Francisco, California ...	November 11-15, 1941
Ambassador Hotel, Los Angeles, California.....	November 11-15, 1941
The Palmer House, Chicago, Illinois	October 16-17, 1942
Hart Hotel, Battle Creek, Michigan.....	September 17-18, 1943
Ashford General Hospital, White Sulphur Springs, West Virginia	September 7-9, 1944
The Homestead, Hot Springs, Virginia	September 9-11, 1946
Broadmoor Hotel, Colorado Springs, Colorado	October 9-11, 1947
Windsor Hotel, Montreal, Canada	September 20-22, 1948
Benson Hotel, Portland, Oregon	October 25-27, 1949
Mayo Clinic, Rochester, Minnesota.....	September 28-30, 1950
Shamrock Hotel, Houston, Texas	October 4-6, 1951
Waldorf-Astoria Hotel, New York City, New York	September 29-October 1, 1952
Biltmore Hotel, Santa Barbara, California	October 12-14, 1953
Broadmoor Hotel, Colorado Springs, Colorado	October 21-23, 1954
The Homestead, Hot Springs, Virginia	October 27-29, 1955
Camelback Inn, Phoenix, Arizona	November 8-10, 1956
The Cloister, Sea Island, Georgia	November 11-13, 1957
The Royal York Hotel, Toronto, Canada	November 6-8, 1958
Del Monte Lodge, Pebble Beach, California.....	October 18-21, 1959
Copley Sheraton Plaza, Boston, Massachusetts	October 5-8, 1960
Royal Orleans, New Orleans, Louisiana	November 7-10, 1962
El Mirador, Palm Springs, California	October 23-26, 1963
The Key Biscayne, Miami, Florida	November 11-14, 1964
Terrace Hilton Hotel, Cincinnati, Ohio	October 14-16, 1965
Fairmont Hotel & Towers, San Francisco, California	October 17-19, 1966
The Key Biscayne, Miami, Florida	November 8-11, 1967
Broadmoor Hotel, Colorado Springs, Colorado	October 6-8, 1968
St. Regis Hotel, New York City	September 21, 1969
Camino Real, Mexico City, Mexico.....	November 18-21, 1970
Sahara-Tahoe Hotel, Stateline, Nevada	September 26-30, 1971
New College, Oxford, England	September 4-7, 1972
Huntington-Sheraton Hotel, Pasadena, California	November 14-17, 1973
Southampton Princess Hotel, Bermuda.....	November 6-9, 1974
The Wigwam (Litchfield Park), Phoenix, Arizona ...	November 5-8, 1975
Mills Hyatt House, Charleston, South Carolina	November 10-13, 1976

Mauna Kea Beach Hotel, Kamuela, Hawaii	November 2-5, 1977
Hotel Bayerischer Hof, Munich, Germany	October 22-25, 1978
Hyatt Regency, Memphis, Tennessee	November 7-10, 1979
Walforf-Astoria Hotel, New York City, New York	October 1-4, 1980
Sheraton Plaza, Palm Springs, California	November 1-4, 1981
Ritz-Carlton Hotel, Boston, Massachusetts	October 10-13, 1982
The Lodge at Pebble Beach, California	October 23-26, 1983
The Homestead, Hot Springs, Virginia	October 17-20, 1984
The Lincoln Hotel Post Oak, Houston, Texas	October 27-30, 1985
The Cloister, Sea Island, Georgia	November 5-8, 1986
Hyatt Regency, San Antonio, Texas	October 7-10, 1987
Omni Netherland Plaza, Cincinnati, Ohio	September 13-17, 1988
Loews Ventana Canyon, Tucson, Arizona	September 27-October 1, 1989
Amelia Island Plantation, Amelia Island, Florida	October 2-7, 1990
Salishan Lodge, Gleneden Beach, Oregon	September 22-26, 1991
Ritz-Carlton Hotel, Naples, Florida	October 21-25, 1992
The Wigwam, Phoenix, Arizona	October 27-30, 1993
The Cloister, Sea Island, Georgia	November 3-6, 1994
Loews Ventana Canyon Resort, Tucson, Arizona	November 1-5, 1995
The Greenbrier, White Sulphur Springs, West Virginia	September 18-22, 1996
Rimrock Resort, Banff, Alberta, Canada	September 10-14, 1997
Four Seasons Biltmore, Santa Barbara, California	November 4-7, 1998
Ritz-Carlton, Amelia Island, Florida	November 10-13, 1999
The Broadmoor, Colorado Springs, Colorado	October 11-14, 2000
The Breakers, Palm Beach, Florida	November 14-17, 2001
The Phoenician, Scottsdale, Arizona	October 16-19, 2002
Colonial Williamsburg, Williamsburg, Virginia	October 29–November 1, 2003
Four Seasons Berlin and Taschenbergpalais Dresden, Germany	October 3-8, 2004

PAST PRESIDENTS

Dean H. Echols.....	1938-39	Lyle A. French	1973
Spence Braden.....	1940	Benjamin B. Whitcomb.....	1974
Joseph P. Evans.....	1941	John R. Green.....	1975
Francis Murphey	1942	William H. Feindel	1976
Frank H. Mayfield.....	1943	William H. Sweet	1977
A. Earl Walker	1944	Arthur A. Ward	1978
Barnes Woodhall.....	1946	Robert B. King	1979
William S. Keith.....	1947	Eben Alexander, Jr.	1980
Howard A. Brown	1948	Joseph Ransohoff II	1981
John Raaf.....	1949	Byron C. Pevehouse	1982
E. Harry Botterell	1950	Sidney Goldring	1983
Wallace B. Hamby	1951	Russel H. Patterson, Jr.....	1984
Henry G. Schwartz	1952	Thomas Langfitt	1985
J. Lawrence Pool	1953	Phanor L. Perot, Jr.....	1986
Rupert B. Raney.....	1954	Shelley N. Chou	1987
David L. Reeves.....	1955	James T. Robertson	1988
Stuart N. Rowe	1956	Thoralf M. Sundt, Jr.	1989
Arthur R. Elvidge.....	1957	Robert Ojemann	1990
Jess D. Herrmann	1958	Nicholas Zervas.....	1991
Edwin B. Boldrey.....	1959	Henry Garretson.....	1992
George S. Baker	1960	George Tindall	1993
C. Hunter Shelden	1961-62	William A. Buchheit	1994
Samuel R. Snodgrass	1963	David L. Kelly, Jr.	1995
Theodore B. Rasmussen.....	1964	John M. Tew, Jr.....	1996
Edmund J. Morrissey	1965	Julian T. Hoff	1997
George Maltby	1966	Edward S. Connolly	1998
Guy L. Odom	1967	J. Charles Rich	1999
James G. Galbraith	1968	George A. Ojemann.....	2000
Robert H. Pudenz	1969-70	Roberto C. Heros.....	2001
William B. Scoville	1971	Donald O. Quest	2002
Robert L. McLaurin	1972	David G. Piepgras	2003

PAST VICE-PRESIDENTS

Francis Murphey	1941	Richard L. DeSaussure	1974
William S. Keith.....	1942	Ernest W. Mack	1975
John Raaf.....	1943	Frank E. Nulsen.....	1976
Rupert B. Raney.....	1944	Robert S. Knighton.....	1977
Arthur R. Elvidge.....	1946	Robert G. Fisher	1978
John Raaf	1947	H Thomas Ballantine, Jr.....	1979
Arthur R. Elvidge	1948	George Ehni.....	1980
F Keith Bradford.....	1949	Courtland H. Davis, Jr.....	1981
David L. Reeves.....	1950	John F. Mullan.....	1982
Henry G. Schwartz.....	1951	Hugo V. Rizzoli.....	1983
J Lawrence Pool.....	1952	James W. Correll	1984
Rupert B. Raney.....	1953	E Bruce Hendrick	1985
David L. Reeves.....	1954	Griffith R. Harsh, III.....	1986
Stuart N. Rowe	1955	Ellis B. Keener	1987
Jess D. Hermann.....	1956	Robert Grossman.....	1988
George S. Baker	1957	Jim Story	1989
Samuel R. Snodgrass.....	1958	John Jane, Sr.....	1990
C Hunter Shelden	1959	Stewart Dunsker	1991
Edmund Morrissey	1960	Burton M. Onofrio.....	1992
Donald F. Coburn	1961-62	Martin H. Weiss	1993
Eben Alexander, Jr.....	1963	John M. Tew, Jr.....	1994
George L. Maltby.....	1964	John C. VanGilder.....	1995
Robert Pudenz.....	1965	Edward S. Connolly.....	1996
Francis A. Echlin.....	1966	George Ojemann.....	1997
Benjamin Whitcomb	1967	Charles H. Tator.....	1998
Homer S. Swanson.....	1968	Donald O. Quest	1999
Augustus McCravey.....	1969-70	Howard M. Eisenberg.....	2000
Edward W. Davis	1971	Richard B. Morawetz.....	2001
John R. Green	1972	Martin B. Camins	2002
George J. Hayes	1973	Arthur L. Day	2003

PAST SECRETARY-TREASURERS

Francis Murphey	1938-40	Eben Alexander, Jr	1954-57
Earl Walker	1941-43	Robert L. McLaurin	1958-62
Theodore C. Erickson	1944-47	Edward W. Davis	1963-65
Wallace B. Hamby	1948-50	Robert G. Fisher	1966-68
Theodore B. Rasmussen ...	1951-53	Byron C. Pevehouse	1969-72

PAST SECRETARIES

Byron C. Pevehouse	1973	Nicholas T. Zervas.....	1987-89
Russel H. Patterson, Jr.	1974-76	William A. Buchheit.....	1990-92
Phanor L. Perot, Jr.....	1977-80	Julian T. Hoff	1992-95
John T. Garner.....	1981-83	Roberto C. Heros.....	1995-98
James T. Robertson.....	1984-86	David G. Piepgras.....	1998-01

PAST TREASURERS

Russel H. Patterson, Jr.	1973	William A. Buchheit	1987-89
Phanor L. Perot, Jr	1974-76	Julian T. Hoff	1990-92
John T. Garner	1977-80	Roberto C. Heros.....	1992-95
James T. Robertson	1981-83	David G. Piepgras	1995-98
Nicholas T. Zervas	1984-86	L. Nelson Hopkins.....	1998-01

HONORARY MEMBERS

- Elected
- GUY LAZORTES** (Annick)..... 1973
5 allée Charles Martel
31300 Toulouse
FRANCE
05 3451 3215
- KELJI SANO** (Yaeko)..... 1975
Fuji Brain Institute and Hospital
270-12 Sugita
Fujinomiya, 4180021
JAPAN
81 544 23 5155, fax 81 544 26 0937

SENIOR MEMBERS

Elected

EBEN ALEXANDER, JR. (Betty)..... 1950

Wake Forest University Medical School
Medical Center Boulevard
Winston-Salem, NC 27157-1002
336-716-3471, fax 336-716-3518, ealexanderiii@earthlink.net

JAMES AUSMAN (Carolyn) 1979

39000 Bob Hope Drive
P-311
Rancho Mirage CA 92270
760-779-8253, fax 760-779-8254, j.ausman@verizon.net

✓ **DONALD BECKER (Maria)**1990

Division of Neurosurgery, Box 957039
UCLA Medical Center
Room 18-228 NPI
Los Angeles, CA 90095-7039
310-825-3998, fax 310-794-5836, dbecker@mednet.ucla.edu

GILLES BERTRAND (Louise).....1967

Montreal Neurological Institute
3801 University Street
Montreal, Quebec H3A 2B4
CANADA
514-398-1935, fax 514-398-2811, luisa.birri@mcgill.ca

JERALD BRODKEY (Arielle).....1977

13901 Shaker Boulevard, #3A
Cleveland, OH 44120
216-752-4545, fax 216-752-9455, jsb@brodkey.com

WILLIS BROWN, JR. (Elizabeth Ann {Ann}).....1984

Center for Neurosurgical Sciences
Univ. of Texas Health Sciences Center at San Antonio
7703 Floyd Curl Drive, MC 7843
San Antonio, TX 78229-3900
210-567-5625, fax 210-567-6066, brownw@uthscsa.edu

✓ **WILLIAM BUCHHEIT (Christa)**.....1980

6014 Cricket Road
Flourtown PA 19031
215-836-9295, fax 215-836-4634, wbuchheit@aol.com

- ✓ **PAUL CHAPMAN**1983
 Massachusetts General Hospital
 55 Fruit Street, GRB 502
 Boston, MA 02114
 617-726-3887, chapman@helix.mgh.harvard.edu
- HARVEY CHENAULT** (Billee).....1949
 952 Edgewater Drive
 Lexington, KY 40502
 859-266-7634
- W. KEMP CLARK** (Fern)1970
 3909 Euclid Avenue
 Dallas, TX 75205-3103
 214-528-5985
- WILLIAM COLLINS, JR.** (Gwendolyn).....1963
 131 Uncas Point Road
 Guilford, CT 06437
 203-453-2034
 wfcollin@aol.com
- 12134 Putting Green Row
 San Diego, CA 92128
 858-673-9025
- EDWARD CONNOLLY** (Elise).....1972
 Department of Neurosurgery, 7th Floor
 Ochsner Foundation Clinic
 1514 Jefferson Highway
 New Orleans, LA 70121
 504-842-4033, fax 504-842-5078, econnelly@ochsner.org
- ✓ **PAUL COOPER** (Leslie)1995
 Department of Neurosurgery/NYU Medical Center
 550 First Avenue
 New York, NY 10016
 212-263-6514, fax 212-263-8225, paul.cooper@med.nyu.edu
- COURTLAND DAVIS, JR.** (Carrie)1967
 2525 Warwick Road
 Winston-Salem, NC 27104-1943
 336-723-7296, chdcdmd@triad.rr.com
- RICHARD DESAUSSURE, JR.** (Phyllis).....1962
 4290 Heatherwood Lane
 Memphis, TN 38117-2302
 901-761-5230, desrichard@aol.com

- DONALD DOHN** (Carolyn).....1968
P.O. Box 998
Point Clear, AL 36564
251-928-7670, fax 251-990-3738
- STEWART DUNSKER** (Ellen)1975
551 Abilene Trail
Cincinnati, OH 45215
513-522-0330, fax 513-522-0333, dunsker@aol.com
- HOWARD EISENBERG**1985
Department of Neurosurgery
22 S. Greene Street, 12 D South
Baltimore, MD 21201
410-328-3514, fax 410-328-1420, heisenberg@smail.umaryland.edu
- MEL EPSTEIN** (Lynn) 1992
411 Poppasquash Road
Bristol, RI 02809
401-254-5083, fax 401-253-6422, melepstein@earthlink.net
- WILLIAM FEINDEL** (Faith) 1959
Montreal Neurological Institute
3801 University Street
Montreal, Quebec H3A 2B4
CANADA
514-398-1939, fax 514-398-1375
- ROBERT FISHER** (Constance)..... 1955
12419 Woodley Avenue
Granada Hills, CA 91344-1817
- ✓ **EUGENE FLAMM** (Susan) 1979
Albert Einstein College of Medicine
Montefiore Medical Center
111 East 210th Street
Bronx, NY 10467
718-920-7400, fax 718-515-8235, eflamm@montefiore.org
- ELDON FOLTZ** (Catherine)..... 1960
2480 Monaco Drive
Laguna Beach CA 92651
949-494-3422, fax 949-494-8947, eldonfoltzmd@aol.com

RICHARD FRASER (Anne) 1976
5 Ellis Court
Rye NY 10580
914-967-6910

LYLE FRENCH (Gene) 1954
7501 East Thompson Peak Parkway
Casita 509
Scottsdale AZ 85255-4540
480-659-6286

JOHN GARNER (Candace) 1971
2834 Dove Run Creek Drive
Las Vegas, NV 89135
949-275-2357, jtgrex@aol.com

✓ **HENRY GARRETSON (Marianna)** 1973
517 Tiffany Lane
Louisville, KY 40207
502-896-8270, fax 502-896-8437
tiffanyhmg2@aol.com
29 Surfsong Road
Kiawah Island, SC 29455
843-768-7260, fax 843-768-7282

SIDNEY GOLDRING (Lois) 1964
11430 Conway Road
St. Louis, MO 63131
314-567-1171

PHILIP GORDY (Silvia) 1968
3601 Carmel Drive
Casper, WY 82604-4949
307-265-7883

ROBERT GROSSMAN (Ellin) 1984
Department of Neurosurgery
Baylor College of Medicine
6560 Fannin, Suite 944
Houston, TX 77030
713-798-4696, fax 713-798-3739, grossman@bcm.tmc.edu

ROBERT GRUBB, JR. (Julia) 1985
Department of Neurological Surgery, Box 8057
Washington University School of Medicine
660 South Euclid Avenue
St. Louis, MO 63110
314-362-3567, fax 314-362-2107, grubbr@nsurg.wustl.edu

- JOSEPH HAHN (Andrea)**..... 1993
 Department of Neurosurgery, S 80
 The Cleveland Clinic Foundation
 9500 Euclid Avenue
 Cleveland, OH 44195
 216-444-5802, fax 216-444-1011, hahnj@ccf.org
- GRIFFITH HARSH, III (Craig)**..... 1980
 P.O. Box 232
 Sweetwater, TN 37874
 423-337-7483, gharsh3@aol.com
- M. PETER HEILBRUN (Robyn)** 1984
 PO Box 920041
 Snowbird UT 84092-0041
 801-742-0516
 mpeterheilbrun@msn.com
 115 Barbarec Way
 Tiburon CA 94920
 415-381-8700
- ROBERTO HEROS (Deborah)**..... 1985
 Department of Neurological Surgery
 1095 NW 14th Terrace (D4-6)
 Miami, FL 33136
 305-243-4572, fax 305-243-3180, rheros@med.miami.edu
- ✓ **CHARLES HODGE, JR. (Catherine)**..... 1982
 Department of Neurosurgery
 611 Jacobsen Hall
 750 East Adams Street
 Syracuse, NY 13210
 315-464-5510/5511, fax 315-464-6384, hodgec@upstate.edu
- ✓ **JULIAN HOFF (Diane)**..... 1975
 Department of Neurosurgery
 University Hospitals
 1500 East Medical Center Drive, Box 038
 Ann Arbor, MI 48109
 734-936-5015, fax 734-936-9294, jhoff@umich.edu
- HAROLD HOFFMAN (Jo Ann)**..... 1982
 110 Blorr Street West, Apartment 607
 Toronto, Ontario M5S 2W7
 CANADA
 416-964-7775, fax 416-964-7848, j.hoffman@sympatico.ca

- EDGAR HOUSEPIAN** (Marion Grace).....1976
710 West 168th Street
New York, NY 10032
212-305-5256, fax 212-305-3250, emh4@columbia.edu
- ALAN HUDSON** (Susan)1978
Cancer Care Ontario
620 University Avenue
Toronto, Ontario M5G 2L9
CANADA
416-971-5100 x1610, fax 416-971-5940,
alan.hudson@cancercare.on.ca
- JOHN JANE, SR.** (Noella).....1982
Department of Neurosurgery
University of Virginia Health System
PO Box 800212
Charlottesville, VA 22908
434-982-3244, fax 434-243-2954, kes4a@virginia.edu
- PETER JANNETTA** (Diana).....1994
Allegheny General Hospital
420 East North Avenue, Suite 302
Pittsburgh, PA 15212
412-359-4810, fax 412-359-4811, pjannett@wpahs.org
- ELLIS KEENER** (Ann).....1978
915 East Lake Drive
Gainesville, GA 30506
770-532-5616, ebkeener@bellsouth.net
- DAVID KELLY, JR.** (Sarah {Sally})1975
Wake Forest University Baptist Medical Center
Medical Center Boulevard
Winston-Salem, NC 27157-1029
336-716-4049, 336-716-3065, dkelly@wfubmc.edu
- PATRICK KELLY** (Carol).....1992
530 First Avenue, Suite 8R
New York, NY 10016
212-263-8002, 212-263-8031, patrick.kelly@med.nyu.edu

- ROBERT KING (Molly)**1958
 S.U.N.Y. Upstate Medical University
 750 E. Adams Street
 Syracuse, NY 13210
 315-464-4470, fax 315-464-5520, kingrb@upstate.edu
- WOLFF KIRSCH (Marie-Claire)**1971
 Neurosurgery Center for Research, Training, and Education
 Loma Linda University
 11175 Campus Street, Suite 11113
 Loma Linda, CA 92350
 909-558-7070, fax 909-558-0472, wkirsch@som.llu.edu
- DAVID KLINE (Helen (Nell))**1971
 Department of Neurosurgery
 LSUHSC
 1542 Tulane Avenue
 New Orleans, LA 70112
 504-568-2641, fax 504-568-6127, vprout@lsuhsc.edu
- THOMAS LANGFITT (Carolyn)**1971
 Glenmede Corporation
 One Liberty Place, Suite 1200
 1650 Market Street
 Philadelphia, PA 19103-7391
 215-419-6010, fax 215-419-6196,
- SANFORD LARSON (Jacquelyn)**1989
 Department of Neurosurgery
 Medical College of Wisconsin
 9200 W. Wisconsin Avenue
 Milwaukee, WI 53226
 414-805-5407
- EDWARD LAWS, JR. (Margaret {Peggy})**1983
 Department of Neurosurgery, Box 800212
 University of Virginia
 Charlottesville, VA 22908-0212
 434-924-2650, fax 434-924-5894, el5g@virginia.edu
- ✓ **RAEBURN LLEWELLYN (Carmen)**1963
 3 Poydras Street, Unit 6D
 New Orleans, LA 70130
 504-581-5252, fax 504-523-1520, carsonllewellyn@yahoo.com

✓ **DONLIN LONG** (Harriett).....1983
600 North Wolfe Street
Carnegie 466
Baltimore, MD 21287
410-614-3536, fax 410-955-6407, dmlong@jhmi.edu

WILLIAM LOUGHEED.....1962
178 Kempenfelt Drive
Barrie, Ontario L4M 1C3
CANADA
705-728-8521

JOHN LOWREY (Catherine {Katy}).....1965
65-1160 Kokuala Road
Kamuela, HI 96743
808-885-5867

ALFRED LUESSENHOP (Frances).....1977
4524 Foxhall Crescents
Washington, DC 20007
202-338-1914, franhop@aol.com
(May-October)

27160 Oak Knoll Drive
Bonita Springs, FL 34134
239-495-9923
(November-April)

LEONARD MALIS (Ruth)1973
219-44 Peck Avenue
Hollis Hills, NY 11427
718-479-9326, fax 718-479-9328, nsdoclen@aol.com

✓ **ROBERT MAXWELL** (Karen).....1992
Department of Neurosurgery, MMC 96
420 Delaware Street SE
Minneapolis, MN 55455
612-626-0137, fax 612-624-0644, rem_kam@yahoo.com

ROBERT MCLAURIN (Sally).....1955
900 Fourth & Vine Tower
5 W Fourth Street
Cincinnati, OH 45202-3688
513-381-9200, fax 513-381-9206, mclaurin@one.net

J. MICHAEL MCWHORTER (Barbara)1989
Carolina Neurosurgical Associates
2810 North Maplewood Avenue
Winston-Salem, NC 27103-4151
336-768-1811, fax 336-768-0360, jmcwhorter@triad.rr.com

JOHN MULLAN (Vivian)1963
5844 Stony Island Avenue
Chicago, IL 60637
773-241-6546, fax 773-241-6546 #51

BLAINE NASHOLD, JR. (Irene)1967
Department of Neurosurgery
Duke University Medical Center, Box 3807
Durham, NC 27710
919-684-2937, fax 919-684-2026, nasho002@aol.com

✓ **GEORGE OJEMANN (Linda)**1975
Department of Neurosurgery
University of Washington
Campus Box 356470
1959 N.E. Pacific Street
Seattle, WA 98195
206-543-3570, fax 206-543-8315, gojemann@u.washington.edu

ROBERT OJEMANN (Jean)1968
Massachusetts General Hospital
Fruit Street
Boston, MA 02114
617-726-2936, fax 617-726-3126, rojemann@partners.org

ANDRE OLIVIER (Nicole Poulin)1989
Montreal Neurological Hospital
3801 University Street, #109
Montreal, Quebec H3A 2B4
CANADA
514-398-1935, fax 514-398-2811, luisa.birri@mcgill.ca

BURTON ONOFRIO (Judy)1975
1105 Tenth Street SW
Rochester, MN 55902
507-289-3684, fax 507-529-9469

✓ **RUSSEL PATTERSON, JR. (Juliet {Julie})**1971
146 West 57th Street
Apartment 65A
New York, NY 10019-3301
212-586-9237, fax 212-315-3877, mail49212@pop.net

✓ **J. CHARLES RICH, JR.** (Jasmine).....1987

2397 East 1300 South
Salt Lake City, UT 84108
801-583-4822, fax 801-582-7644, jcrichnsur@aol.com

HUGO RIZZOLI1973

6100 Kennedy Drive
Chevy Chase MD 20815-06510
301-654-6486, fax 301-907-4619, hrizzoli@comcast.net

THEODORE ROBERTS (Joan).....1976

4800 Sand Point WY. N.E.
Seattle, WA 98105
206-328-5259, fax 206-764-2529, troberts@u.washington.edu

✓ **JAMES ROBERTSON** (Valeria).....1971

847 Monroe Avenue, Suite 427
Memphis, TN 38163
901-448-6375, fax 901-448-8468, j.robertson@utm.edu

R. MICHAEL SCOTT (Susan).....1991

Children's Hospital
300 Longwood Avenue, Bader 319
Boston, MA 02115
617-355-6011, fax 617-734-2628,
michael.scott@childrens.harvard.edu

✓ **EDWARD SELJESKOG** (Peg)1992

4141 5th Street
Rapid City, SD 57701
605-341-2424, fax 604-341-4547, edskog@aol.com

WILLIAM SHUCART (Laura)1989

Department of Neurosurgery
750 Washington Street
Boston, MA 02111
617-636-5858, 617-636-7587, wshucart@tufts-nemc.org

JAMES SIMMONS (Vanita)1975

190 South Grove Park Road
Memphis, TN 38117
901-767-9060

- ✓ **KENNETH SMITH, JR. (Marjorie)**1987
 Division of Neurosurgery
 3635 Vista
 St. Louis, MO 63110
 314-577-8795, fax 314-268-5061, smithj5@slu.edu
- BENNETT STEIN (Bonita)**1970
 411 Claremont Road
 Bernardsville, NJ 07924
 908-696-0293, fax 908-696-0283, novauntb@aol.com
- JIM STORY (Joanne)**1972
 315 North San Saba, #1210
 San Antonio, TX 78207
 210-354-0877, fax 210-354-0880, jlstory@swbell.net
- ANTHONY SUSEN (Patricia)**1965
 193 Old Glebe Point Road
 Burgess, VA 22432
 804-455-4025, w3aoh@direcway.com
- RONALD TASKER**1971
 Neurosurgery, The Toronto Western Hospital
 399 Bathurst Street, Suite 2-432 McL
 Toronto, Ontario M5T 2S8
 CANADA
 416-603-5771, fax 416-603-5298
- CHARLES TATOR (Carol)**1991
 Neurosurgery, The Toronto Western Hospital
 399 Bathurst Street, Suite 4W.433
 Toronto, Ontario M5T 2S8
 CANADA
 416-603-5889, fax 416-603-5298, charles.tator@uhn.on.ca
- ✓ **JOHN TEW, JR. (Susan)**1971
 Department of Neurosurgery
 234 Goodman Street
 Cincinnati, OH 45219-0724
 513-584-2214, fax 513-584-6846, tewjm@healthall.com

- GEORGE TINDALL (Wendy)**.....1968
 227 Rose Hill Road
 Meansville, GA 30256
 770-567-3874, fax 770-567-3746, gtindall@midgeorgiansy.com
- RUSSELL TRAVIS (Jill)**.....1994
 2050 Versailles Road
 Lexington, KY 40504
 859-455-9960, fax (same #), rltravis@aol.com
- JOHN TYTUS (Virginia)**1967
 3827 East Crockett Street
 Seattle, WA 98112
- JOHN VAN GILDER (Kerstin)**.....1980
 Department of Neurological Surgery
 University of Iowa Hospitals and Clinics
 Iowa City, IA 52242
 319-356-2772, fax 319-353-6605, john-vangilder@uiowa.edu
- EXUM WALKER (Nellie)**.....1938
 735 Peachtree Battle Avenue, NW
 Atlanta, GA 30327-1250
 404-523-1521
- CLARK WATTS (Patricia)**.....1975
 5922 Northwest Place
 Austin, TX 78731
 512-459-1195, fax 512-459-2199, cwatts@lawpark.com
- BRYCE WEIR (Mary Lou)**.....1984
 230 Westridge Road
 Edmonton, Alberta T5T 1C1
 CANADA
 780-486-9429, fax 780-487-9428, bkaweir@telus.net
- MARTIN WEISS (Debby)**.....1981
 1200 North State Street, Suite 5046
 Los Angeles, CA 90033
 323-226-7421, fax 323-226-7833, weiss@email.usc.edu
- LOWELL WHITE, JR.**.....1971
 11009 E. Villa Monte Drive
 Mukilteo, WA 98275
 425-315-8030, budwhite@gte.net

- ROBERT WILKINS (Gloria)** 1973
 Box 3807, Duke University Medical Center
 Durham NC 27710
 919-684-3034, 919-542-3144, rhwilkins@aol.com
- CHARLES WILSON (Francie Petrocelli)** 1966
 524 Second Street
 San Francisco, CA 94107
 415-537-6961, fax 415-831-1947, cwilson@healthtechcenter.org
- H. RICHARD WINN (Debbie)** 1993
 Mt. Sinai School of Medicine, Box 1136
 One Gustave L. Levy Place
 New York, NY 10029-6574
 212-241-4220, rwinn01@msnyuhealth.org
- ✓ **FREMONT P. WIRTH (Lynn)** 1993
 4 Jackson Boulevard
 Savannah, GA 31405-5895
 912-355-1010, fax 912-354-1441, fpwirth@bellsouth.net
- DAVID YASHON**..... 1972
 340 E. Town Street, 7-600
 Columbus, OH 43215
 614-224-1720, fax 614-221-9805
- HAROLD YOUNG (Theresa)** 1994
 1200 East Broad Street
 Post Office Box 980631
 Richmond, VA 23298-0631
 804-828-9167, 804-828-0374, schoolfpx@comcast.net
- RONALD YOUNG**..... 1999
 Northwest Gamma Knife Center, #G-5
 1560 North 115th Street
 Seattle, WA 98133
 213-977-2234, fax 213-482-2157
- NICHOLAS ZERVAS (Thalia)** 1972
 Massachusetts General Hospital
 Fruit Street, Warren 905
 Boston, MA 02114
 617-726-4141, fax 617-726-6789, nzervas@partners.org

ACTIVE MEMBERS

Elected

EBEN ALEXANDER, III (Holley).....1999

Division of Neurosurgery
UMass Memorial Hospital
119 Belmont Street
Worcester, MA 01605
508-334-5589, fax 508-334-5217, ealexand@earthlink.net

✓ **MICHAEL APUZZO**.....1988

Department of Neurological Surgery
LAC/USC Medical Center
1200 North State Street, Suite 5046
Los Angeles, CA 90033
323-226-7421, fax 323-226-5897, apuzzo@usc.edu

ISSAM AWAD (Catherine)1996

Department of Neurosurgery
Northwestern University Feinberg School of Medicine
Evanston Northwestern Healthcare
2650 Ridge Avenue, Room 4215
Evanston, IL 60201
847-570-1440, fax 847-570-1442, iawad@enh.org

JULIAN BAILES (Colleen)2002

PO Box 9183
Morgantown, WV 26506-9183
304-293-5041, fax 304-293-4819, jbailes@hsc.wvu.edu

NICHOLAS BARBARO (Sue Ellen).....2002

UCSF Neurosurgery
Box 0112
San Francisco CA 94143
415-502-3744, fax 415-476-9701, barbaron@neurosurg.ucsf.edu

✓ **GENE BARNETT (Cathy Sila)**.....2000

Brain Tumor Institute, Neurosurgery/S80
Cleveland Clinic Foundation
9500 Euclid Avenue
Cleveland, OH 44195
216-445-1379, fax 216-636-2437, barnett@neus.ccf.org

DANIEL BARROW (Mollie).....1993
1365 B Clifton Road NE, Suite 6400
Atlanta, GA 30322
404-778-3895, fax 404-778-4472,
daniel_barrow@emoryhealthcare.org

H. HUNT BATJER (Janet).....1996
233 East Erie Street, Suite 614
Chicago, IL 60611
312-695-6285, fax 312-695-0225, hbatjer@nmff.org

MITCHEL BERGER (Joan).....1997
UCSF Department of Neurosurgery
505 Parnassus Avenue, M-786
Box 0112
San Francisco, CA 94143-0112
415-502-7673, fax 415-502-1106, bergerm@neurosurg.ucsf.edu

KEITH BLACK (Carol Bennett).....1995
Cedars-Sinai Medical Center
Maxine Dunitz Neurosurgical Institute
8631 West Third Street, Suite 800 East
Los Angeles, CA 90048
310-423-1773, fax 310-423-1008, black@cshs.org

✓ **PETER BLACK** (Katharine).....1988
Department of Neurosurgery
Children's Hospital
300 Longwood Avenue
Boston, MA 02115
617-355-7795, fax 617-730-0903, pblack@partners.org

LAWRENCE BORGES (Susan)1993
Massachusetts General Hospital
55 Fruit Street, White 1205
Boston, MA 02114
617-726-6156, fax 617-724-7407, lborges@partners.org

✓ **CHARLES BRANCH, JR.** (Lesa)1996
WFU Baptist Medical Center
Medical Center Boulevard
Winston-Salem, NC 27157-1029
336-716-4038, fax 336-716-3065, cbranch@wfubmc.edu

- HENRY BREM (Rachel)**.....1996
 Johns Hopkins University
 600 N. Wolfe Street / Meyer 7-113
 Baltimore, MD 21287
 410-955-2252, fax 410-955-8263, hbrem@jhmi.edu
- ✓ **JEFFREY BRUCE (Rebecca)**.....2002
 Neurological Institute, Rm. 434
 710 W. 168th Street
 New York, NY 10032
 212-305-7346, fax 212-305-2026, jnb2@columbia.edu
- KIM BURCHIEL (Debra)**.....1992
 Department of Neurological Surgery
 Oregon Health Sciences University
 Portland, OR 97201
 503-494-6207, fax 503-494-7161, burchiek@ohsu.edu
- ✓ **MARTIN CAMINS (Joan)**.....1995
 205 East 68th Street #TIC
 New York, NY 10021
 212-570-0100, fax 212-570-0117, martin_camins@msn.com
- ✓ **PETER CARMEL (Jacqueline Bello)**.....1991
 UMDNJ - Neurosurgery
 90 Bergen Street, Suite 8100
 Newark, NJ 07103
 973-972-2323, fax 973-972-2340, carmel@umdnj.edu
- ✓ **WILLIAM CHANDLER (Susan)**.....1989
 University of Michigan Hospital
 Taubman Health Center, 2124D
 1500 E. Medical Center Drive
 Ann Arbor, MI 48109-0338
 734-936-5020, fax 734-936-9294, wchndlr@umich.edu
- ✓ **FADY CHARBEL (Alexandra)**.....2003
 Department of Neurosurgery
 University of Illinois at Chicago
 912 S. Wood Street (MC 799)
 Chicago, IL 60612
 312-996-8741, fax 312-966-9018, fcharbel@uic.edu

ALAN COHEN.....1999

Rainbow Babies and Children's Hospital
Room B-501
11100 Euclid Avenue
Cleveland, OH 44106
216-844-5741, fax 216-844-5710, alan.cohen@uhhs.com

G. REES COSGROVE (Karen Ann Roche).....1997

Massachusetts General Hospital
15 Parkman Street, ACC #331
Boston, MA 02114
617-724-0357, fax 617-726-7546, cosgrove@helix.mgh.harvard.edu

WILLIAM COULDWELL (Marie).....1999

Department of Neurosurgery
30 North 1900 East, Suite 3B409
Salt Lake City, UT 84132
801-581-6908, fax 801-581-4385, william.couldwell@hsc.utah.edu

RALPH DACEY, JR. (Corinne).....1990

Department of Neurological Surgery
Washington University School of Medicine
660 South Euclid, Campus Box 8057
St. Louis, MO 63110
314-362-5039, fax 314-362-2107, daceyr@nsurg.wustl.edu

ARTHUR DAY (Dana).....1990

Department of Neurosurgery
75 Francis Street
Boston, MA 02115
617-525-7777, fax 617-734-8342, aday1@partners.org

✓ **ROBERT DEMPSEY (Diane)**.....1996

Department of Neurological Surgery
University of Wisconsin
600 Highland Avenue, Rm. K4/822
Madison, WI 53792
608-263-9585, fax 608-263-1728, dempsey@neurosurg.wisc.edu

MICHAEL EDWARDS (Linda).....1992

Sutter Neuroscience Medical Group
2800 L Street, Suite 340
Sutter Cancer Center
Sacramento, CA 95816
916-454-6850, fax 916-454-6852, edwardm@sutterhealth.org

- KEVIN FOLEY (Lynn)**.....1999
 Image-Guided Surgery Research Center
 Semmes-Murphey Clinic
 1211 Union Avenue, Suite 200
 Memphis, TN 38104
 901-516-0742, fax 901-516-0744, kfoley@usit.net
- ALLAN FRIEDMAN (Elizabeth Bullitt)**1994
 Division of Neurological Surgery
 Duke University Medical Center
 Box 3807
 Durham, NC 27710
 919-684-3271, fax 919-681-7973, fried010@mc.duke.edu
- DANIEL FULTS, III (Carol)**1997
 Department of Neurosurgery
 University of Utah, School of Medicine
 30 N. 1900 E. Suite 3B409
 Salt Lake City, UT 84132-2303
 801-581-6908, fax 801-581-4385, daniel.fults@hsc.utah.edu
- STEVEN GIANNOTTA (Sharon)**1992
 1200 North State Street
 Suite 5046
 Los Angeles, CA 90033-4525
 323-226-7421, 323-226-7833, giannott@usc.edu
- ✓ **M. SEAN GRADY (Debra)**2003
 Neurosurgery, University of Pennsylvania
 3400 Spruce Street
 5th Floor Silverstein Pavilion
 Philadelphia, PA 19104
 215-349-8325, fax 215-349-5108, gradys@uhs.upenn.edu
- MARK HADLEY (Lori)**.....2001
 Neurosurgery, University of Alabama
 1030 Faculty Office Tower
 510 20th Street South
 Birmingham AL 35294
 205-934-3655, fax 205-975-6081, mhadley@uabmc.edu

- ✓ **STEPHEN HAINES** (Jennifer Plombon)1994
 Department of Neurosurgery
 University of Minnesota Medical School
 D429 Mayo Memorial Building
 420 Delaware Street, SE, MMC #96
 Minneapolis MN 55455
 612-626-5767, fax 612-624-0644, shaines@umn.edu
- ROBERT HARBAUGH** (Kimberly).....2001
 Department of Neurosurgery
 Penn State University–Milton S. Hershey Medical Center
 C3830, Biomedical Research Building
 500 University Drive
 Hershey PA 17033-0850
 717-531-4383, fax 717-531-3858, rharbaugh@psu.edu
- HAYNES LOUIS HARKEY, III** (Alison)2002
 Department of Neurosurgery
 University of Mississippi Medical Center
 2500 North State Street
 Jackson, MS 39216-4505
 601-984-5714, fax 601-815-5680,
 lharkey@neurosurgery.umsmed.edu
- ✓ **GRIFFITH HARSH, IV** (Meg Whitman).....2001
 Department of Neurosurgery, MC 5327
 Stanford Medical Center, #R227
 300 Pasteur Drive
 Stanford, CA 94305
 650-725-8430, fax 650-723-7813, gharsh@stanford.edu
- CARL HEILMAN** (Carolyn)2002
 Department of Neurosurgery, 178
 750 Washington Street
 Boston, MA 02111
 617-636-5860, fax 617-636-7587, cheilman@tufts-nemc.org
- ✓ **L. NELSON (NICK) HOPKINS, III** (Ann {Bonnie}).....1992
 University at Buffalo Neurosurgery
 3 Gates Circle
 Buffalo, NY 14209
 716-887-5210, fax 716-887-4378, lnhl@buffalo.edu

- IAIN KALFAS**.....2003
 Department of Neurosurgery (S80)
 Cleveland Clinic Foundation
 9500 Euclid Avenue
 Cleveland, OH 44195
 216-444-9064, fax 216-445-6801, kalfas@neus.ccf.org
- ✓ **GLENN KINDT (Charlotte)**.....1977
 4200 E. 9th Avenue, Box C307
 Denver, CO 80262
 303-315-1429, fax 303-315-6197, glenn.kindt@uchsc.edu
- DOUGLAS KONDZIOLKA (Susan)**.....1998
 Department of Neurological Surgery
 UPMC, Suite B-400
 200 Lothrop Street
 Pittsburgh, PA 15213
 412-647-6782, fax 412-647-0989, kondziolkads@msx.upmc.edu
- ✓ **MICHAEL LAWTON (Suzanne)**.....2003
 UCSF Department of Neurosurgery
 505 Parnassus Avenue, M-780C
 San Francisco, CA 94143-0112
 415-502-5823, fax 415-502-2059, lawtonm@neurosurg.ucsf.edu
- MICHAEL LEVY (Karen)**.....2003
 8010 Frost Street, Suite 502
 San Diego, CA 92123
 858-966-8574, fax 858-966-7930, mlevy@chsd.org
- CHRISTOPHER LOFTUS (Sara Sirna)**.....1992
 Department of Neurosurgery
 Temple University
 3401 N. Broad Street
 Parkinson Pavilion – Suite 580
 Philadelphia PA 19140
 215-707-9790, fax 215-707-3831, cloftus@temple.edu
- L. DADE LUNSFORD (Julianne (Julie))**.....1992
 UPMC Presbyterian
 200 Lothrop Street, Suite B400
 Pittsburgh, PA 15213
 412-647-6781, fax 412-647-6483, lunsfordld@msx.upmc.edu

- R. LOCH MACDONALD** (Sheilah).....2000
 Section of Neurosurgery, MC 3026
 University of Chicago Medical Center
 5841 South Maryland Avenue
 Chicago, IL 60637
 773-702-2123, fax 773-702-3518, rlmacdon@uchicago.edu
- ROBERT MACIUNAS** (Ann Failing)1999
 Department of Neurological Surgery
 University Hospitals
 11100 Euclid Avenue
 Cleveland, OH 44106
 216-844-5743, fax 216-844-3014, robert.maciunas@uhhs.com
- JOSEPH MADSEN** (Ilonna Rimm)2003
 Department of Neurosurgery
 Children's Hospital, Boston
 300 Longwood Avenue
 Boston, MA 02115
 617-355-6005, fax 617-734-2628, joseph.madsen@tch.harvard.edu
- JAMES MARKERT** (Laili)2002
 Neurosurgery, University of Alabama at Birmingham
 1050 Faculty Office Towers
 510 20th Street South
 Birmingham, AL 35294-3410
 205-975-6985, fax 205-975-3203, markert@uabmc.edu
- NEIL MARTIN** (Colleen)1997
 UCLA Neurosurgery
 Box 957039
 Los Angeles, CA 90095-7039
 310-206-3579, fax 310-206-6242, neilmartin@mednet.ucla.edu
- ROBERT MARTUZA** (Jill).....1989
 Department of Neurosurgery
 Massachusetts General Hospital
 55 Fruit Street, White 502
 Boston, MA 02114
 617-726-8583, fax 617-726-4814, rmartuza@partners.org

- MARC MAYBERG (Teresa)** 1995
 Department of Neurosurgery/S80
 Cleveland Clinic Foundation
 9500 Euclid Avenue
 Cleveland, OH 44195
 216-445-4430, fax 216-636-2061, mayberg@neus.ccf.org
- ✓ **J. GORDON MCCOMB (Rhoda)** 1998
 1300 North Vermont Avenue, #1006
 Los Angeles, CA 90027
 323-663-8128, fax 323-668-1870, gmccomb@chla.usc.edu
- ✓ **PAUL MCCORMICK (Doris)** 1998
 710 West 168th Street
 New York, NY 10032
 212-305-7976, fax 212-305-3629, pcm6@columbia.edu
- FREDRIC MEYER (Irene)** 1995
 Mayo Clinic
 200 First Street SW
 Rochester, MN 55905
 507-284-5317, fax 507-284-5206, meyer.fredric@mayo.edu
- RICHARD MORAWETZ (Mary Jean)** 1990
 510 Twentieth Street South
 1060 Faculty Office Tower
 Birmingham, AL 35294-3410
 205-934-2918, fax 205-975-5791, pparker@uabmc.edu
- JACQUES MORCOS (Fiona)** 2003
 Department of Neurological Surgery
 1095 NW 14th Terrace (D4-6)
 Miami, FL 33136
 305-243-4675, fax 305-243-3337, jmorcos@med.miami.edu
- ✓ **PAUL NELSON (Teresa)** 1991
 Indiana University Neurosurgery
 545 Barnhill Drive
 Emerson Hall 139
 Indianapolis, IN 46202
 317-274-5725, fax 317-274-7351, pnelson1@iupui.edu

- ✓ **DAVID NEWELL** (Shirley).....2002
 700 9th Avenue
 Seattle, WA 98104
 206-521-1841, fax 206-521-1881, dwn@u.washington.edu
- W. JERRY OAKES** (Jean).....1999
 Pediatric Neurosurgery
 The Children's Hospital of Alabama
 1600 7th Avenue South, ACC 400
 Birmingham, AL 35233
 205-939-6914, fax 205-939-9972, wjomd@uab.edu
- CHRISTOPHER OGILVY**2000
 Neurosurgery, VBK710
 Massachusetts General Hospital
 55 Fruit Street
 Boston, MA 02114
 617-726-3303, fax 617-726-7501, cogilvy@partners.org
- EDWARD OLDFIELD** (Susan Shawler Wachs).....1975
 National Institutes of Health
 10 Center Drive, Room 5D37
 Bethesda, MD 20892-1414
 301-496-5728, fax 301-402-0380, oldfielde@ninds.nih.gov
- STEPHEN PAPADOPOULOS** (Penny).....2000
 Barrow Neurological Institute
 2910 N. Third Avenue
 Phoenix, AZ 85013
 602-406-3159, fax 602-406-3181, stvpapa@bnaneuro.net
- ✓ **TAE SUNG PARK**.....1996
 St. Louis Children's Hospital
 One Children's Place, Suite 4S20
 St. Louis, MO 63110
 314-454-4629, fax 314-454-2818, park@nsurg.wustl.edu
- LAWRENCE PITTS** (Mary)1997
 505 Parnassus Avenue, M780
 San Francisco, CA 94143
 415-502-5823, fax 415-502-2059, pittsl@neurosurg.ucsf.edu

A. JOHN POPP (Margaret Vosburgh)2001
Department of Surgery
Albany Medical College
47 New Scotland Avenue, Mailcode 61
Albany, NY 12208
518-262-5314, fax 518-262-5692, poppj@mail.amc.edu

KALMON POST (Linda Farber-Post)1995
Mount Sinai Medical Center
One Gustave L. Levy Place, Box 1136
New York, NY 10029
212-241-0933, fax 212-423-9285, kalmon.post@msnyuhealth.org

✓ **COREY RAFFEL** (Kathy)1998
Department of Neurologic Surgery E6B
Mayo Clinic
200 First Street SW
Rochester, MN 55905
507-284-8167, fax 507-284-5206, raffel.corey@mayo.edu

DAVID ROBERTS (Kathryn)1996
Neurosurgery, Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, NH 03756
603-650-8736, fax 603-650-4547, david.w.roberts@dartmouth.edu

✓ **JON ROBERTSON** (Carol Ann)1992
1211 Union Avenue, Suite 200
Memphis, TN 38104
901-259-5335, fax 901-259-5300
jrobertson@semmes-murphey.com

GERALD RODTS (Chaille)2003
550 Peachtree Street NE
Suite 806 Neurosurgery
Atlanta, GA 30308
404-686-8101, fax 404-686-4805,
gerald_rodts@emoryhealthcare.org

ROBERT ROSENWASSER (Deborah August)1996
909 Walnut Street, 3rd Floor
Philadelphia, PA 19107
215-503-7004, fax 215-503-7007, robert.rosenwasser@mail.tju.edu

- ✓ **JAMES RUTKA (Mari)**..... 1996
 Division of Neurosurgery, The Hospital for Sick Children
 555 University Avenue, Suite 1504
 Toronto, Ontario M5G 1X8
 CANADA
 416-813-6425, fax 416-813-4975, james.rutka@sickkids.ca
- DUKE SAMSON (Patricia Bergen)**.....1994
 Neurological Surgery
 University of Texas Southwestern Medical School
 5323 Harry Hines Boulevard
 Dallas, TX 75390
 214-648-4551, fax 214-648-2822,
 duke.samson@utsouthwestern.edu
- RAYMOND SAWAYA (Kristin)**2003
 The University of Texas M.D. Anderson Cancer Center
 Department of Neurosurgery
 1515 Holcombe Boulevard
 Houston, TX 77030
 713-792-2400; fax 713-563-1804, rsawaya@mdanderson.org
- WARREN SELMAN (Diana)**1995
 Neurological Surgery, University Hospitals
 11100 Euclid Avenue
 Cleveland, OH 44106
 216-844-7600, fax 216-844-3014, warren.selman@uhhs.com
- ✓ **CHRISTOPHER SHIELDS (Deborah)**.....1993
 Neurosurgery, University of Louisville
 210 East Gray Street, Suite 1102
 Louisville, KY 40202
 502-629-5510, fax 502-629-5512, cbshields1@aol.com
- J. MARC SIMARD (Monique Bellefleur)**1999
 University of Maryland Neurosurgery
 22 South Greene Street, Suite S12D
 Baltimore, MD 21201
 410-328-0850, fax 410-328-0756,
 msimard@surgery1.umaryland.edu

- FREDERICK SIMEONE** (Terry Ryan) 1981
 Medical College of Pennsylvania Hospital
 Simeone Center for Neurosurgery
 3300 Henry Avenue, Suite 901
 Philadelphia, PA 19129
 215-842-6200, fax 215-842-7001, acb@drexel.edu
- ROBERT SOLOMON** (Barbara).....1996
 The Neurological Institute of New York
 710 West 168th Street
 New York, NY 10032
 212-305-4118, fax 212-305-2026, ras5@columbia.edu
- ✓ **VOLKER SONNTAG** (Lynne).....1995
 2910 North Third Avenue
 Phoenix, AZ 85013
 602-406-3458, fax 602-406-6110, vsonntag@thebni.com
- DENNIS SPENCER** (Susan).....1989
 Neurosurgery, Yale University School of Medicine
 333 Cedar Street, PO Box 208082
 New Haven, CT 06520-8082
 203-785-2285, fax 203-785-4161, dennis.spencer@yale.edu
- ✓ **ROBERT SPETZLER** (Nancy).....1997
 Barrow Neurological Institute
 350 W. Thomas Road
 Phoenix, AZ 85013
 602-406-3489, fax 602-406-4402, rspetzler@thebni.com
- PHILIP STIEG** (Janet).....2001
 Neurological Surgery, Weill Medical College – Cornell University
 525 E. 68th Street
 New York, NY 10021
 212-746-4684, fax 212-746-6607, pes2008@med.cornell.edu
- VINCENT TRAYNELIS** (Joan).....2001
 Neurosurgery, The University of Iowa
 200 Hawkins Drive
 Iowa City, IA 52242
 319-356-2774, fax 319-353-6603, vincent-traynelis@uiowa.edu

HARRY VAN LOVEREN (Judy).....1995

USF Department of Neurosurgery
4 Columbia Drive, Suite 730
Tampa, FL 33606
813-259-0901, fax 813-259-0944, hvanlove@hsc.usf.edu

DENNIS VOLLMER (Dorothy)2001

Neurosurgery, UT Houston
6410 Fannin Street, Suite 1020
Houston, TX 77030
713-704-6445, fax 713-704-6462, dennis.g.vollmer@uth.tmc.edu

✓ **RAND VOORHIES (Terry)**1996

Neurosurgery, Ochsner Clinic Foundation
1514 Jefferson Highway
New Orleans, LA 70121
504-842-4033, fax 504-842-6531, rvoorhies@ochsner.org

M. CHRISTOPHER WALLACE (Katie).....2003

Division of Neurosurgery WW 4-450
The Toronto Western Hospital
399 Bathurst Street
Toronto, Ontario M5T 2S8
CANADA
416-603-5428, fax 416-603-5298, chris.wallace@uhn.on.ca

RONALD WARNICK (Ana).....2000

222 Piedmont Avenue, #3100
Cincinnati, OH 45219
513-558-3179, fax 513-558-0885, nsgymd@mac.com

✓ **A. BYRON YOUNG (Judith)**1989

Division of Neurosurgery, University of Kentucky
800 Rose Street, Room MS 101
Lexington, KY 40536-0298
859-323-5864, fax 859-257-8011, byounl@email.uky.edu

SENIOR CORRESPONDING MEMBERS

Elected

HIROSHI ABE (Yoko)1999

Medical Scanning Sapporo Clinic
North 4, West 5, Choku, Sapporo
Hokkaido, 060-0004
JAPAN

81 11 208 3501, fax 81 11 208 3502, abe@med.akita-u.ac.jp

JOAO (JOHN) ANTUNES (Maria ceu Machado).....2001

Hospital Santa Maria
Servico de Neurocirurgia
Av. Prof Egas Moniz
1649-035, Lisbon
PORTUGAL

351 21 797 2855, fax (same #), jlobo.antunes@mail.telepac.pt

R. LEIGH ATKINSON (Noela)1989

201 Wickham Terrace
Brisbane, Queensland 4000
AUSTRALIA
61 7 3839 3393, fax 61 7 3832 2005,
leighatkinson@optusnet.com.au

ARMANDO BASSO (Milva) 1996

Ayacucho 1342
Buenos Aires, 1111
ARGENTINA
54 11 4806 3635, fax 54 11 4806 6531, armondobasso@aol.com

ALBINO BRICOLO (Annapaola Zandomeneghi)..... 2002

Department of Neurosurgery
University Hospital
Piazzale Stefani 1
Verona, 37126 ITALY
39 045 80 72 007, fax 39 045 916 790, albino.bricolo@univr.it

✓ **MARIO BROCK** (Christina)..... 2001

Neurochirurgische Klinik, U.K.B.F.
Hindenburgdamm 30
D-12200, Berlin
GERMANY
49 30 8445 2531, fax 49 30 8445 3569, prof.m@riobrock.de

- FERNANDO CABIESES**1966
 Clinica San Borja
 Av. Guardia Civil 337
 Lima, 27
 PERU
- LUC CALLIAUW (Dora)**1988
 Sint-Annarei 19
 B 8000, Brugge
 BELGIUM
 11 32 50 344377, fax (same #), luccalliau@hotmail.com
- H. ALAN CROCKARD (Caroline)**.....1992
 Surgical Neurology (Box 3)
 The National Hospital for Neurology and Neurosurgery
 Queen Square
 London, England WC1N 3BG
 UNITED KINGDOM
 44 207 829 8714, fax 44 207 676 2045, alan.crockard@uclh.org
- GUISEPPE DALLE ORE (Guisi)**1970
 Via San Mattia 5
 Verona, 37128
 ITALY
- NOEL DAN (Adrienne)**1989
 Specialist Medical Centre
 235 New South Head Road
 Edgecliff, N.S.W. 2027
 AUSTRALIA
 61 2 9327 8133, fax 61 2 9327 5807, noeld@med.usyd.edu.au
- NICOLAS DE TRIBOLET (Veronica)**1995
 Department of Neurosurgery, University Hospital
 Rue Micheli-du-Crest 24
 CH-1211, Geneva 14
 SWITZERLAND
 41 22 372 82 01, fax 41 22 372 82 25, Nicolas.deTribolet@hcuge.ch
- JACQUES DE VILLIERS (Jeanne Marie)**.....1986
 7 Finsbury Avenue
 Newlands
 Cape Town, 7700
 SOUTH AFRICA
 021 674 3828, fax (same #), jcdevill@iafrica.com

- HANS ERICH DIEMATH**1970
 Gerichtssachverstaendiger
 Maxglaner Hauptstrasse 6
 A-5020, Salzburg
 AUSTRIA
 43 662 62 28 50, fax 43 662 62 28 501, diemath@salzburg.co.at
- HERMANN DIETZ (Elfrun)**1930
 An Der Trift 10/B
 D-30559, Hannover
 GERMANY
 49 511 525686, fax (same #)
- VINKO DOLENC**1988
 Neurosurgical Department
 University Hospital Center - Ljubljana
 Zaloska 7
 Ljubljana, 1525
 SLOVENIA
 38 61 522 2218, fax (same #)
- ✓ **RUDOLF FAHLBUSCH (Hanna)**1991
 Neurochirurgische Klinik der Universitat Erlangen-Nurnberg
 Schwabachanlage 6
 Erlangen, D-91054
 GERMANY
 49 9131 853 4565, fax 49 9131 853 4476,
 rudolf.fahlbusch@nch.imed.uni-erlangen.de
- F. JOHN GILLINGHAM (Judy)**1962
 Easter Park House
 Easter Park Drive
 Edinburgh, Scotland EH4 6SN
 UNITED KINGDOM
 44 131 336 3528, fax (same #)
- HECTOR GIOCOLI (Maria Cristina Garcia)**2000
 M. T. de Alvear 2346
 Buenos Aires, C 1122 AAL
 ARGENTINA
 5411 4963 9500, fax (same #), hgiocoli@intramed.net.ar

- JAIME GOMEZ (Lucy)**.....1975
 148 Newcastle Drive
 Jupiter, FL 33458-3021
 561-575-1966
- SALVADOR GONZALEZ-CORNEJO (Rosa)**1982
 Av. Chapultepec Sur 130-204
 Colonia Americana
 Guadalajara, Jal. 44140
 MEXICO
 33 36 30 30 33, fax 33 36 42 42 79
- ERNST GROTE (Julianna)**.....1984
 Neurochirurgische Universitaetsklinik
 Hoppe – Seyler - Str. 3
 Tuebingen, 72076
 GERMANY
 49 7071 2980325, fax 49 7071 295245
 ehgrote@med.uni-tuebingen.de
- DAE HEE HAN (Sung Soon Cho)**1991
 #28 Yongon-dong
 Chongno-gu
 Seoul, 110-744
 SOUTH KOREA
 82 2 760 2352, fax 82 2 766 3322, daehan@snu.ac.kr
- HAJIME HANDA (Hiroko)**1985
 Takeda General Hospital
 28-1 Moriminami-cho, Ishida
 Fushimi-ku
 Kyoto, T601-1495
 JAPAN
 81 75 572 6331, fax 81 75 571 8877, info@takedahp.or.jp
- JOHN HANKINSON (Nicole)**.....1973
 Mill Greens Hemmel
 Angerton, Morpeth
 Northumberland, England NE61 4EY
 UNITED KINGDOM
 0191 772206

- FABIAN ISAMAT** (Maria Victoria (Marivi)).....1989
 Clinica Sagrada Familia
 Torras y Pujalt, 1
 08022 Barcelona
 SPAIN
 34 3 211 8991, fax 34 3 212 4050
- SHOZO ISHII** (Akiko).....1975
 2-1-1 Hongo, Bunkyo-ku
 Tokyo, 113-8421
 JAPAN
 81 3 3813 3111, fax 81 3 3811 7893
- TAKESHI KAWASE** (Mieko).....1997
 Department of Neurosurgery
 Keio University, School of Medicine
 35 Shinanomachi, Shinjuku-ku
 Tokyo 160-8582
 JAPAN
 81 3 5363 3807, fax 81 3 3358 0479, kawase@sc.itc.keio.ac.jp
- KATSUTOSHI KITAMURA** (Yoshiko).....1970
 2-5-7 Shodai, Sawara-ku
 Fukuoka, 814-0012
 JAPAN
 092 821 8533, fax (same #), katkit@jcom.home.ne.jp
- SHIGEAKI KOBAYASHI** (Hideko).....1998
 Komoro Kosei General Hospital
 Yora-machi 3-2-31
 Komoro, 384-8588
 JAPAN
 81 267 22 6925, fax 81 267 22 6926, skb0305@wa2.so-net.ne.jp
- LAURI LAITINEN** (Kerstin).....1972
 Dano
 Geta, FI-22340
 FINLAND
 358 1849 486, lauril@aland.net

- H.C. RUEDIGER LORENZ**1998
 Neurosurgery, J. W. Goethe University Clinic
 Schleusenweg 2-16
 Frankfurt, Main 60528
 GERMANY
 49 69 630 15295, fax 49 69 630 16322,
 prof.lorenz-frankfurt@t-online.de
- RAUL MARINO, JR (Angela)**1977
 University Sao Paulo Medical School
 R. Maestro Cardim 808
 Sao Paulo 01323
 BRAZIL
 5511 824 9060
- JORGE S. MENDEZ (Soledad)**.....1997
 Marcoleta 377
 Santiago
 CHILE
 562 633930, fax 562 6395534, jorsol@entelchile.net
- ✓ **HANS-J. REULEN (Ute)**1998
 Department of Neurosurgery, Ludwig-Maximilian University
 Klinikum Grosshadern
 Marchioninistrasse 15
 Munich, 81377
 GERMANY
 49 89 7095 6556, fax 49 89 7095 2592,
 Ilona.Anders@nc.med.uni-muenchen.de
- MADJID SAMII (Mahschid)**1996
 INI - Hannover
 Alexis – Carrel - Str.4
 30625, Hannover
 GERMANY
 49 511 270 92 700, fax 49 511 270 92 706, samii@ini-hannover.de
- KURT-FRIEDRICH SCHURMANN**.....1978
 Am Eselsweg 29
 Mainz 55128
 GERMANY
 61 31 3 48 61

- CHARAS SUWANWELA (Nitaya)**.....1972
 Chulalongkorn University Council
 Chulalongkorn University
 Bangkok, 10330
 THAILAND
 02 215 0505, fax 02 218 3309, charas.s@chula.ac.th
- LINDSAY SYMON (Pauline)**1982
 Maple Lodge, Rivar Road
 Shalbourne, Marlborough
 Wiltshire, England SN8 3QE
 UNITED KINGDOM
 01672 870 501
- KINTOMO TAKAKURA (Tsuneko)**.....1988
 Tokyo Women's Medical University
 8-1, Kawada-cho, Shinjuku-ku
 Tokyo 162-8666
 JAPAN
 81 3 3353 8111, fax 81 3 5269 7400, ktakakura@nij.twmu.ac.jp
- ✓ **DAVID THOMAS (Hazel)**.....1995
 Institute of Neurology
 The National Hospital, Box 32
 Queen Square
 London, England WC1N 3BG
 UNITED KINGDOM
 44 207 829 8750, fax 44 207 278 7894,
 neurological.surgery@ion.ucl.ac.uk
- KJELD VAERNET**.....1970
 Gardes Alle 7, 4 TV
 Hellerup, 2900
 DENMARK
 (*Last known address*)
- SYDNEY ERIC WATKINS (Susan)**.....1975
 Royal London Hospital
 Whitechapel
 London, England E1 1BB
 UNITED KINGDOM
 (*Last known address*)

M. GAZI YASARGIL (Dianne).....1975
Neurosurgery, #507
University of Arkansas for Medical Sciences
4301 West Markham
Little Rock, AR 72205-7199
501-686-5275, fax 501-686-7928

CORRESPONDING MEMBERS

Elected

✓ **JACQUES BROTCHE** (Rachel).....2003

Department of Neurosurgery

Erasme Hospital

808 Route de Lennik

B-1070 Brussels

BELGIUM

32 2 555 37 51, fax 32 2 555 37 55, jbrotschi@ulb.ac.be

EVANDRO DE OLIVEIRA (Marina).....2002

Praca Amadeu Amaral 27 Andar 5

03127-010 Sao Paulo, SP

BRAZIL

55 11 288 8635, fax 55 11 251 1766, icne@uol.com.br

NOBUO HASHIMOTO.....2003

Department of Neurosurgery

Kyoto University Graduate School of Medicine

54 Kawahara-cho, Shogoin

Sakyo-ku, Kyoto 606-8507

JAPAN

81 75 751 3653, fax 81 75 771 6415, nhashimo@kuhp.kyoto-u.ac.jp

ANDREW KAYE (Judith).....1996

Department of Surgery

The Royal Melbourne Hospital

The University of Melbourne

Melbourne, 3052

AUSTRALIA

61 3 9342 8218, fax 61 3 9347 8332, a.kaye@unimelb.edu.au

HARUHIKO KIKUCHI (Yuriko).....1993

5-7-1 Fujishiro-dai, Suita

Osaka, 565-0873

JAPAN

81 6 6872 8061, fax 81 6 6872 8063

✓ **MICHAEL MORGAN** (Elizabeth) 1999

Neurosurgery
Hengrove Hall, Level 8
193 Macquarie Street
Sydney, N.S.W. 2000
AUSTRALIA
61 2 9223 6500, fax 61 2 9223 6855, morgan@med.uysd.edu.au

JOHN PICKARD (Mary) 2001

Academic Neurosurgery Unit
Box 167, Level A4, Addenbrookes Hospital
Cambridge, England CB2 2QQ
UNITED KINGDOM
1223 336946, fax 1223 216926, jdpsecretary@medschl.cam.ac.uk

✓ **GABRIEL SCHACKERT** (Hans) 2003

Department of Neurosurgery
University of Technology, Dresden
Fetscherstrasse 74
D-01307 Dresden
GERMANY
49 351 458 2883, fax 49 351 458 4304
neurochirurgie@mailbox.tu-dresden.de

JOHANNES SCHRAMM (Dorothea) 2002

Neurochirurgische Univ.-Klinik
Sigmund-Freud Str. 25
D-53105, Bonn
GERMANY
49 228 287 6500, fax 49 228 287 6573,
johannes.schramm@ukb.uni-bonn.de

DECEASED MEMBERS

	Elected	Deceased
JAMES R. ATKINSON	1970.....	1978
Phoenix, Arizona (Active)		
PERCIVAL BAILEY	1960.....	1973
Evanston, Illinois (Honorary)		
GEORGE BAKER	1940.....	1993
Litchfield Park, Arizona (Senior)		
H. THOMAS BALLANTINE, JR. ...	1951.....	1996
Boston, Massachusetts (Senior)		
WILLIAM F. BESWICK	1959.....	1971
Buffalo, New York (Active)		
EDWIN B. BOLDREY	1941.....	1988
San Francisco, California (Senior)		
E. HARRY BOTTERELL	1938.....	1997
Kingston, Ontario, CANADA (Senior)		
ROBERT BOURKE	1983.....	1996
Rockville, Maryland (Senior)		
SPENCER BRADEN	Founder.....	1969
Cleveland, Ohio (Active)		
F. KEITH BRADFORD	1938.....	1971
Houston, Texas (Active)		

- JEAN BRIHAYE**..... 1975.....1999
 Bruxelles, BELGIUM
 (Senior Corresponding)
- KARL-AUGUST BUSHE**..... 1972.....1999
 Wurzburg, GERMANY
 (Senior Corresponding)
- HOWARD BROWN** 1939.....1990
 San Francisco, California
 (Senior)
- JUAN CARDENAS**..... 1966.....1996
 Mexico City, MEXICO
 (Senior Corresponding)
- SHELLEY CHOU**..... 1974.....2001
 Rio Verde, Arizona
 (Senior)
- JUAN CARLOS CHRISTENSEN** ... 1970.....2003
 Buenos Aires, ARGENTINA
 (Senior Corresponding)
- GALE CLARK** 1970.....1996
 Oakland, California
 (Senior)
- DONALD COBURN** 1938.....1988
 Wilmington, Delaware
 (Senior)
- JAMES CORRELL** 1966.....2004
 Hampstead, North Carolina
 (Senior)
- WINCHELL McK. CRAIG** 1942.....1960
 Rochester, Minnesota
 (Honorary)
- EDWARD DAVIS** 1949.....1988
 Portland, Oregon
 (Senior)

- PEARDON DONAGHY** 1970.....1991
 Burlington, Vermont
 (Senior)
- CHARLES DRAKE**..... 1958.....1998
 London, Ontario, CANADA
 (Senior)
- FRANCIS ECHLIN** 1944.....1988
 New Paltz, New York
 (Senior)
- DEAN ECHOLS**..... Founder.....1991
 New Orleans, Louisiana
 (Senior)
- GEORGE EHNI**..... 1964.....1986
 Houston, Texas
 (Senior)
- ARTHUR ELVIDGE** 1939.....1985
 Montreal, Quebec, CANADA
 (Senior)
- THEODORE ERICKSON** 1940.....1986
 Madison, Wisconsin
 (Senior)
- JOSEPH EVANS**..... Founder.....1985
 Kensington, Maryland
 (Senior)
- JOHN FRENCH**..... 1951.....1989
 Los Angeles, California
 (Senior)
- JAMES GALBRAITH**..... 1947.....1997
 Birmingham, Alabama
 (Senior)
- EVERETT GRANTHAM**..... 1942.....1997
 Louisville, Kentucky
 (Senior)

- JOHN GREEN** 1953.....1990
Phoenix, Arizona
(Senior)
- JAMES GREENWOOD, JR.** 1952.....1992
Houston, Texas
(Senior)
- WESLEY GUSTAFSON** 1942.....1975
Jensen Beach, Florida
(Senior)
- WALLACE HAMBY**..... 19411999
Pompano Beach, Florida
(Senior)
- HANNIBAL HAMLIN** 1949.....1982
Providence, Rhode Island
(Senior)
- JOHN HANBERY** 1959.....1996
Palo Alto, California
(Senior)
- MAJOR GEN. GEORGE HAYES**...19622002
Washington, D. C.
(Senior)
- E. BRUCE HENDRICK** 1968.....2001
Toronto, Ontario, CANADA
(Senior)
- JESS HERRMANN**..... 1938.....1994
Oklahoma City, Oklahoma
(Senior)
- HENRY HEYL**..... 19511975
Hanover, New Hampshire
(Senior)
- WILLIAM HUNT** 1970.....1999
Columbus, Ohio
(Senior)

- OLAN HYNDMAN**..... 1942.....1966
Iowa City, Iowa
(Senior)
- KENNETH JAMIESON**..... 1970.....1976
Brisbane, AUSTRALIA
(Corresponding)
- SIR GEOFFREY JEFFERSON**..... 1951.....1961
Manchester, ENGLAND
(Honorary)
- HANS-PETER JENSEN**..... 1980.....2000
Kiel, GERMANY
(Senior Corresponding)
- RICHARD JOHNSON** 1974.....1997
Manchester, ENGLAND
(Senior Corresponding)
- WILLIAM KEITH**..... Founder.....1987
Toronto, Ontario, CANADA
(Senior)
- ROBERT KNIGHTON**..... 1966.....2004
Cherry Valley, California
(Senior)
- RICHARD KRAMER** 1978.....2001
Durham, North Carolina
(Inactive)
- HUGO KRAYENBUHL**..... 1974.....1985
Zurich, SWITZERLAND
(Honorary)
- KRISTIAN KRISTIANSEN**..... 1967.....1993
Oslo, Norway
(Senior Corresponding)
- THEODORE KURZE** 1967.....2002
Newport Beach, California
(Senior)

- WALPOLE LEWIN**..... 1973.....1980
Cambridge, ENGLAND
(Corresponding)
- VALENTINE LOGUE**..... 1974.....2000
London, ENGLAND
(Honorary)
- HERBERT LOURIE** 1965.....1987
Syracuse, New York
(Senior)
- WILLEM LUYENDIJK**..... 1973.....1995
Oegstgeest, NETHERLANDS
(Senior Corresponding)
- ERNEST MACK** 1956.....2000
Reno, Nevada
(Senior)
- M. STEPHEN MAHALEY**..... 1972.....1992
Birmingham, Alabama
(Active)
- GEORGE MALTBY** 1942.....1988
Scarsborough, Maine
(Senior)
- FRANK MARGUTH** 1978.....1991
Munich, GERMANY
(Senior Corresponding)
- DONALD MATSON**..... 1950.....1969
Boston, Massachusetts
(Active)
- FRANK MAYFIELD**..... Founder.....1991
Cincinnati, Ohio
(Senior)
- AUGUSTUS McCRAVEY** 1944.....1990
Chattanooga, Tennessee
(Senior)

- KENNETH McKENZIE**..... 1960.....1964
 Toronto, Ontario, CANADA
 (Honorary)
- WILLIAM MEACHAM**..... 1952.....1999
 Nashville, Tennessee
 (Senior)
- JAMES MEREDITH** 1946.....1962
 Richmond, Virginia
 (Active)
- J. DOUGLAS MILLER**..... 1988.....1995
 Edinburgh, SCOTLAND
 (Corresponding)
- W. JASON MIXTER** 19511968
 Woods Hole, Massachusetts
 (Honorary)
- EDMUND MORRISSEY**..... 19411986
 San Francisco, California
 (Senior)
- FRANCIS MURPHEY** Founder1994
 Naples, Florida
 (Senior)
- GOSTA NORLEN**..... 1973.....1985
 Goteborg, SWEDEN
 (Honorary)
- FRANK NULSEN** 1956.....1994
 Naples, Florida
 (Senior)
- SIXTO OBRADOR**..... 1973.....1978
 Madrid, SPAIN
 (Honorary)
- GUY ODOM**..... 1946.....2001
 Durham, North Carolina
 (Senior)

- PIETRO PAOLETTI**..... 1989.....1991
 Milan, ITALY
 (Corresponding)
- WILDER PENFIELD**..... 1960.....1976
 Montreal, Quebec, CANADA
 (Honorary)
- HELMUT PENZHOLZ**..... 1978.....1985
 Heidelberg, WEST GERMANY
 (Corresponding)
- BERNARD PERTUISET** 1986.....2000
 Paris, FRANCE
 (Honorary)
- HANS-WERNER PIA** 1978.....1986
 Giessen, WEST GERMANY
 (Corresponding)
- J. LAWRENCE POOL** 1940.....2004
 Canaan, CT
 (Senior)
- ROBERT PUDENZ** 1943.....1998
 South Pasadena, California
 (Senior)
- JOHN RAAF** Founder.....2000
 Portland, Oregon
 (Senior)
- B. RAMAMURTHI**..... 1973.....2003
 Tharamani, Chennai, INDIA
 (Senior Corresponding)
- AIDAN RANEY** 1946.....2002
 Los Angeles, California
 (Senior)
- RUPERT RANEY** 1939.....1959
 Los Angeles, California
 (Active)

JOSEPH RANSOHOFF	1965.....	2001
Tampa, Florida (Senior)		
THEODORE RASMUSSEN	1947.....	2002
Montreal, Quebec, CANADA (Senior)		
BRONSON RAY	1992.....	1993
New York, New York (Honorary)		
DAVID REEVES	1939.....	1970
Santa Barbara, California (Active)		
DAVID REYNOLDS	1964.....	1978
Tampa, Florida (Active)		
R. C. L. ROBERTSON	1946.....	1985
Houston, Texas (Senior)		
STEWART ROWE	1938.....	1984
Pittsburgh, Pennsylvania (Senior)		
RICHARD SCHNEIDER	1970.....	1986
Ann Arbor, Michigan (Senior)		
HENRY SCHWARTZ	1942.....	1998
St. Louis, Missouri (Senior)		
WILLIAM SCOVILLE	1944.....	1984
Hartford, Connecticut (Senior)		
R. EUSTACE SEMMES	1955.....	1982
Memphis, Tennessee (Honorary)		

- C. HUNTER SHELDEN**..... 19412003
Pasadena, California
(Senior)
- ROBERT SMITH**..... 19892003
Jackson, Mississippi
(Senior)
- SAMUEL SNODGRASS** 19391975
Galveston, Texas
(Senior)
- GLEN SPURLING**..... 19421968
La Jolla, California
(Honorary)
- C. WILLIAM STEWART**..... 19481948
Montreal, Quebec, CANADA
(Corresponding)
- KENICHIRO SUGITA**..... 19881994
Nagoya, Japan
(Senior Corresponding)
- THORALF SUNDT, JR.**..... 19711992
Rochester, Minnesota
(Active)
- HENDRIK SVIEN** 19571972
Rochester, Minnesota
(Active)
- HOMER SWANSON** 19491987
Atlanta, Georgia
(Senior)
- WILLIAM SWEET** 19502001
Brookline, Massachusetts
(Senior)
- ALFRED UIHLEIN** 19501990
Rochester, Minnesota
(Senior)

- A. EARL WALKER**..... 1938.....1995
 Albuquerque, New Mexico
 (Senior)
- ARTHUR WARD, JR.**..... 1953.....1997
 Seattle, Washington
 (Senior)
- THOMAS WEAVER, JR.**..... 1943.....1985
 Dayton, Ohio
 (Senior)
- W. KEASLEY WELCH** 1957.....1996
 Waban, Massachusetts
 (Senior)
- BENJAMIN WHITCOMB**..... 1947.....1998
 Surrey, Maine
 (Senior)
- BARNES WOODHALL** 1941.....1985
 Durham, North Carolina
 (Senior)
- FRANK WRENN** 1973.....1990
 Greenville, South Carolina
 (Senior)





